

**ECCO**  
**18**

18<sup>th</sup> ECCO - 40<sup>th</sup> ESMO  
**European Cancer Congress**  
*Reinforcing multidisciplinary*  
VIENNA, AUSTRIA, 25 - 29 SEPTEMBER 2015

**ESMO**  
**40**



[www.europeancancercongress.org](http://www.europeancancercongress.org)

**ADVANCE PROGRAMME**  
**#ECC2015**

# #ECC2015: We're Going Digital

The ECCO App has proven itself with over **20 000 downloads** to date.

Download the latest interactive personalised Congress Programme to your device to achieve the most from #ECC2015



- Easily search and browse your tracks
  - Access the latest about your sessions, presentations, posters, abstracts and exhibitors
  - Create your personalised programme
  - Find your way around
- And much, much more**

[www.europeancancercongress.org/app](http://www.europeancancercongress.org/app)

Download for iOS  
or Android



Or search for **ECCO Cancer** in  
App Store/Google Play

**PLEASE NOTE: no printed programme book will be provided at the Congress**

The Organising Committee gratefully acknowledges the support and collaboration of all Member Societies of ECCO, the European Cancer organisation, without which this Congress would not be possible.

## Acknowledgements



## Official Media Partners

On behalf of the Executive Scientific Committee, we gratefully acknowledge the collaboration and support of our official media partners for the European Cancer Congress 2015:



## Table of Contents

Acknowledgements	3
Save the Dates	5
Chairs' Introduction	6
European Cancer Congress 2015 Committees	8
Opening Ceremony	13
Programme at a Glance	14
Detailed Advance Programme	20
Young Oncologists @ ECC2015	60
Patient Advocacy Track	62
Oncopolicy Track	63
Call for Abstracts	64
Abstract Topic Categories	67
Fellowship Grants and Educational Awards	70
Why you should participate at ECC2015	77
Digital Scientific Programme	80
Registration	84
Exhibition & Sponsorship	86
General Information	87

## Save the Dates

**18<sup>th</sup> ECCO - 40<sup>th</sup> ESMO European Cancer Congress**  
**25 – 29 September 2015**

### KEY DATES AND DEADLINES

Abstract submission opens	26 January 2015
Early rate registration deadline	9 April 2015
Abstract submission deadline	28 April 2015
Fellowship grant application deadline	29 April 2015
Late breaking abstract submission opens	22 July 2015
Regular rate registration deadline	4 August 2015
Late breaking abstract submission deadline	5 August 2015
Late rate registration deadline	18 September 2015
Congress in Vienna	25-29 September 2015

## Congress Venue

### Messe Wien Exhibition & Congress Centre

Messeplatz 1, 1021 Vienna, Austria  
 Detailed information about the venue:  
[www.messe.at/en](http://www.messe.at/en)

## Congress Secretariat

c/o ECCO – the European CanCer Organisation  
 Avenue E. Mounier 83, B-1200 Brussels  
 Telephone: +32 (0)2 775 02 01  
 Fax: +32 (0)2 775 02 00  
 Email: [ECC2015@ecco-org.eu](mailto:ECC2015@ecco-org.eu)

[www.europeancancercongress.org](http://www.europeancancercongress.org)



## Chairs' Introduction

The 18<sup>th</sup> ECCO – 40<sup>th</sup> ESMO European Cancer Congress (**ECC2015**) is the largest European multidisciplinary oncology platform for presenting ground-breaking data to a global audience this year.

We are on a path where each ECC Congress sets new records – increasing in the number of participants and submitted abstracts. The most recent ECC2013 in Amsterdam registered 16% growth in delegates and a massive **38% increase** in the number of submitted abstracts compared to our event in Stockholm in 2011.

The European Cancer Congress is now giving fresh impetus to its unique philosophy of collaborative innovation to improve outcomes and find new solutions to pressing issues. Led by the ECC2015 Education Committee Chair, the educational programme is a result of the collaboration of all ECCO founding members, all experts in their respective fields. The programme is more streamlined, with fewer tracks, facilitating an even more productive experience for delegates. This Congress bridges basic and translational research to the clinic as research drives the change in how we treat our patients.

Topics of the greatest interest to a multidisciplinary audience will be presented by the very experts who will implement them. There are multidisciplinary tumour board sessions with a clinical orientation supported by case presentations. These sessions emulate multidisciplinary teams working in the real world and provide participants with concrete insights for immediate practical application. The scientific symposia will focus on the new developments in research and treatment that will impact the future of cancer diagnosis and care. ECC2015 will expand the much needed dialogue between basic and clinical researchers as well as the one between pathologists, molecular imaging specialists and clinicians whenever possible. The educational symposia and teaching lectures will provide state-of-the-art training in the most relevant topics in oncology at this time. We have designed more integrated sessions bringing about dialogue and discussion in overlapping areas of scientific research. The Oxford style debates are designed to shed light on the controversial topics impacting an oncologist's practice today.

The ECC programme also includes a track dedicated to public policy in cancer control. The **Oncopolicy Forum** harnesses the expertise and experience of the entire oncology community to bridge the gap between science and policy, and maximise the potential for achieving positive policy development with patient interests at the core.

The patient perspective is at the heart of the programme and of our collaborative innovation philosophy aimed at improving outcomes and including patients in identifying breakthrough solutions. The patient voice is now even more present in scientific sessions and delivers essential understanding enabling us to learn and to provide the best possible treatment and care.

Following its record number of abstract submissions in previous congresses, ECC2015 is again opening for abstract submission in January with a deadline of **28 April 2015**. Abstracts will be selected to populate the presidential and proffered paper sessions and the poster and poster discussion sessions.

Each poster session is a must-attend event with over 3000 participants viewing the posters. This year, we will host "Posters in the spotlight" where selected authors will present their data during the poster sessions. This unique viewing will take place in the poster area.

And finally our **late-breaking submission policy** is specially designed to ensure the Congress embraces all promising new developments to ensure a very advanced, forward-looking scientific programme.

An application has been made to the EACCME® for CME accreditation of this event.

We have enriched the programme with new elements over and above those of CME – there are unique mentorship opportunities, a special leadership programme, and a number of targeted sessions offering insights into important areas of professional development for oncologists.

**ECC2015** is a unique multidisciplinary Congress with a programme looking to the future through education, research and development, changing the landscape of oncology to improve the quality of treatment and care of cancer patients.

You may now browse the details of the scientific programme for the hot topics which will be presented by leading experts in each of our 27 tracks and for all the integrated sessions making the most of promising connections in research and clinical practice.

***We are confident that you will discover much to interest you and we look forward to seeing you in Vienna in September!***

*Martine Piccart, Congress Chair, ECCO President*

*Rolf A. Stahel, ESMO President*

*Peter Naredi, ECCO Scientific Co-Chair*

*Elisabeth De Vries, ESMO Scientific Co-Chair*

*Jean-Yves Douillard, ECC2015 Education Committee Chair*

*Christoph Zielinski, National Organising Committee Chair*

European Cancer Congress 2015 Committees

Organising Committee

Martine Piccart	Congress Chair, ECCO President
Rolf A. Stahel	ESMO President
Peter Naredi	ECCO Scientific Co-Chair
Elisabeth De Vries	ESMO Scientific Co-Chair
Christoph Zielinski	National Organising Committee Chair
Wim J.G. Oyen	ECCO Treasurer

Executive Scientific Committee

Peter Naredi	ECCO Scientific Co-Chair
Elisabeth De Vries	ESMO Scientific Co-Chair
Philip Poortmans	Radiation Oncology Vice Chair
Richard Marais	Basic Science Vice Chair
Martine Piccart	Congress Chair, ECCO President
Rolf A. Stahel	ESMO President
Jean-Yves Douillard	ECC2015 Education Committee Chair
Christoph Zielinski	National Organising Committee Chair

Education Committee

Jean-Yves Douillard
Andrés Cervantes
Nikolaos Pavlidis
Michele Ghilmini
Giampaolo Tortora
Raffaele Califano
Claus-Henning Koehne
Robert Eckert
Florian Strasser
Richard Herrmann
Lorenz Jost
Karin Haustermans
Linda Wyld
Verena Jendrossek
Riccardo Riccardi

National Organising Committee

Christoph C. Zielinski
Walter Berger
Günter Gastl
Michael Gnant
Richard Greil
Wolfgang Hofer
Lukas A. Huber
Ulrich Jäger
Karin Kapp
Walter Klepetko
Ruth Ladenstein
Peter H. Lukas
Richard Pötter
Maria Sabilia
Hellmut Samonigg
Martin Schindl
Sebastian Schoppmann
Felix Sedlmayer
Veronika Sexl
Harald Titzer

Names in blue denote Chairs

European Cancer Congress 2015  
Programme Tracks, Chairs and Experts

Track				Track			
Breast Cancer - Advanced Disease	Eniu	Alexandru	RO	Clinical Trial Design and Regulatory Affairs	Dafni	Urania	GR
	Børresen-Dale	Anne-Lise	NO		Kearns	Pamela	UK
	Aebi	Stefan	CH		Angenete	Eva	SE
	Brada	Michael	UK		Bogaerts	Jan	BE
	Brouwers	Adrienne H.	NL		Deutsch	Eric	FR
	Caldas	Carlos	UK		Litiere	Saskia	BE
	Cardoso	Fátima	PT		Marsoni	Silvia	IT
	Colleoni	Marco	IT		Dittrich	Christian	AT
	Fenlon	Deborah	UK		Siu	Lillian L.	CA
	Leidenius	Marjut	FI	Early Drug Development	Schellens	Jan H.M.	NL
Breast Cancer - Early Disease	Zielinski	Christoph C.	AT		Vens	Conchita	NL
	Wyld	Lynda	UK		von Kalle	Christof	DE
	Coles	Charlotte E.	UK		Aboagye	Eric O.	UK
	Di Leo	Angelo	IT		Sessa	Cristiana	CH
	Briskén	Catherine	CH		Soria	Jean Charles	FR
	Karlsson	Per	SE		Tabernero	Josep	ES
	Loibl	Sibylle	DE		Twelves	Chris	UK
	Poortmans	Philip	NL	Gastrointestinal Malignancies - Colorectal Cancer	Tejpar	Sabine	BE
	Sotiriou	Christos	BE		Rutten	Harm	NL
	Viale	Giuseppe	IT		Valentini	Vincenzo	IT
Cancer Prevention and Screening	Wengström	Yvonne	SE		Glynne-Jones	Robert	UK
	Yarnold	John R.	UK		Köhne	Claus-Henning	DE
	Cuzick	Jack	UK		Martling	Anna	SE
	Baildam	Andrew D.	UK		Ouwkerk	Jan	NL
	Storme	Guy	BE		Oyen	Wim J.G.	NL
	Autier	Philippe	FR		Van Cutsem	Eric	BE
	Boyle	Peter	FR	Gastrointestinal Malignancies - Noncolorectal Cancer	Roviello	Franco	IT
	Eeles	Rosalind A.	UK		Cunningham	David	UK
	La Vecchia	Carlo	IT		Morganti	Alessio	IT
Central Nervous System	Preusser	Matthias	AT		Cervantes	Andres	ES
	Combs	Stephanie	DE		Ducreux	Michel	FR
	Walker	David	UK		Gruenberger	Thomas	AT
	Soffietti	Riccardo	IT		Lordick	Florian	DE
	Baumert	Brigitta	NL		Verheij	Marcel	NL
	Steeg	Patricia S.	US	Genitourinary Malignancies - Nonprostate Cancer	Escudier	Bernard	FR
	Stupp	Roger	CH		de Reijke	Theo	NL
	van den Bent	Martin J.	NL		De Wit	Ronald	NL
	Wick	Wolfgang	DE		Eisen	Tim	UK
					Fanti	Stefano	IT
					Gillessen	Silke	CH
					Schmidinger	Manuela	AT
					van As	Nicholas	UK

Names in blue denote Track Chairs

Track				Track			
Genitourinary Malignancies - Prostate Cancer	Hoyer	Morten	DK	Lung Cancer - Localised/ Local Regional Disease	Lievens	Yolande	BE
	Cathomas	Richard	CH		Veronesi	Giulia	IT
	Van Poppel	Hendrik	BE		Dzadzadzko	Rafal	PL
	De Bono	Johann	UK		Faivre-Finn	Corinne	UK
	Haustermans	Karin	BE		Novello	Silvia	IT
	Khoo	Vincent	UK		Shackcloth	Michael	UK
	Powles	Thomas	UK		Senan	Suresh	NL
	Schalken	Jack	NL		Smit	Egbert F.	NL
	Sternberg	Cora N.	IT		Vansteenkiste	Johan	BE
	van Muilekom	Erik	NL		Verschuren	Emmy	FI
Gynaecological Cancer	Rovirosa	Angeles	ES	Lung Cancer - Metastatic Disease	Reck	Martin	DE
	Giavazzi	Raffaella	IT		Kerr	Keith	UK
	Ray-Coquard	Isabelle	FR		Buettner	Reinhard	DE
	Colombo	Nicoletta	IT		De Ruyscher	Dirk	BE
	Dahm Kahler	Pernilla	SE		Felip	Enriqueta	ES
	Banerjee	Susana	UK		Margulies	Anita	CH
	Pötter	Richard	AT		Mok	Tony	CN
	Vergote	Ignace B.	BE		Mordant	Pierre	FR
Haematological Malignancies	Ladetto	Marco	IT		Peters	Solange	CH
	Schrappé	Martin	DE		Popat	Sanjay	UK
	Ghielmini	Michele	CH	Melanoma and Skin Cancer	Marais	Richard	UK
	Montoto	Silvia	UK		Ascierto	Paolo Antonio	IT
	Scheid	Christof	DE		Zoras	Odysseas	GR
	Specht	Lena	DK		Eggermont	Alexander M.M.	FR
Head and Neck Cancer	Stary	Jan	CZ		Haanen	John B.A.G.	NL
	Langendijk	Hans	NL		Creutzberg	Carien	NL
	Psyrrí	Amanda	GR		Lorigan	Paul	UK
	Dietz	Andreas	DE		Michelin	Olivier	CH
	Giralt	Jordi	ES	Oncology Nursing	Kelly	Daniel	UK
	Hainaut	Pierre	FR		Ripamonti	Carla	IT
	Licitra	Lisa	IT		Bunskoek	Sophie	NL
	Noonan	Brendan	IE		Eicher	Manuela	CH
	Oosting	Sjoukje	NL		Fenlon	Deborah	UK
Immunotherapy of Cancer	Oyen	Wim J.G.	NL		Titzer	Harald	AT
	Melero	Ignacio	ES		Margulies	Anita	CH
	Galon	Jerome	FR		Moore	Sally	UK
	Jerezek-Fossa	Barbara	IT		Wells	Mary	UK
	Beckhove	Philippe	DE		van Muilekom	Erik	NL
	Formenti	Silvia	US		Wengström	Yvonne	SE
	Gerritsen	Winald R.	NL				
	Nathan	Paul	UK				
	Petrasch	Ulf	CH				
Innovations in Radiation Oncology	Zips	Daniel	DE				
	Shiloh	Yossi	IL				
	Baumann	Michael	DE				
	Giammarile	Francesco	FR				
	Lara	Pedro C.	ES				
	Essers	Marion	NL				
	Wouters	Brad	CA				

Names in blue denote Track Chairs

Track			
Oncopolicy	Piccart	Martine	BE
	Naredi	Peter	SE
	Oyen	Wim J.G.	NL
	Costa	Alberto	IT
	Margulies	Anita	CH
	Vassal	Gilles	FR
	Marais	Richard	UK
	Taphoorn	Martin	NL
	Poortmans	Philip	NL
	Audisio	Riccardo	UK
	Stahel	Rolf A.	CH
	Casali	Paolo	IT
	Abrahamsson	Per-Anders	SE
	Gregoire	Vincent	BE
	Banks	Ian	BE
Paediatric Oncology	Vassal	Gilles	FR
	Bielack	Stefan	DE
	Dieckmann	Karin	DE
	Carrie	Christian	FR
	Delattre	Olivier	FR
	Ferrari	Andrea	IT
	Kelly	Daniel	UK
	Ladenstein	Ruth	AT
	Pearson	Andy	UK
	Rossig	Claudia	DE
	Stark	Daniel	UK
Patient Advocacy	Banks	Ian	BE
	Bode	Gerlind	DE
	Diler	Sarper	TR
	Erdem	Sema	TR
	Geissler	Jan	DE
	Gore-Booth	Jola	UK
	Kelly	Joan	IE
	Oliver	Kathy	UK
	Pelouchová	Jana	CZ
	Mastris	Ken	UK
Sarcoma: Soft Tissue and Bone	Blay	Jean Yves	FR
	Bonvalot	Sylvie	FR
	Haas	Rick	NL
	Casali	Paolo G.	IT
	Sandrucci	Sergio	IT
	Juergens	Heribert F.	DE
	Brugieres	Laurence	FR
	Ferrari	Andrea	IT
	Van der Graaf	Winette	NL

Track			
Supportive Care and Palliation	Charalambous	Andreas	CY
	Poston	Graeme	UK
	Ripamonti	Carla	IT
	van der Linden	Yvette	NL
	Bernot	Marjana	SI
	Cherny	Nathan I.	IL
	Kazmierska	Joanna	PL
	Popescu	Razvan	CH
	Sedlmayer	Felix	AT
	Strasser	Florian	CH
Surgical Oncology	Audisio	Riccardo A.	UK
	Lichosik	Danuta	IT
	Gonzalez-Moreno	Santiago	ES
	Malik	Hassan	UK
	Rubio	Isabel T.	ES
	Sandrucci	Sergio	IT
Young Oncologists	Banerjee	Susana	FR
	Rouschop	Kasper	NL
	van der Vorst	Joost Renier	NL
	Califano	Raffaele	UK
	Ozturk	Mehmet Akif	TR
	Petrova	Mila	BG
	Qvortrup	Camilla	DK
	Schmid	Maximillian	AT
	Sund	Malin	SE

## Opening Ceremony



The Opening Ceremony for the European Cancer Congress will take place on Friday 25 September from 19:15 in the Congress Centre.

The keynote speech will be given by **Margaret Foti**, PhD, MD (hc), Chief Executive Officer of AACR and Secretary-Treasurer of the AACR Foundation. She earned a master’s degree and a doctorate in communications from Temple University in Philadelphia, Pennsylvania.

At the AACR, Margaret Foti worked collaboratively with its elected officers to provide the corporate knowledge and continuity of leadership that have been critical to the association’s progress and its mission to prevent and cure cancer. During Foti’s tenure, the AACR’s membership has grown from about 3,000 to 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 97 countries. Margaret Foti has since launched seven major peer-reviewed scientific journals: Cancer Epidemiology, Biomarkers & Prevention; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Prevention Research; Cancer Discovery; and Cancer Immunology Research. Dr Foti also leads the AACR’s scientific partnership with **Stand Up To Cancer**, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. Dr Foti is the recipient of many national and international awards for her contributions to cancer research including the European CanCer Organisation Lifetime Achievement Award.

Dr Foti will deliver a lecture focusing on “**New Funding Models for Accelerating Progress Against Cancer**”.

The Opening Ceremony will also feature an inspiring talk on science and music. As is customary, the National Organising Committee will introduce Vienna and Austria to the Congress participants. Prof. Dr. Klaus Laczika will present a “History of the Viennese Waltz - the Complexity of Ease - How did it all start, how did it evolve and where has it lead us?”

Following the ceremony, there will be a Networking Reception - an opportunity for Society Members and all experts participating in the Congress to meet and begin their exchange of ideas and thoughts on the latest achievements in research laboratories and clinical environments.





ES = Educational Symposium I.S. Integrated Session OF = Oncopolicy Forum PAS= Patient Advocacy Session SS = Scientific Symposium Spec. S. = Special Session

ES = Educational Symposium I.S. Integrated Session OF = Oncology Forum PAS = Patient Advocacy Session SS = Scientific Symposium Spec. S. = Special Session

[illegible]

8:00	Breast	Lung	Colorectal	Melanoma	General	Gynaecological	Supportive care		Haem.	Paediatric	
	TL	TL	TL	TL		TL	TL	TL	TL		
8:45	Staging the Axilla: Imaging and Sentinel Node Technologies										
	Is There a Dose Response Relationship in Localised Lung Cancer	Rectal Cancer and the Role of Imaging in Treatment Planning	Update on the Role of Surgery in Melanoma: From Margins to SLNB to Metastasectomy	Highlight Session	Laparoscopic and Robotic Surgery in the Treatment of Gynaecological Malignancy	Lessons Learned from a Study to Reduce Fatigue in Men with Prostate Cancer	The Spectrum of Cutaneous Lymphomas: From Molecular Biology to Therapy				
9:00	Breast	Integrated	Noncolorectal	Integrated	CU-Prostate	Gynaecological	Clinical Trials	Immv.RO	Supportive care	Haem.	Paediatric
	SS	I.S.	PP	I.S.	Soc. S.	PP	SS	SS	ES	PP	ES
	Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy	Immunotherapy in NSCLC - 2015	Proffered Paper Session	Immunotherapy in the Management of Metastatic Melanoma	EAU Society Session - Urothelial Cancer in 2015	Proffered Paper Session	Bayesian, Adaptive and Rare Disease Design	High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit	New Drugs for Symptom Management of Pain, Cancer Cachexia and Depression in Cancer Patients	Proffered Paper Session	Common Approaches & Pathways in Adult and Paediatric Malignancies
		Immunotherapy		Immunotherapy							
10:30		Lung		Melanoma							
11:00	Breast	Lung	Colorectal	Melanoma	CU-nonprostate	Gynaecological	Clinical Trials	Immv.RO	Supportive care	Haem.	Paediatric
11:15	Spec. S.	Spec. S.	Spec. S.	Spec. S.	Spec. S.	Debate	Spec. S.	Spec. S.	Spec. S.	Debate	PP
	Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer	Resistance in Patients with Oncogenic Alterations	Clinical Challenges in Adjuvant Therapy in Rectal and Colon Cancer	How Do We Sequence or Combine Immunotherapies with Targeted Therapies in Melanoma?	Immunotherapy in Genitourinary Cancer	This House Believes that Ovarian Platinum-Sensitive Carcinoma in Relapse Needs Platinum Based Chemotherapy	The Global Impact of the EU Paediatric Regulation across All Ages	Stereotactic Hypofractionated Radiation Therapy for Oligometastatic Disease: For Whom and When?	Paediatric Palliative Care - Complexity Calls for Novelty	This House Believes that We Should Treat First Line Advanced Follicular Lymphoma without Chemotherapy	Proffered Paper Session
12:15											
12:30	Take Home Message										
13:30											

ES = Educational Symposium I.S. Integrated Session OF = Oncology Forum PAS= Patient Advocacy Session SS = Scientific Symposium Spec. S. = Special Session

# ECC2015 Detailed Advance Programme

## GENERAL

### FRIDAY 25 SEPTEMBER 2015

#### Opening Ceremony

■ 19:15 - 21:00

#### New funding models for accelerating progress against cancer

Speaker: M. Foti (United States)

Details to be announced in the online searchable programme and final programme as soon as possible

### SATURDAY 26 SEPTEMBER 2015

#### Opening Plenary Session

■ 08:45 - 10:15

#### Welcome by Congress President

Speaker: M. Piccart (Belgium)

#### Chair of ECCO Patient Advisory Committee

Panel: I. Banks (Belgium)

#### EONS President

Panel: E. van Muilekom (Netherlands)

#### EACR President

Panel: R. Marais (United Kingdom)

#### ESTRO President

Panel: P. Poortmans (Netherlands)

#### ESSO President

Panel: R.A. Audisio (United Kingdom)

#### SIOPE President

Panel: G. Vassal (France)

#### ESMO President

Panel: R. Stahel (Switzerland)

#### ECCO Scientific Co-Chair

Panel: P. Naredi (Sweden)

#### ESMO Scientific Co-Chair

Panel: E.G.E. De Vries (Netherlands)

#### Genomic alterations in cancer

Speaker: L. Garraway (USA)

#### Immunotherapy, past, present and future

Speaker: C. Robert (France)

#### Special Session: EURECCA

■ 12:45 - 14:30

Chair: C.J.H. van de Velde (Netherlands)

Chair: R.A. Audisio (United Kingdom)

#### Optimising oesophageal-gastric cancer care

Speaker: W. Allum (United Kingdom)

#### Prospective International Watch and Wait Database (IWWD) for complete responders of neoadjuvant therapies for rectal cancer

Speaker: N. Figueiredo (Portugal)

#### Breast cancer in Europe

Speaker: E. Bastiaannet (Netherlands)

#### Discussion

#### Special Session: Women in Oncology Forum

■ 13:00 - 14:30

Details to be announced in the online searchable programme and final programme as soon as possible

#### Presidential Session I

■ 14:30 - 16:30

#### Keynote Lecture

Speaker: To be announced

#### ECCO Lifetime Achievement Award

Awardee: To be announced

Includes best and late breaking abstracts

#### Leadership Programme 1

■ 15:15 - 16:15

#### The objective of this workshop is to learn how to be an effective leader in your institute/department

Ticketed session

Details to be announced in the online searchable programme and final programme as soon as possible

#### Society Session: European School of Oncology (ESO): Is Innovation Affordable?

■ 16:45 - 18:15

Chair: A. Costa (Italy)

#### Economics for oncologists: The reality of costs

Speaker: P. Cornes (United Kingdom)

#### Concerns or solutions: The ESO Innovation Task Force

Speaker: M. Aapro (Switzerland)

#### The World Oncology Forum: Treat the treatable

Speaker: F. Peccatori (Italy)

#### The ESMO initiative on affordable drugs

Speaker: M. Piccart (Belgium)

#### Affordability of innovative cancer medicine: A research perspective

Speaker: P. Workman (United Kingdom)

#### Roundtable discussion with the audience

#### Special Session: ESMO Designated Centres of Integrated Oncology and Palliative Care

■ 18:15 - 20:15

Chair: F. Stasser (Switzerland)

Details to be announced in the online searchable programme and final programme as soon as possible

### SUNDAY 27 SEPTEMBER 2015

#### Highlight Session

■ 08:00-08:45

Details to be announced in the online searchable programme and final programme as soon as possible

#### Scientific Symposium: ESMO Clinical Practice Guidelines

■ 09:15 - 11:15

Chair: A. Cervantes (Spain)

Co-Chair: G. Pentheroudakis (Greece)

#### Introduction to the ESMO Clinical Practice Guidelines

Speaker: A. Cervantes (Spain)

#### Questionnaire

Speaker: G. Pentheroudakis (Greece)

#### Colon cancer case presentation

Speaker: Lisa Salvatore (Italy)

Discussant: Dirk Arnold (Germany)

#### Questions & Answers

#### Multiple myeloma case presentation

Speaker: To be announced

Discussant: To be announced

#### Questions & Answers

#### Malnutrition/cachexia case presentation

Speaker: To be announced

Discussant: Florian Strasser (Switzerland)

#### Questions & Answers

#### Breast cancer case presentation: HER2+ metastatic disease after adjuvant trastuzumab

Speaker: Emmanouil Saloustros (Greece)

Discussant: Elzbieta Senkus-Konefka (Poland)

#### Questions & Answers

#### Scientific Symposium: ECCO/SIOG Joint Symposium: Geriatric Oncology - A Multidisciplinary Approach to Reinforce Positive Outcomes in Older Patients

■ 09:15 - 10:45

Chair: M. Aapro (Switzerland)

Chair: E. Brain (France)

#### A case among others in your MDT meeting: An 83 year old breast cancer patient

#### Presentation of the patient

Speaker: M. Aapro (Switzerland)

#### Operating the older patient: Yes, it is possible!

Speaker: R.A. Audisio (United Kingdom)

#### Irradiate or not the older breast cancer patient

Speaker: I. Kunkler (United Kingdom)

#### Chemotherapy: Which one and why

Speaker: S. Loibl (Germany)

#### But what about her quality of life?

Speaker: R. Britz (Spain)

#### The role of the geriatrician

Speaker: M. Rainfray (France)

#### Not competing but collaborating and final words

Speaker: E. Brain (France)

#### Questions & Answers

#### Leadership Programme 2

■ 13:00 - 14:00

#### The objective of this workshop is to learn how to be an effective leader in your institute/department

Ticketed session

Details to be announced in the online searchable programme and final programme as soon as possible

#### Presidential Session II

■ 14:45 - 16:45

#### ECCO Pezcoller Award

Awardee: To be announced

#### ESMO Hamilton-Fairly Award

Awardee: To be announced

Includes best and late breaking abstracts

#### Scientific Symposium: ECCO/ASCO Joint Symposium

■ 17:00 - 18:30

Details to be announced in the online searchable programme and final programme as soon as possible

### MONDAY 28 SEPTEMBER 2015

#### Highlight Session

■ 08:00-08:45

Details to be announced in the online searchable programme and final programme as soon as possible

#### Society Session: European Organisation for Research and Treatment of Cancer (EORTC) - Precision Medicine: Are We Stalling?

■ 09:15 - 11:15

Chair: R. Stupp (Switzerland)

Chair: D. Lacombe (Belgium)

#### Title to be announced

Speaker: V. Gelfinopoulos (Belgium)

#### Title to be announced

Speaker: U. McDermott (United Kingdom)

#### Title to be announced

Speaker: H. Eichler (United Kingdom)

#### ECCO/CDDF Joint Session: European Regulation and Health Technology Assessments in Immunotherapy

■ 11:30 - 12:30

#### The session will focus on the European regulation and Health Technology Assessment (HTA) appraisals of novel immuno-oncology products, it will address hurdles and explore potential solutions.

Details to be announced in the online searchable programme and final programme as soon as possible

#### Roundtable: Oncology Drug Development in the Era of Genomic Sequencing

■ 13:00 - 14:30

Chair: J.C. Soria (France)

#### Academic perspective

Speaker: D. Solit (USA)

#### Industry perspective

Speaker: A. Riva (USA)

#### FDA perspective

Speaker: P. Cortazar (USA)

#### EMA perspective

Speaker: F. Pignatti (United Kingdom)

#### Patient advocate perspective

Speaker: J. Gore-Booth (France)

#### Paediatric oncologist perspective

Speaker: R. Ladenstein (Austria)

#### Discussion



Presidential Session III

■ 14:45-16:45

**Keynote Lecture: Revolution in clinical trials in early drug development**  
*Speaker: J.C. Soria (France)*

*Includes best and late breaking abstracts*

*ECCO Clinical Research Award*

**Special Session: The Prerequisite for Ideal Biobanking**

■ 15:15 - 16:15

*Chair: J. Dillner (Sweden)*

**How much is important for the basic research the material and the dataset?**  
*Speaker: F. Carneiro (Portugal)*

**From the operating room to the laboratory. The value of surgery standardisation and data collection in a tissue bank**  
*Speaker: G. Corso (Italy)*

**The importance of image guided oncologic intervention standardisation and database collection**  
*Speaker: J. Futterer (Netherlands)*

Discussion

**Leadership Programme 3**

■ 15:15 - 16:15

**The objective of this workshop is to learn how to be an effective leader in your institute/department**

*Ticketed session*

*Details to be announced in the online searchable programme and final programme as soon as possible*

**Scientific Symposium: ECCO/JSCO Joint Symposium: Improved Cancer Care through Innovative Surgical Techniques**

■ 17:00 - 18:30

*Chair: P. Naredi (Sweden)*  
*Chair: Y. Kitagawa (Japan)*

**Introduction**  
*Speaker: P. Naredi (Sweden)*  
*Speaker: Y. Kitagawa (Japan)*

**Fluorescence-guided surgery**  
*Speaker: Alex Vahrmeijer (Netherlands)*

**Laparoscopy and endoscopy combined sentinel node navigation surgery for gastric cancer**  
*Speaker: Yuko Kitagawa (Japan)*

**The future for rectal cancer surgery – taTME**  
*Speaker: Antonio Lacy (Spain)*

**Surgery of advanced hilar cholangiocarcinoma utilising 3D computer assisted surgery planning and navigation**  
*Speaker: Itaru Endo (Japan)*

**Society Session: European Society for Medical Oncology (ESMO)**

■ 16:45 - 18:45

*Chair: R.A. Stahel (Switzerland)*  
*Co-Chair: F. Ciardiello (Italy)*

**Welcome and general introduction**  
*Speaker: R.A. Stahel (Switzerland)*

**Introduction and overview of ESMO public policy**  
*Speaker: P.G. Casali (Italy)*

**ESMO Magnitude of Clinical Benefits Scale**  
*Speaker: E.G.E de Vries (Netherlands)*

**ESMO International Anti-Neoplastic Medicines Study**  
*Speaker: N.I. Cherny (Israel)*

**How the ESMO Magnitude of Clinical Benefits Scale is applied**  
*Speaker: A. Eniu (Romania)*

**ESMO Award and Lecture**  
*Award Lecturer: To be announced*

**ESMO Lifetime Achievement Award and Lecture**  
*Award Lecturer: To be announced*

**Women in Oncology Award**  
*Awardee: To be announced*

**ESMO Fellowships**  
*Awardee: To be announced*

**ESMO Best Examination 2014**  
*Awardee: U. Bokal (Slovenia)*

**Scientific Symposium: Making Survivor Care Evidence Based for the Growing Number of Survivors: Patients at the Forefront of Their Own Survivorship Care**

■ 17:00 - 18:30

*Chair: S. Diler (Turkey)*  
*Co-Chair: J. Gietema (Netherlands)*

**How late effects in testicular cancer guide follow-up**  
*Speaker: H.S. Haugnes (Norway)*

**Exploiting dormant information on long-term follow-up outcome of EORTC Lymphoma trials: The EORTC survivorship initiative**  
*Speaker: L. Moser (Portugal)*

**How to involve the primary care physician in survivor care for growing number of survivors**  
*Speaker: E. Grunfeld (Canada)*

**Patients in control of navigating their own survivor care plan**  
*Speaker: J. Gietema (Netherlands)*

Discussion & Roundup

**Society Session: European Association of Nuclear Medicine (EANM) - The Sentinel Node Procedure, Current Status and Future Perspectives**

■ 17:00 - 18:30

*Chair: G. Mariani (Italy)*  
*Chair: R. Valdés Olmos (Netherlands)*

**The sentinel node in breast cancer: State of the art of a consolidated technique**  
*Speaker: F. Giammarile (France)*

**The sentinel node in gynaecological malignancies: Guideline recommendations of the EANM**  
*Speaker: S. Vidal-Sicart (Spain)*

**The sentinel node in melanoma: 2014 update**  
*Speaker: G. Mariani (Italy)*

**Recent evolutions and future trends in radioguided surgery**  
*Speaker: R. Valdés Olmos (Netherlands)*

TUESDAY 29 SEPTEMBER 2015

Highlight Session

■ 08:00-08:45

*Details to be announced in the online searchable programme and final programme as soon as possible*

INTEGRATED

SUNDAY 27 SEPTEMBER 2015

**Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols**

■ 09:15 - 11:15

*Chair: M. Pfreundschuh (Germany)*  
*Co-Chair: G. Mann (Austria)*

**Introduction**  
*Speaker: M. Pfreundschuh (Germany)*

**Burkitt's lymphoma in children**  
*Speaker: V. Minard-Colin (France)*

**Burkitt's lymphoma in adults**  
*Speaker: L. Trümper (Germany)*

**Lymphoblastic leukaemia in children**  
*Speaker: M. Heyman (Sweden)*

**Lymphoblastic leukaemia in adults**  
*Speaker: N. Boissel (France)*

Discussion & Roundup

**Integrated Session: Teenage and Young Adult Oncology**

■ 16:45 - 18:45

*Chair: R. Ladenstein (Austria)*  
*Co-Chair: S. Bielack (Germany)*

**Introduction**  
*Speaker: R. Ladenstein (Austria)*

**Improving access to clinical trials**  
*Speaker: N. Gaspar (France)*

**EU Curriculum**  
*Speaker: D. Stark (United Kingdom)*

**Treatment and care of teenagers and young adults with a germ cell tumour?**  
*Speaker: G. Calaminus (Germany)*

**How to build on networking**  
*Speaker: L. Fern (United Kingdom)*

Discussion & Roundup

MONDAY 28 SEPTEMBER 2015

**Integrated Session: Novel Approaches to Brain Metastases**

■ 09:15 - 11:15

*Chair: S. Combs (Germany)*  
*Co-Chair: A. Eniu (Romania)*

**Biology of brain metastases**  
*Speaker: P.S. Steeg (USA)*

**Novel systemic therapy approaches to brain metastases: Lung**  
*Speaker: S. Popat (United Kingdom)*

**Novel systemic therapy approaches to brain metastases: Breast**  
*Speaker: M. Preusser (Austria)*

**Novel systemic therapy approaches to brain metastases: Melanoma**  
*Speaker: D. Schadendorf (Germany)*

**Advances in loco-regional treatments**  
*Speaker: M. Brada (United Kingdom)*

**Tolerability of brain metastasis treatments**  
*Speaker: R. Soffietti (Italy)*

**Response assessment in brain metastases**  
*Speaker: N. Lin (USA)*

Discussion & Roundup

**Integrated Session: How to Personalise Treatment Modalities in Locally Advanced Rectal Cancer**

■ 16:45 - 18:45

*Chair: A.F. Sobrero (Italy)*  
*Co-Chair: R.J. Heald (United Kingdom)*

**Introduction**  
*Speaker: A.F. Sobrero (Italy)*

**By imaging**  
*Speaker: G. Brown (United Kingdom)*

**By drug combination**  
*Speaker: R. Glynn-Jones (United Kingdom)*

**By modulation radiotherapy volume and dose**  
*Speaker: C. Marijnen (Netherlands)*

**By supporting decision tools**  
*Speaker: V. Valentini (Italy)*

Discussion & Roundup

**Integrated Session: Medulloblastoma**

■ 16:45 - 18:45

*Chair: S.J. Rutkowski (Germany)*  
*Co-Chair: B. Geoerger (France)*

**Introduction**  
*Speaker: S.J. Rutkowski (Germany)*

**Molecular classification of medulloblastoma**  
*Speaker: S. Pfister (Germany)*

**Current concepts and future directions in pharmacotherapy of medulloblastoma**  
*Speaker: B. Geoerger (France)*

**Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOP-Europe PNET working group**  
*Speaker: S.J. Rutkowski (Germany)*

**Optimising efficacy and limiting toxicity of radiotherapy for medulloblastoma**  
*Speaker: S. Combs (Germany)*

**Management of adult medulloblastoma - using the evidence from children and adolescents**  
*Speaker: A.A. Brandes (Italy)*

Discussion & Roundup

TUESDAY 29 SEPTEMBER 2015

**Integrated Session: Immunotherapy in NSCLC - 2015**

■ 09:00 - 11:00

*Chair: L. Paz-Ares (Spain)*  
*Co-Chair: M. Reck (Germany)*

**Introduction**  
*Speaker: L. Paz-Ares (Spain)*

**Lung cancer: An immunogenic tumour?**  
*Speaker: S.A. Quezada (United Kingdom)*

**Any place for vaccination strategies?**  
*Speaker: J. Vansteenkiste (Belgium)*

**Check point inhibitors - where do we stand and where are we going?**  
*Speaker: M. Reck (Germany)*

**Biomarkers - a realistic perspective?**  
*Speaker: K. Kerr (United Kingdom)*

Discussion & Roundup



### Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

■ 09:00 - 11:00

Chair: A.M.M. Eggermont (France)  
Co-Chair: P.A. Ascierto (Italy)

#### Introduction

Speaker: A.M.M. Eggermont (France)

#### Biomarkers for the complex biology of melanoma immunotherapy

Speaker: C. Robert (France)

#### Immunogens and immunostimulatory monoclonal antibodies

Speaker: I. Melero (Spain)

#### Melanoma targeted therapies in the interface with immunotherapy

Speaker: A. Ribas (USA)

#### Virotherapy and immunotherapy

Speaker: A. Melcher (United Kingdom)

#### Discussion & Roundup

## BASIC SCIENCE/ TRANSLATIONAL RESEARCH

### SATURDAY 26 SEPTEMBER 2015

#### Teaching Lecture: Use of Liquid Biopsies

■ 07:45 - 08:30

Chair: C. Caldas (United Kingdom)  
Speaker: C. Dive (United Kingdom)

#### Society Session: European Association for Cancer Research (EACR)

■ 10:30 - 12:30

Details to be announced in the online  
searchable programme and final programme  
as soon as possible

### Scientific Symposium: Cellular Immunotherapy of Cancer

■ 10:30 - 12:00

Chair: I. Melero (Spain)  
Co-Chair: To be announced

#### Making the most adoptive T-cell therapy

Speaker: P. Hwu (USA)

#### Deploying gene-engineered T-cells in the cancer battlefield

Speaker: C. June (USA)

#### Making the most of dendritic cell- based immunotherapy

Speaker: C. Figdor (Netherlands)

#### Is cancer immunosurveillance relevant?

Speaker: J. Galon (France)

#### Discussion & Roundup

#### Special Session: Combining Radiation and Immunotherapy

■ 15:15 - 16:15

Chair: A. Melcher (United Kingdom)

#### Molecular basis for radiotherapy in synergy with immunotherapy

Speaker: S. Demaria (USA)

#### Radiotherapy, immunotherapy and virotherapy riddles

Speaker: K. Harrington (United Kingdom)

#### Learning radioimmunotherapy

Speaker: P. Beekhove (Germany)

#### Discussion

#### Special Session: Successes and Uncertainties for Targeted Therapies of Sarcomas

■ 15:15 - 16:15

Chair: J.Y. Blay (France)

#### Trabectedine and M2 macrophages

Speaker: M. D'Incalci (Italy)

#### MDM2/CDK4: Good targets?

Speaker: O. Mir (France)

#### CSF1R Ab or Ib

Speaker: G. Demetri (USA)

#### Discussion

### Special Session: Precision Medicine and New Drugs for the Treatment of Children and Adolescents with Cancer

■ 15:15 - 16:15

Chair: G. Vassal (France)

#### Tumour molecular profiling to guide new drug development: Experiences from Germany, France, UK and Netherlands

Speaker: S. Pfister (Germany)

#### Is B-RAF and MEK pathway relevant in paediatric malignancies?

Speaker: B. Geoerger (France)

#### Monoclonal antibodies in paediatric acute leukaemias

Speaker: A. Von Stackelberg (Germany)

#### Discussion

#### Scientific Symposium: New Insights in Colon Cancer

■ 16:45 - 18:15

Chair: D. Aust (Germany)  
Co-Chair: P. Laurent Puig (France)

#### Biomarkers to guide therapy today, what to assess and how

Speaker: H. Van Krieken (Netherlands)

#### Novel insights into CRC biology

Speaker: S. Tejpar (Belgium)

#### The immune landscape of colon cancer

Speaker: J. Galon (France)

#### Novel insights on tumour adaptation and clinical implications

Speaker: E.S. Kopetz (USA)

#### Discussion & Roundup

#### Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer

■ 16:45 - 18:15

Chair: L. Licitra (Italy)  
Co-Chair: U. Keilholz (Germany)

#### Genomic landscape of HPV related head and neck cancer

Speaker: C.H. Chung (USA)

### HPV targeted therapies in HPV associated oropharynx cancer

Speaker: A. Psyrri (Greece)

#### EGFR targeted approaches in HPV related head and neck cancer: Is there any role?

Speaker: L. Licitra (Italy)

#### Deintensification strategies in HPV positive oropharynx tumours

Speaker: P. Lassen (Denmark)

#### Discussion & Roundup

#### Scientific Symposium: New Trends in Molecular Targeting for Radiation Oncology

■ 16:45 - 18:15

Chair: Y. Shiloh (Israel)  
Co-Chair: B. Wouters (Canada)

#### Immunotherapy and radiation therapy

Speaker: E. Deutsch (France)

#### The link between receptors and signalling pathways and radiation therapy

Speaker: K. Harrington (United Kingdom)

#### Angiogenesis and tumour vasculature influences radiation effects

Speaker: M. Pruschy (Switzerland)

#### Why DNA repair is so important for radiation oncologists

Speaker: T. Helleday (Sweden)

#### Discussion & Roundup

#### Scientific Symposium: Childhood Cancer: Bad Luck or Bad Genes?

■ 16:45 - 18:15

Chair: L. Brugieres (France)  
Co-Chair: H. Vasen (Netherlands)

#### Status of predisposition to paediatric malignancies: The known and unknown

Speaker: K. Wimmer (Austria)

#### Dysregulated RAS signalling in paediatric cancer and developmental disorders

Speaker: M. Tartaglia (Italy)

#### Li-Fraumeni syndrome

Speaker: M.T. Frebourg (France)

### Research and counselling in genetic predisposition to paediatric malignancies: Ethical issues

Speaker: F. Bourdeaut (France)

#### Discussion & Roundup

### SUNDAY 27 SEPTEMBER 2015

#### Teaching Lecture: Recent Developments in the Treatment of Metastatic Breast Cancer: Translational Aspects

■ 08:00 - 08:45

Chair: A. Di Leo (Italy)  
Speaker: C.C. Zielinski (Austria)

#### Teaching Lecture: New Targets in Renal Cell Carcinoma: What Can We Expect for the Future?

■ 08:00 - 08:45

Chair: C. Sternberg (Italy)  
Speaker: B. Escudier (France)

#### Teaching Lecture: Technical Innovations in Radiotherapy

■ 08:00 - 08:45

Chair: D. Verellen (Belgium)  
Speaker: C. Grau (Denmark)

#### Teaching Lecture: Use of the Preoperative Window for Early Drug Development

■ 08:00 - 08:45

Chair: R. Plummer (United Kingdom)  
Speaker: H. Zwierzina (Austria)

#### Teaching Lecture: Epigenetics in Cancer Genesis

08:00 - 08:45

Chair: V. Jendrossek (Germany)  
Speaker: M. Esteller (Spain)

### Scientific Symposium: New Drugs on the Horizon I

■ 09:15 - 10:45

Chair: J.H.M. Schellens (Netherlands)  
Co-Chair: W. Eberhardt (Germany)

#### Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What's next?

Speaker: C. Blank (Netherlands)

#### Lung cancer: New targets, new drugs, will we eventually even improve survival?

Speaker: M. O'Brien (United Kingdom)

#### Myelodysplastic syndrome: The epigenetic model for drug development?

Speaker: G. Garcia-Manero (USA)

#### Discussion & Roundup

#### Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

■ 09:15-11:15

Chair: B. Van den Eynde (Belgium)

#### Role of the immune system on the outcome of cancer therapy

Speaker: G. Coukos (Switzerland)

#### How does ionising radiation contribute to the induction of anti-tumour immunity?

Speaker: G. Multhoff (Germany)

#### Targeting tumour microenvironment

Speaker: P. Allavena (Italy)

#### Adoptive cell therapy

Speaker: R. Hawkins (United Kingdom)

#### Discussion & Roundup

### Special Session: Reducing the Size of the Drug Development Graveyard

■ 11:30 - 12:30

Chair: C. Vens (Netherlands)

#### Considering resistance mechanisms and genetic tumour context

Speaker: R. Bernards (Netherlands)

#### Drug development approaches and inconsistencies in pharmacogenomics studies

Speaker: J. Quackenbush (USA)

#### Good drugs, bad trials

Speaker: R. Plummer (United Kingdom)

Discussion

### Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer

■ 17:00 - 18:30

Chair: A. Børresen-Dale (Norway)  
Co-Chair: C. Caldas (United Kingdom)

#### Inference of tumour evolution during chemotherapy

Speaker: S. Aparicio (Canada)

#### Heterogeneity and treatment failure in HER2 positive breast cancers

Speaker: L. Carey (USA)

#### Role of liquid vs solid biopsies in monitoring treatment

Speaker: C. Caldas (United Kingdom)

#### New frontiers in molecular imaging to improve targeting of high risk disease

Speaker: E.G.E. De Vries (Netherlands)

#### Discussion & Roundup

### Scientific Symposium: Onco-Immunology in Brain Tumours

■ 17:00 - 18:30

Chair: R. Stupp (Switzerland)  
Co-Chair: S. Combs (Germany)

#### The immune microenvironment in gliomas: scientific concepts

Speaker: M. Platten (Germany)

### Immunotherapy biomarkers in extracranial tumours and their potential role in brain tumours

Speaker: M. Preusser (Austria)

#### Immunotherapy- response assessment in extracranial tumours and potential issues in brain tumours

Speaker: D. Reardon (USA)

#### Immunotherapy - current trials

Speaker: M. Weller (Switzerland)

#### Discussion & Roundup

### Scientific Symposium: Novel Look to Chronic Lymphoid Leukaemia

■ 17:00 - 18:30

Chair: M. Ladetto (Italy)  
Co-Chair: A. Osterborg (Sweden)

#### The molecular basis of CLL

Speaker: G. Gaidano (Italy)

#### The CLL microenvironment

Speaker: J.G. Gribben (United Kingdom)

#### First line treatment

Speaker: T. R. Robak (Poland)

#### Treatment for relapse/refractory disease

Speaker: J. Delgado (Spain)

#### Discussion & Roundup

## MONDAY 28 SEPTEMBER 2015

### Teaching Lecture: Functional Screening for New Drug Discovery in Colorectal Cancer

■ 08:00 - 08:45

Chair: F. Ciardiello (Italy)  
Speaker: R. Bernards (Netherlands)

### Teaching Lecture: How Can We Address Tumour Heterogeneity and Clonal Evolution When Treating Cancer?

■ 08:00 - 08:45

Chair: L. Carey (US)  
Speaker: N. McGranahan (United Kingdom)

### Integrated Session: Novel Approaches to Brain Metastases

■ 09:15 - 11:15

Chair: S. Combs (Germany)  
Co-Chair: A. Eniu (Romania)

#### Biology of brain metastases

Speaker: P.S. Steeg (USA)

#### Novel systemic therapy approaches to brain metastases: Lung

Speaker: S. Popat (United Kingdom)

#### Novel systemic therapy approaches to brain metastases: Breast

Speaker: M. Preusser (Austria)

#### Novel systemic therapy approaches to brain metastases: Melanoma

Speaker: D. Schadendorf (Germany)

#### Advances in loco-regional treatments

Speaker: M. Brada (United Kingdom)

#### Tolerability of brain metastasis treatments

Speaker: R. Soffietti (Italy)

#### Response assessment in brain metastases

Speaker: N. Lin (USA)

#### Discussion & Roundup

### Scientific Symposium: New Drugs on the Horizon II

■ 09:15 - 10:45

Chair: E. Raymond (Switzerland)  
Co-Chair: M.E. Scheulen (Germany)

#### TNBC: Biomarkers and opportunities for individualised therapy

Speaker: F. Cardoso (Portugal)

#### Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?

Speaker: B. Tombal (Belgium)

#### Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

#### Discussion & Roundup

### Scientific Symposium: Evolving Concepts in T-Cell Lymphomas

■ 09:15 - 10:45

Chair: N. Schmitz (Germany)  
Co-Chair: S.A. Pileri (Italy)

#### Biology of T-cell lymphoma

Speaker: P. Gaulard (France)

#### Frontline treatment

Speaker: F.A. D'Amore (Denmark)

#### Relapsed disease

Speaker: O. O'Connor (USA)

#### Transplantation in T-cell lymphoma

Speaker: P. Corradini (Italy)

#### Discussion & Roundup

### Special Session: Biomarkers in Melanoma

■ 11:30 - 12:30

Chair: H. Gogas (Greece)

#### Immunotherapy: Is there any predictive biomarkers?

Speaker: L. Zitvogel (France)

#### The role circulating tumour cells in melanoma

Speaker: C. Dive (United Kingdom)

#### cfDNA

Speaker: A. Thierry (France)

#### Discussion

### Special Session: The Molecular and Histological Classification of Gastro-Oesophageal Cancer: Implications for Treatment

■ 11:30 - 12:30

Chair: M. Hidalgo (Spain)

#### Re-classification of OG Cancer through distinct molecular phenotypes

Speaker: A. Bass (USA)

#### Implication for therapeutic exploitation

Speaker: D. Cunningham (United Kingdom)

#### Tailored surgical approach

Speaker: F. Roviello (Italy)

#### Discussion

### Special Session: Genetic Traits for Myeloid Malignancies

■ 11:30 - 12:30

Chair: J. Stary (Czech Republic)

#### Current concepts for familial AML

Speaker: J. Fitzgibbon (United Kingdom)

#### GATA2 deficiency

Speaker: M. Wlodarski (Germany)

#### Genetic counselling

Speaker: B. Schlegelberger (Germany)

#### Discussion

### Special Session: Immunotherapy of Paediatric Malignancies

■ 11:30 - 12:30

Chair: M. Schrappe (Germany)

#### CAR T cell targeting of childhood cancers

Speaker: C. Rossig (Germany)

#### Are PD1 and PDL1 relevant targets in paediatric malignancies?

Speaker: J. Gray (United Kingdom)

#### Discussion

### Roundtable: Oncology Drug Development in the Era of Genomic Sequencing

■ 13:00 - 14:30

Chair: J.C. Soria (France)

#### Academic perspective

Speaker: D. Solit (USA)

#### Industry perspective

Speaker: A. Riva (USA)

#### FDA perspective

Speaker: P. Cortazar (USA)

#### EMA perspective

Speaker: F. Pignatti (United Kingdom)

#### Patient advocate perspective

Speaker: J. Gore-Booth (France)

#### Paediatric oncologist perspective

Speaker: R. Ladenstein (Austria)

#### Discussion

### Special Session: How to Use Omics Data for Precision Radiation Oncology

■ 15:15 - 16:15

Chair: D. Zips (Germany)

#### How to bring "radio-omics" and functional tests in the clinic

Speaker: B. Wouters (Canada)

#### Systems biology for precision radiation oncology: Moving between the forest and the trees

Speaker: Y. Shiloh (Israel)

#### Implications of new knowledge for trial design

Speaker: A.H. Ree (Norway)

#### Discussion

**Special Session: The Prerequisite for Ideal Biobanking**

■ 15:15 - 16:15

*Chair: J. Dillner (Sweden)*

**How much is important for the basic research the material and the dataset?**  
*Speaker: F. Carneiro (Portugal)*

**From the operating room to the laboratory. The value of surgery standardisation and data collection in a tissue bank**  
*Speaker: G. Corso (Italy)*

**Interventional radiologist (please suggest your title)**  
*Speaker: J. Futterer (Netherlands)*

**Discussion**

**Scientific Symposium: Evolution of Targeted Therapies in Lung Cancer: Where Are We Today and Where Are We Going?**

■ 17:00 - 18:30

*Chair: R. Buettner (Germany)*  
*Co-Chair: S. Popat (United Kingdom)*

**Targeted treatment in squamous cell lung cancer**  
*Speaker: J. Wolf (Germany)*

**EGFR Inhibition - current status and future perspectives**  
*Speaker: T. Mok (China)*

**ALK Inhibition - current status and future perspectives**  
*Speaker: A.T. Shaw (USA)*

**Beyond EGFR and ALK - future targets**  
*Speaker: S. Peters (Switzerland)*

**Discussion & Roundup****Scientific Symposium: Mechanisms of Resistance to Targeted Therapies**

■ 17:00 - 18:30

*Chair: R. Marais (United Kingdom)*  
*Co-Chair: D. Schadendorf (Germany)*

**BRAF signalling in melanoma**  
*Speaker: R. Marais (United Kingdom)*

**Signalling networks and resistance**  
*Speaker: R. Dummer (Switzerland)*

**Metabolism and resistance**  
*Speaker: D. Peeper (Netherlands)*

**Mechanisms and resistance**  
*Speaker: G. Long (Australia)*

**Discussion & Roundup**

**Scientific Symposium: Biology Based Selected Drugs in Ovarian Cancer Treatment**

■ 17:00 - 18:30

*Chair: R. Giavazzi (Italy)*  
*Co-Chair: I.B. Vergote (Belgium)*

**Drug acting on ovarian cancer cells and tumour microenvironment**  
*Speaker: M. D'Incalci (Italy)*

**Folate receptor blockers**  
*Speaker: I.B. Vergote (Belgium)*

**Treatment opportunities for homologous recombinant deficiency (PARP Inhibitors)**  
*Speaker: S. Banerjee (United Kingdom)*

**Immunotherapy opportunities in ovarian cancer**  
*Speaker: G. Coukos (Switzerland)*

**Discussion & Roundup**

**Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics**

■ 17:00 - 18:30

*Chair: S. Litière (Belgium)*  
*Co-Chair: L.L. Siu (Canada)*

**Pharmacologic biomarkers in the development of stratified cancer medicine**  
*Speaker: H. Newell (United Kingdom)*

**One size doesn't fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer**  
*Speaker: M. Buyse (Belgium)*

**Companion diagnostic co-development in personalised medicine (including circulating tumour cells)**  
*Speaker: L.L. Siu (Canada)*

**Is MRD a valid surrogate endpoint for evaluation of new drugs in leukaemia?**  
*Speaker: M.G. Valsecchi (Italy)*

**Discussion & Roundup****TUESDAY 29 SEPTEMBER 2015**

**Scientific Symposium: Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy**

■ 09:00 - 10:30

*Chair: M.A. Colleoni (Italy)*  
*Co-Chair: S.A.W. Fuqua (USA)*

**How to optimise endocrine sequence in luminal breast cancer**  
*Speaker: S.A.W. Fuqua (USA)*

**Introducing mTOR and PI3K inhibitors**  
*Speaker: M. Martin (Spain)*

**Genomics and response to endocrine therapies**  
*Speaker: M. Ellis (USA)*

**Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy**  
*Speaker: F. Cardoso (Portugal)*

**Discussion & Roundup**

**Integrated Session: Immunotherapy in NSCLC - 2015**

■ 09:00 - 11:00

*Chair: L. Paz-Ares (Spain)*  
*Co-Chair: M. Reck (Germany)*

**Introduction**  
*Speaker: L. Paz-Ares (Spain)*

**Lung cancer: An immunogenic tumour?**  
*Speaker: S.A. Quezada (United Kingdom)*

**Any place for vaccination strategies?**  
*Speaker: J. Vansteenkiste (Belgium)*

**Check point inhibitors - where do we stand and where are we going?**  
*Speaker: M. Reck (Germany)*

**Biomarkers - a realistic perspective?**  
*Speaker: K. Kerr (United Kingdom)*

**Discussion & Roundup**

**Integrated Session: Immunotherapy in the Management of Metastatic Melanoma**

■ 09:00 - 11:00

*Chair: A.M.M. Eggermont (France)*  
*Co-Chair: P.A. Ascierto (Italy)*

**Introduction**  
*Speaker: A.M.M. Eggermont (France)*

**Biomarkers for the complex biology of melanoma immunotherapy**  
*Speaker: C. Robert (France)*

**Immunogens and immunostimulatory monoclonal antibodies**  
*Speaker: I. Melero (Spain)*

**Melanoma targeted therapies in the interface with immunotherapy**  
*Speaker: A. Ribas (USA)*

**Virotherapy and immunotherapy**  
*Speaker: A. Melcher (United Kingdom)*

**Discussion & Roundup**

**Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit**

■ 09:00 - 10:30

*Chair: P. Poortmans (Netherlands)*  
*Co-Chair: D. Georg (Austria)*

**How can protons contribute to radiation oncology**  
*Speaker: M. Schwarz (Italy)*

**Might it be heavier? Irradiation with carbon and other ions**  
*Speaker: R. Orecchia (Italy)*

**How to get most out of photon based radiation therapy**  
*Speaker: D. Verellen (Belgium)*

**MR-Linac is a way to improve treatment delivery**  
*Speaker: M. Van Vulpen (Netherlands)*

**Discussion & Roundup****Educational Symposium: Common Approaches & Pathways in Adult and Paediatric Malignancies**

■ 09:00 - 11:00

*Chair: R. Riccardi (Italy)*

**AML biology in adults and children**  
*Speaker: M. Van den Heuvel (Netherlands)*

**Data mining in cancer: Interim's report from p-Medicine**  
*Speaker: N. Graf (Germany)*

**Targeting osteosarcoma: What is different between adult and paediatric patients?**  
*Speaker: S. Bielack (Germany)*

**Robust endpoints when evaluating novel "targeted" therapies**  
*Speaker: M.G. Valsecchi (Italy)*

**Discussion & Roundup**

**Special Session: Resistance in Patients with Oncogenic Alterations**

■ 11:15 - 12:15

*Chair: D.R. Camidge (USA)*

**Tumour cells heterogenetics evolution**  
*Speaker: C. Swanton (United Kingdom)*

**Overcoming resistance in patients with ALK translocations**  
*Speaker: D.R. Camidge (USA)*

**Perspectives in management of EGFR resistance**  
*Speaker: F. Cappuzzo (Italy)*

**Discussion**

**Special Session: Immunotherapy in Genitourinary Cancer**

■ 11:15 - 12:15

*Chair: B. Escudier (France)*

**Basic science of immunotherapy**  
*Speaker: C. Drake (USA)*

**Immunotherapy in renal cancer**  
*Speaker: T. Powles (United Kingdom)*

**Immunotherapy in genitourinary cancer**  
*Speaker: W.R. Gerritsen (Netherlands)*

**Discussion****BREAST CANCER - EARLY DISEASE AND ADVANCED DISEASE****SATURDAY 26 SEPTEMBER 2015**

**Teaching Lecture: Surgery for Bone Metastases: Indications, Techniques and Outcomes**

■ 07:45 - 08:30

*Chair: R.A. Audisio (United Kingdom)*  
*Speaker: R. Ashford (United Kingdom)*

**Molecular Screening Tumour Board: Breast Cancer**

■ 15:15 - 16:15

*Chair: To be announced*

**Case presentation by young oncologist**  
*Speaker: D. T'Kint de Roodenbeke (Belgium)*

**Panel Discussion**

**Molecular Oncologist**  
*Panel: R. Bernards (Netherlands)*

**Basic Scientist**  
*Panel: C. Desmedt (Belgium)*

**Medical Oncologist**  
*Panel: To be announced*

**Geneticist**  
*Panel: A. Irrthum (Belgium)*

**Educational Symposium: What is the Optimal Endocrine Therapy in Premenopausal Women with Early Breast Cancer**

■ 16:45 - 18:45

*Chair: F. André (France)*

**What is the definition of an ER+ breast cancer?**  
*Speaker: J. Reis-Filho (United Kingdom)*

**Which endocrine therapy for a premenopausal woman with ER+/Her2+++ disease? Update on TEKST and SOFT trials**  
*Speaker: V. Tjan-Heijnen (Netherlands)*

**Unusual molecular and clinical profiles: ER+ 1-10%, ER-/PR+ and large tumours in premenopausal women**  
*Speaker: J. Bergh (Sweden)*



### Pregnancy and adjuvant endocrine therapy: Is there any window for opportunity?

Speaker: S. Loibl (Germany)

### Discussion & Roundup

## SUNDAY 27 SEPTEMBER 2015

### Teaching Lecture: Recent Developments in the Treatment of Metastatic Breast Cancer: Translational Aspects

■ 08:00 - 08:45

Chair: A. Di Leo (Italy)  
Speaker: C.C. Zielinski (Austria)

### Multidisciplinary Tumour Board: Breast Cancer

■ 11:30 - 12:30

Chair: P. Poortmans (Netherlands)

### Case presentation by young oncologist: Early disease

Speaker: I. Kindts (Belgium)

### Panel Discussion: Early disease

### Case presentation by young oncologist: Locally advanced disease

Speaker: E. Vicini (Italy)

### Panel Discussion: Locally advanced disease

### Case presentation by young oncologist: Advanced disease

Speaker: M.V. Dieci (Italy)

### Panel Discussion: Advanced disease

### Pathologist

Panel: H.G. Russnes (Norway)

### Medical Oncologist

Panel: F. Cardoso (Portugal)

### Surgical Oncologist

Panel: I.T. Rubio (Spain)

### Pathologist

Panel: J. Reis-Filho (United Kingdom)

### Medical Oncologist

Panel: M. Campone (France)

### Oncology Nurse

Panel: Y. Wengström (Sweden)

### Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer

■ 17:00 - 18:30

Chair: A. Børresen-Dale (Norway)  
Co-Chair: C. Caldas (United Kingdom)

### Inference of tumour evolution during chemotherapy

Speaker: S. Aparicio (Canada)

### Heterogeneity and treatment failure in HER2 positive breast cancers

Speaker: L. Carey (USA)

### Role of liquid vs solid biopsies in monitoring treatment

Speaker: C. Caldas (United Kingdom)

### New frontiers in molecular imaging to improve targeting of high risk disease

Speaker: E.G.E. De Vries (Netherlands)

### Discussion & Roundup

## MONDAY 28 SEPTEMBER 2015

### Integrated Session: Novel Approaches to Brain Metastases

■ 09:15 - 11:15

Chair: S. Combs (Germany)  
Co-Chair: A. Eniu (Romania)

### Biology of brain metastases

Speaker: P.S. Steeg (USA)

### Novel systemic therapy approaches to brain metastases: Lung

Speaker: S. Popat (United Kingdom)

### Novel systemic therapy approaches to brain metastases: Breast

Speaker: M. Preusser (Austria)

### Novel systemic therapy approaches to brain metastases: Melanoma

Speaker: D. Schadendorf (Germany)

### Advances in loco-regional treatments

Speaker: M. Brada (United Kingdom)

### Tolerability of brain metastasis treatments

Speaker: R. Soffietti (Italy)

### Response assessment in brain metastases

Speaker: N. Lin (USA)

### Discussion & Roundup

### Society Session: European Society of Breast Cancer Specialists (EUSOMA)

■ 09:15 - 11:15

Chair: M. Leidenius (Finland)  
Chair: L. Wyld (United Kingdom)

### Radiotherapy and DCIS

Speaker: B. Cutuli (France)

### What are the chemoprevention options for high risk woman?

Speaker: J. Cuzick (United Kingdom)

### Treating positive nodes in the axilla

Speaker: C. Markopoulos (Greece)

### How much oncoplastic surgery?

Speaker: R.E. Mansel (United Kingdom)

### Should we tailor adjuvant therapy to specific sub-types?

Speaker: L. Biganzoli (Italy)

### Genetic counselling for women with DCIS and positive family history

Speaker: B. Bonanni (Italy)

### Discussion

### Debate: This House Believes that Mammographic Screening Should Be Discontinued

■ 11:30 - 12:30

Moderator: M. Rosselli del Turco (Italy)  
Speaker in favour: P. Zahl (Norway)  
Speaker against: D.A. Cameron (United Kingdom)  
Seconder in favour: G. Liefers (Netherlands)  
Seconder against: B. Borisch (Switzerland)

### Discussion & Voting

### Scientific Symposium: New Techniques in Avoiding Overtreatment in Early Breast Cancer

■ 17:00 - 18:30

Chair: M. Leidenius (Finland)  
Co-Chair: A. Di Leo (Italy)

### Avoiding surgery in DCIS: How can we select low risk disease

Speaker: A. Francis (United Kingdom)

### Minimising harm and maximising benefit with radiotherapy: New horizons

Speaker: C.E. Coles (United Kingdom)

### Reversing escalation of antiHER2 therapy in early breast cancer

Speaker: M. Piccart (Belgium)

### Adjuvant systemic therapy: Could it be less intensive?

Speaker: M.A. Colleoni (Italy)

### Discussion & Roundup

## TUESDAY 29 SEPTEMBER 2015

### Teaching Lecture: Staging the Axilla: Imaging and Sentinel Node Technologies

■ 08:00 - 08:45

Chair: L. Wyld (United Kingdom)  
Speaker: I.T. Rubio (Spain)

### Scientific Symposium: Optimal Treatment of Luminal Breast Cancer: Emerging Data on Improving Response to Hormone Therapy

■ 09:00 - 10:30

Chair: M.A. Colleoni (Italy)  
Co-Chair: S.A.W. Fuqua (USA)

### How to optimise endocrine sequence in luminal breast cancer

Speaker: S.A.W. Fuqua (USA)

### Introducing mTOR and PI3K inhibitors

Speaker: M. Martin (Spain)

### Genomics and response to endocrine therapies

Speaker: M. Ellis (USA)

### Role of cyclin-dependent kinase 4/6 inhibitors in endocrine therapy

Speaker: F. Cardoso (Portugal)

### Discussion & Roundup

### Special Session: Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer

■ 11:15 - 12:15

Chair: P. Poortmans (Netherlands)

### Expanding the range of gene testing as next generation sequencing enters clinical practice

Speaker: F. Fostira (Greece)

### Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy

Speaker: O. Gentilini (Italy)

### Tailoring chemotherapy for hereditary breast cancer carriers

Speaker: A. Tutt (United Kingdom)

### Discussion

## CANCER IN ELDERLY

## SATURDAY 26 SEPTEMBER 2015

### Scientific Symposium: Managing Older People with Cancer and Other Co-Morbidities - An Increasing Challenge

■ 16:45 - 18:15

Chair: M. Wells (United Kingdom)  
Co-Chair: L. Sharp (Sweden)

### New models of follow-up for increasingly complex patient profiles

Speaker: G. Catania (Italy)

### Meeting complex care needs in the clinic. The example of polypharmacy

Speaker: F. Van den Berkmortel (Netherlands)

### The importance of appropriate assessment for older people with cancer

Speaker: C. Kenis (Belgium)

### Being innovative to support older people with cancer in clinical settings

Speaker: I. Rahm Hallberg (Sweden)

### Discussion & Roundup

## MONDAY 28 SEPTEMBER 2015

### Educational Symposium: Combined Modality Treatment in Elderly with Bladder Cancer

■ 09:15 - 11:15

Chair: J. Droz (France)

### Hazards of radical cystectomy in the elderly

Speaker: M. Brausi (Italy)

### Carboplatin based chemotherapy

Speaker: M. De Santis (Austria)

### Reducing the toxicity of radiotherapy

Speaker: R. Huddart (United Kingdom)

### Combined modality treatment put into context for practice

Speaker: J. Droz (France)

### Discussion & Roundup

### Special Session: The Right Surgery for the Right Patient: Predictions & Outcomes

■ 15:15 - 16:15

Chair: T. Gruenberger (Austria)

### Selection for risk reduction surgery in hereditary syndromes

Speaker: To be announced

### Individualised treatment for older cancer patients

Speaker: R.A. Audisio (United Kingdom)

### Have guidelines improved outcomes or not?

Speaker: S. Sandrucci (Italy)

### Discussion

### Scientific Symposium: The Challenges of Treating the Older Patient with Upper GI Cancer

■ 17:00 - 18:30

Chair: M. Aapro (Switzerland)  
Co-Chair: D. Papamichael (Cyprus)

### Assessing patients for treatment

Speaker: S.R. Rostoft (Norway)

### The oncologist's perspective

Speaker: S. Al-Batran (Germany)

### Are you ever too old for complex upper GI surgery?

Speaker: W. Allum (United Kingdom)

### A radiotherapist perspective

Speaker: A.G. Morganti (Italy)

### Discussion & Roundup



**TUESDAY 29 SEPTEMBER 2015****Special Session: Clinical Challenges in Adjuvant Therapy in Rectal and Colon Cancer**

■ 11:15 - 12:15

*Chair: A. Cervantes (Spain)***Adjuvant therapy in rectal cancer**  
*Speaker: K. Haustermans (Belgium)***Adjuvant therapy in the elderly**  
*Speaker: D. Papamichael (Cyprus)***Adjuvant therapy in stage II colon cancer**  
*Speaker: J. Taieb (France)***Discussion****CANCER PREVENTION AND SCREENING****SUNDAY 27 SEPTEMBER 2015****Special Session: HPV Vaccine for Cancer Prevention**

■ 15:15 - 16:15

*Chair: K. Soldan (United Kingdom)***Achieving high coverage of HPV vaccination**  
*Speaker: X. Bosch (Spain)***Vaccination of boys/young males**  
*Speaker: R. Herrero (France)***Preclinical vaccines**  
*Speaker: C.J.M. Melief (Netherlands)***Discussion****Scientific Symposium: Personalised Screening and Preventative Strategies**

■ 17:00 - 18:30

*Chair: C. La Vecchia (Italy)*  
*Co-Chair: P. Autier (France)***Integrating breast density into classic risk models**  
*Speaker: J. Cuzick (United Kingdom)***De-code genetic analysis of the population**  
*Speaker: K. Stefansson (Iceland)***How best to deliver risk assessment: When and where?***Speaker: A. Howell (United Kingdom)***How do we increase utilisation of preventative strategies***Speaker: A.D. Baildam (United Kingdom)***Discussion & Roundup****MONDAY 28 SEPTEMBER 2015****Special Session: Role of Exercise in Cancer Prevention and Management**

■ 15:15 - 16:15

*Chair: M. Harvie (United Kingdom)***Exercise and cancer – mechanisms and interventions**  
*Speaker: C. Ulrich (Germany)***How acceptable is exercise intervention to cancer patients**  
*Speaker: C. Hudis (USA)***Body weight, exercise and colorectal cancer screening**  
*Speaker: A. Anderson (United Kingdom)***Discussion****CENTRAL NERVOUS SYSTEM****SATURDAY 26 SEPTEMBER 2015****Society Session: European Association of Neuro-Oncology (EANO) - New Tools and Toys in Neuro-Oncology**

■ 10:30 - 12:30

*Chair: R. Soffietti (Italy)*  
*Chair: M. Weller (Switzerland)***EANO Award**  
*Awardee: J.Y. Delattre (France)***Advanced molecular genetic diagnostics and the next WHO classification**  
*Speaker: G. Reifenberger (Germany)***New devices and strategies for brain tumour surgery**  
*Speaker: C. Watts (United Kingdom)***Tumour-treating fields***Speaker: R. Stupp (Switzerland)***Neurocognitive and patient-reported outcomes and quality of life***Speaker: M.J.B. Taphoorn (The Netherlands)***SUNDAY 27 SEPTEMBER 2015****Debate: This House Believes that MGMT Methylation Should Be Tested in All Patients with Malignant Gliomas**

■ 11:30 - 12:30

*Moderator: M.J. Van den Bent (Netherlands)*  
*Speaker in favour: M. Weller (Switzerland)*  
*Speaker against: G. Reifenberger (Germany)*  
*Seconder in favour: M. Hegi (Switzerland)*  
*Seconder against: M. Brada (United Kingdom)***Discussion & Voting****Scientific Symposium: Onco-Immunology in Brain Tumours**

■ 17:00 - 18:30

*Chair: R. Stupp (Switzerland)*  
*Co-Chair: S. Combs (Germany)***The immune microenvironment in gliomas: Scientific concepts**  
*Speaker: M. Platten (Germany)***Immunotherapy biomarkers in extracranial tumours and their potential role in brain tumours**  
*Speaker: M. Preusser (Austria)***Immunotherapy- response assessment in extracranial tumours and potential issues in brain tumours**  
*Speaker: D. Reardon (USA)***Immunotherapy - current trials**  
*Speaker: M. Weller (Switzerland)***Discussion & Roundup****MONDAY 28 SEPTEMBER 2015****Teaching Lecture: Antiangiogenic Therapies in Neuro-Oncology: Current State of Development**

■ 08:00 - 08:45

*Chair: R. Soffietti (Italy)*  
*Speaker: W. Wick (Germany)***Integrated Session: Novel Approaches to Brain Metastases**

■ 09:15 - 11:15

*Chair: S. Combs (Germany)*  
*Co-Chair: A. Eniu (Romania)***Biology of brain metastases**  
*Speaker: P.S. Steeg (USA)***Novel systemic therapy approaches to brain metastases: Lung**  
*Speaker: S. Popat (United Kingdom)***Novel systemic therapy approaches to brain metastases: Breast**  
*Speaker: M. Preusser (Austria)***Novel systemic therapy approaches to brain metastases: Melanoma**  
*Speaker: D. Schadendorf (Germany)***Advances in loco-regional treatments**  
*Speaker: M. Brada (United Kingdom)***Tolerability of brain metastasis treatments**  
*Speaker: R. Soffietti (Italy)***Response assessment in brain metastases**  
*Speaker: N. Lin (USA)***Discussion & Roundup****Special Session: Advances in the Management of Low Grade Gliomas**

■ 11:30 - 12:30

*Chair: C. Watts (United Kingdom)***The importance of extent of resection**  
*Speaker: J. Tonn (Germany)***Does an optimal chemotherapy treatment exist in adults?**  
*Speaker: R. Soffietti (Italy)***Radiotherapy techniques and indications for the treatment of low grade gliomas**  
*Speaker: S. Combs (Germany)***Discussion****Integrated Session: Medulloblastoma**

■ 16:45 - 18:45

*Chair: S.J. Rutkowski (Germany)*  
*Co-Chair: B. Geoerger (France)***Introduction**  
*Speaker: S.J. Rutkowski (Germany)***Molecular classification of medulloblastoma**  
*Speaker: S. Pfister (Germany)***Current concepts and future directions in pharmacotherapy of medulloblastoma**  
*Speaker: B. Geoerger (France)***Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOP-Europe PNET working group**  
*Speaker: S.J. Rutkowski (Germany)***Optimising efficacy and limiting toxicity of radiotherapy for medulloblastoma**  
*Speaker: S. Combs (Germany)***Management of adult medulloblastoma - using the evidence from children and adolescents**  
*Speaker: A.A. Brandes (Italy)***Discussion & Roundup****CLINICAL TRIAL DESIGNS AND REGULATORY AFFAIRS****SATURDAY 26 SEPTEMBER 2015****Society Session: European Society of Oncology Pharmacy (ESOP)**

■ 16:45 - 18:15

*Chair: K. Meier (Germany)***ESOP-ESMO Drug shortage survey**  
*Speaker: M. Saar (Estonia)*  
*Speaker: G. Wiedemann (Germany)***EPIC project on oral chemotherapy**  
*Speaker: A. Eberl (Slovenia)***Pharmacovigilance in Slovenia**  
*Speaker: M. Sonc (Slovenia)***Cytotoxic contamination project**  
*Speaker: E. Korczowska (Poland)***Centres of exchange**  
*Speaker: C. Bardin (France)**Klaus Meier Award***SUNDAY 27 SEPTEMBER 2015****Special Session: How to Pay for New “Innovative” Anticancer Drugs?**

11:30 - 12:30

*Chair: A. Astier (France)***A new way to pay high costly drugs: Payment for the performance**  
*Speaker: F. Megerlin (France)***Does the claims of “innovation” of new anticancer drugs justify their too high costs?**  
*Speaker: G.J. Wiedemann (Germany)***Cost constraints in cancer treatment: What can nations do?**  
*Speaker: P. Cornes (United Kingdom)***Discussion**

### Special Session: Values and Perspectives on the Role of Hospital Pharmacists' Contribution to Clinical Research

■ 13:00 – 14:00

Chair: K. Meier (Germany)

#### Managing investigational medicinal products: The hospital pharmacist perspective

Speaker: To be announced

#### How can sponsors facilitate quality of IMPs management at the hospital pharmacy

Speaker: C. de Balincourt (Belgium)

#### Discussion

### Special Session: Oncology Pharmacy Aspects of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

■ 15:15 - 16:15

Chair: K. Meier (Germany)

#### Safe handling considerations in HIPEC

Speaker: I. Netikova (Czech Republic)

#### Pharmacokinetic aspects of HIPEC

Speaker: A. Paci (France)

#### State of the art of HIPEC clinical benefits

Speaker: L. Petruzella (Czech Republic)

#### Discussion

### Scientific Symposium: Therapeutic Drug Monitoring in Cancer

■ 17:00 - 18:30

Chair: A. Astier (France)

Co-Chair: C. Csajka (Switzerland)

#### TDM of cytotoxic drugs

Speaker: E. Chatelut (France)

#### Is it useful to follow drug levels for targeted therapies?

Speaker: G. Veal (United Kingdom)

#### TDM of monoclonal antibodies: State of the art

Speaker: C. Csajka (Switzerland)

#### TDM in pediatric oncology

Speaker: A. Paci (France)

#### Discussion & Roundup

## MONDAY 28 SEPTEMBER 2015

### Special Session: The Quality of Reporting Clinical Trials

■ 11:30 - 12:30

Chair: C. Dittrich (Austria)

#### Why the reported results of clinical trials are often false

Speaker: To be announced

#### Under-reporting of harm in clinical trials

Speaker: B. Seruga (Slovenia)

#### Use and misuse of efficacy endpoints in phase III trials

Speaker: J. Douillard (France)

#### Discussion

### Special Session: Evaluating Clinical Benefit of Cancer Drugs across Tumours

■ 15:15 - 16:15

Chair: E.G.E. De Vries (Netherlands)

#### Clinical benefit scale: The European proposal

Speaker: M. Piccart (Belgium)

#### Clinical benefit scale: The challenge of fairness

Speaker: U. Dafni (Greece)

#### Clinical benefit scale: The EMA opinion

Speaker: F. Pignatti (United Kingdom)

#### The effect of CBS on patient care: The patient's perspective

Speaker: K. Oliver (United Kingdom)

#### Discussion

### Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

17:00 - 18:30

Chair: S. Litière (Belgium)

Co-Chair: L.L. Siu (Canada)

#### Pharmacologic biomarkers in the development of stratified cancer medicine

Speaker: H. Newell (United Kingdom)

#### One size doesn't fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer

Speaker: M. Buyse (Belgium)

#### Companion diagnostic co-development in personalised medicine (including circulating tumour cells)

Speaker: L.L. Siu (Canada)

#### Is MRD a valid surrogate endpoint for evaluation of new drugs in leukaemia?

Speaker: M.G. Valsecchi (Italy)

#### Discussion & Roundup

## TUESDAY 29 SEPTEMBER 2015

### Scientific Symposium: Bayesian, Adaptive and Rare Disease Designs

■ 09:00 - 10:30

Chair: U. Dafni (Greece)

Co-Chair: B. Ryll (Sweden)

#### Design in rare disease: The oncologist perspective

Speaker: P.G. Casali (Italy)

#### Implementing innovative trial design in small patient populations in childhood cancers

Speaker: K. Wheatley (United Kingdom)

#### Pitfalls and advantages of using adaptive trial designs in phase III trials

Speaker: M. Mauer (Belgium)

#### Multi-arm, multi-stage designs: Are they deliverable?

Speaker: M. Sydes (United Kingdom)

#### Discussion & Roundup

### Special Session: The Global Impact of the EU Paediatric Regulation across All Ages

■ 11:15 - 12:15

Chair: P. Kearns (United Kingdom)

#### Implementing the Paediatric Regulation: Lessons learnt from the first 5 years?

Speaker: R. Herold (United Kingdom)

#### Unintended consequences of regulatory initiatives in childhood and adult cancer drug development

Speaker: P. Adamson (USA)

#### The Paediatric Regulation: Force for good or evil for cancer drug development?

Speaker: G. Vassal (France)

#### Discussion

## EARLY DRUG DEVELOPMENT

## SUNDAY 27 SEPTEMBER 2015

### Teaching Lecture: Use of the Preoperative Window for Early Drug Development

■ 08:00 - 08:45

Chair: R. Plummer (United Kingdom)

Speaker: H. Zwierzina (Austria)

### Scientific Symposium: New Drugs on the Horizon I

■ 09:15 - 10:45

Chair: J.H.M. Schellens (Netherlands)

Co-Chair: W. Eberhardt (Germany)

#### Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What's next?

Speaker: C. Blank (Netherlands)

#### Lung cancer: New targets, new drugs, will we eventually even improve survival?

Speaker: M. O'Brien (United Kingdom)

#### Myelodysplastic syndrome: The epigenetic model for drug development?

Speaker: G. Garcia-Manero (USA)

#### Discussion & Roundup

### Special Session: Reducing the Size of the Drug Development Graveyard

■ 11:30 - 12:30

Chair: C. Vens (Netherlands)

#### Considering resistance mechanisms and genetic tumour context

Speaker: R. Bernards (Netherlands)

#### Drug development approaches and inconsistencies in pharmacogenomics studies

Speaker: J. Quackenbush (USA)

#### Good drugs, bad trials

Speaker: R. Plummer (United Kingdom)

#### Discussion

### Debate: This House Believes that Single Agent Activity is Required for Development in Combination Therapy

■ 15:15 - 16:15

Moderator: R. Salazar (Spain)

Speaker in favour: T. Yap (United Kingdom)

Speaker against: J.H.M. Schellens (Netherlands)

Seconder in favour: J.C. Soria (France)

Seconder against: A. Chalmers (United Kingdom)

#### Discussion & Voting

## MONDAY 28 SEPTEMBER 2015

### Scientific Symposium: New Drugs on the Horizon II

■ 09:15 - 10:45

Chair: E. Raymond (Switzerland)

Co-Chair: M.E. Scheulen (Germany)

#### TNBC: Biomarkers and opportunities for individualised therapy

Speaker: F. Cardoso (Portugal)

#### Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?

Speaker: B. Tombal (Belgium)

#### Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

#### Discussion & Roundup

## GASTROINTESTINAL MALIGNANCIES - COLORECTAL CANCER

## SATURDAY 26 SEPTEMBER 2015

### Teaching Lecture: What We Know and What We Don't Know (Yet!) about Targeted Agents in Colorectal Cancer

07:45 - 08:30

Chair: C.J.A. Punt (Netherlands)

Speaker: G. Tortora (Italy)

### Scientific Symposium: New Insights in Colon Cancer

■ 16:45 - 18:15

Chair: D. Aust (Germany)

Co-Chair: P. Laurent Puig (France)

#### Biomarkers to guide therapy today, what to assess and how

Speaker: H. Van Krieken (Netherlands)

#### Novel insights into CRC biology

Speaker: S. Tejpar (Belgium)

#### The immune landscape of colon cancer

Speaker: J. Galon (France)

#### Novel insights on tumour adaptation and clinical implications

Speaker: E.S. Kopetz (USA)

#### Discussion & Roundup

## SUNDAY 27 SEPTEMBER 2015

### Debate: This House Believes that Supplementary Rectal Irradiation Can Avoid Surgery and Achieve more Complete Clinical Remission

11:30 - 12:30

Moderator: H. Rutten (Netherlands)

Speaker in favour: C. Rödel (Germany)

Speaker against: D. Sebag-Montefiore (United Kingdom)

Seconder in favour: C. Marijnen (Netherlands)

Seconder against: A. Martling (Sweden)

#### Discussion & Voting

### Educational Symposium: The Management of Advanced Colorectal Cancer

■ 16:45 - 18:45

Chair: E. Van Cutsem (Belgium)

#### First line induction therapy

Speaker: D. Arnold (Germany)

#### Maintenance therapy

Speaker: C.J.A. Punt (Netherlands)

#### Re-challenge: Early, as part of first line and late

Speaker: T. Andre (France)

#### Combined modality treatment

Speaker: T. Gruenberger (Austria)

#### Discussion & Roundup

### MONDAY 28 SEPTEMBER 2015

#### Teaching Lecture: Functional Screening for New Drug Discovery in Colorectal Cancer

■ 08:00 - 08:45

Chair: F. Ciardiello (Italy)

Speaker: R. Bernards (Netherlands)

#### Multidisciplinary Tumour Board: Gastrointestinal Malignancies - Colorectal Cancer

■ 11:30 - 12:30

Chair: G. Beets (Netherlands)

#### Case presentation by young oncologist: Early disease

Speaker: J.R. Van der Vorst (Netherlands)

#### Panel Discussion: Early disease

#### Case Presentation by young oncologist: Locally advanced disease

Speaker: F. Cellini (Italy)

#### Panel Discussion: Locally advanced disease

#### Case presentation by young oncologist: Advanced disease

Speaker: A. Hollebecque (France)

#### Panel Discussion: Advanced disease

#### Medical Oncologist

Panel: C. Koehne (Germany)

#### Radiation Oncologist

Panel: K. Haustermans (Belgium)

#### Pathologist

Panel: P. Quirke (United Kingdom)

#### Radiologist

Panel: G. Brown (United Kingdom)

#### Integrated Session: How to Personalise Treatment Modalities in Locally Advanced Rectal Cancer

■ 16:45 - 18:45

Chair: A.F. Sobrero (Italy)

Co-Chair: R.J. Heald (United Kingdom)

#### Introduction

Speaker: A.F. Sobrero (Italy)

#### By imaging

Speaker: G. Brown (United Kingdom)

#### By drug combination

Speaker: R. Glynne-Jones (United Kingdom)

#### By modulation radiotherapy volume and dose

Speaker: C. Marijnen (Netherlands)

#### By supporting decision tools

Speaker: V. Valentini (Italy)

#### Discussion & Roundup

### TUESDAY 29 SEPTEMBER 2015

#### Teaching Lecture: Rectal Cancer and the Role of Imaging in Treatment Planning

■ 08:00 - 08:45

Chair: V. Valentini (Italy)

Speaker: G. Beets (Netherlands)

#### Special Session: Clinical Challenges in Adjuvant Therapy in Rectal and Colon Cancer

11:15 - 12:15

Chair: A. Cervantes (Spain)

#### Adjuvant therapy in rectal cancer

Speaker: K. Haustermans (Belgium)

#### Adjuvant therapy in the elderly

Speaker: D. Papamichael (Cyprus)

#### Adjuvant therapy in stage II colon cancer

Speaker: J. Taieb (France)

#### Discussion

## GASTROINTESTINAL MALIGNANCIES - NONCOLORECTAL CANCER

### MONDAY 28 SEPTEMBER 2015

#### Special Session: The Molecular and Histological Classification of Gastro-Oesophageal Cancer: Implications for Treatment

■ 11:30 - 12:30

Chair: M. Hidalgo (Spain)

#### Re-classification of OG cancer through distinct molecular phenotypes

Speaker: A. Bass (USA)

#### Implication for therapeutic exploitation

Speaker: D. Cunningham (United Kingdom)

#### Tailored surgical approach

Speaker: F. Roviello (Italy)

#### Discussion

#### Debate: This House Believes that Neoadjuvant Therapy is a Promising Treatment in Resectable Pancreatic Cancer

■ 15:15 - 16:15

Moderator: J. Souglakos (Greece)

Speaker in favour: M. Falconi (Italy)

Speaker against: M. Benauides (Spain)

Seconder in favour: T. Brunner (Germany)

Speaker against: To be announced

#### Discussion & Voting

### Scientific Symposium: The Challenges of Treating the Older Patient with Upper GI Cancer

■ 17:00 - 18:30

Chair: M. Aapro (Switzerland)

Co-Chair: D. Papamichael (Cyprus)

#### Assessing patients for treatment

Speaker: S.R. Rostoft (Norway)

#### The oncologist's perspective

Speaker: S. Al-Batran (Germany)

#### Are you ever too old for complex upper GI surgery?

Speaker: W. Allum (United Kingdom)

#### A radiotherapist perspective

Speaker: A.G. Morganti (Italy)

#### Discussion & Roundup

## GENITOURINARY MALIGNANCIES - NON PROSTATE

### SUNDAY 27 SEPTEMBER 2015

#### Teaching Lecture: New Targets in Renal Cell Carcinoma: What Can We Expect for the Future?

■ 08:00 - 08:45

Chair: C.N. Sternberg (Italy)

Speaker: B. Escudier (France)

#### Scientific Symposium: Muscle Invasive Bladder Cancer

■ 17:00 - 18:30

Chair: T. De Reijke (Netherlands)

Co-Chair: C.N. Sternberg (Italy)

#### Biomarkers in bladder cancer

Speaker: J. Bellmunt (USA)

#### Surgical treatments: What is new?

Speaker: T. Lebreton (France)

#### Chemoradiotherapy

Speaker: N.D. James (United Kingdom)

#### Neo-adjuvant versus adjuvant treatment

Speaker: C.N. Sternberg (Italy)

#### Discussion & Roundup

### MONDAY 28 SEPTEMBER 2015

#### Educational Symposium: Combined Modality Treatment in Elderly with Bladder Cancer

■ 09:15 - 11:15

Chair: J. Droz (France)

#### Hazards of radical cystectomy in the elderly

Speaker: M. Brausi (Italy)

#### Carboplatin based chemotherapy

Speaker: M. De Santis (Austria)

#### Reducing the toxicity of radiotherapy

Speaker: R. Huddart (United Kingdom)

#### Combined modality treatment put into context for practice

Speaker: J. Droz (France)

#### Discussion & Roundup

#### Debate: This House Believes that All Patients with Stage I Testicular Cancer (Seminoma and Non-Seminoma) Should Go on Active Surveillance

■ 15:15 - 16:15

Moderator: S. Gillissen (Switzerland)

Speaker in favour: C. Kollmannsberger (Canada)

Speaker against: J. Beyer (Switzerland)

Seconder in favour: G. Daugaard (Denmark)

Seconder against: J. Aparicio Urtasun (Spain)

#### Discussion & Voting

### TUESDAY 29 SEPTEMBER 2015

#### Special Session: Immunotherapy in Genitourinary Cancer

■ 11:15 - 12:15

Chair: B. Escudier (France)

#### Basic science of immunotherapy

Speaker: C. Drake (USA)

#### Immunotherapy in renal cancer

Speaker: T. Powles (United Kingdom)

#### Immunotherapy in genitourinary cancer

Speaker: W.R. Gerritsen (Netherlands)

#### Discussion

## GENITOURINARY MALIGNANCIES - PROSTATE

### SATURDAY 26 SEPTEMBER 2015

#### Teaching Lecture: The Role of Radiotherapy in Locally Advanced Prostate Cancer: Is the Target Changing?

■ 07:45 - 08:30

Chair: K. Haustermans (Belgium)

Speaker: A. Bossi (France)

#### Special Session: Minimally Elevated PSA after Prostatectomy: Hold Your Horses or All Hands on Deck?

■ 15:15 - 16:15

Chair: W.J.G. Oyen (Netherlands)

#### Role of advanced MRI for detection of minimal disease

Speaker: H.C. Thoeny (Switzerland)

#### Role of PSMA-PET/CT for detection of minimal disease

Speaker: B.J. Krause (Austria)

#### All hands on deck: Early image-guided high-precision treatment

Speaker: V. Khoo (United Kingdom)

#### Hold your horses: Wait and see, do not overtreat

Speaker: P. Abrahamsson (Sweden)

#### Discussion

#### Scientific Symposium: Predictive Factors in Different Areas of Prostate Cancer

■ 16:45 - 18:15

Chair: R. Cathomas (Switzerland)

Co-Chair: B. Tombal (Belgium)

#### How to distinguish between significant and insignificant localised prostate cancer

Speaker: A. Bjartell (Sweden)

#### Predictive factors in radiotherapy induced toxicity

Speaker: D.P. Dearnaley (United Kingdom)



#### Detection of predictive biomarkers in prostate cancer with novel molecular tools

*Speaker: T. Van Der Kwast (Canada)*

#### Predictive factors for treatment choice in metastatic castration resistant prostate cancer

*Speaker: H. Scher (USA)*

#### Discussion & Roundup

### SUNDAY 27 SEPTEMBER 2015

#### Debate: This House Believes that Androgen Deprivation Therapy is Indicated in Combination with Adjuvant or Salvage Radiotherapy for Localised/Relapsed Prostate Cancer

■ 11:30 - 12:30

*Moderator: M. Hoyer (Denmark)*  
*Speaker in favour: G. De Meerleer (Belgium)*  
*Speaker against: P. Nguyen (USA)*  
*Seconder in favour: T. Wiegel (Germany)*  
*Seconder against: M. Bolla (France)*

#### Discussion & Voting

#### Multidisciplinary Tumour Board: Genitourinary Malignancies - Prostate Cancer

■ 15:15 - 16:15

*Chair: B. Escudier (France)*

#### Case presentation by young oncologist: Early disease

*Speaker: G. Giannarini (Switzerland)*

#### Panel Discussion: Early disease

#### Case presentation by young oncologist: Locally advanced disease

*Speaker: B. De Bari (Switzerland)*

#### Panel Discussion: Locally advanced disease

#### Case presentation by young oncologist: Advanced

*Speaker: M.A. Ozturk (Turkey)*

#### Panel Discussion: Advanced disease

#### Urologist

*Panel: T. de Reijke (Netherlands)*

#### Radiotherapist

*Panel: V. Khoo (United Kingdom)*

#### Radiologist

*Panel: J. Barentsz (Netherlands)*

#### Pathologist

*Panel: T. Van Der Kwast (Canada)*

### MONDAY 28 SEPTEMBER 2015

#### Special Session: High Risk and Locally Advanced Prostate Cancer

■ 11:30 - 12:30

*Chair: H. Van Poppel (Belgium)*

#### Place of radiotherapy

*Speaker: A. Bossi (France)*

#### Place of drug therapy

*Speaker: V. Kataja (Finland)*

#### Place of surgery

*Speaker: A. Heidenreich (Germany)*

#### Discussion

### TUESDAY 29 SEPTEMBER 2015

#### Society Session: European Association of Urology (EAU) - Urothelial Cancer in 2015

■ 09:00 - 11:00

*Chair: A. Stenzl (Germany)*

#### Risk stratification of urothelial cancer in the lower and upper urinary tract

*Speaker: S. Shariat (Austria)*

#### How to prevent progression of early stage urothelial cancer

*Speaker: G. Gakis (Germany)*

#### Matula Award Lecture: Biomarkers in urothelial cancer: When and where to use

*Speaker: M. Roupret (France)*

#### Does minimisation of surgery improve the outcome of cystectomy for urothelial cancer?

*Speaker: P. Wiklund (Sweden)*

#### Treatment of Urothelial Cancer in the octogenarians

*Speaker: N. Clarke (United Kingdom)*

## GYNAECOLOGICAL CANCER

### MONDAY 28 SEPTEMBER 2015

#### Teaching Lecture: Image Guided Dose and Volume Adaptation in Cervix Cancer

■ 08:00 - 08:45

*Chair: P. Hoskin (United Kingdom)*  
*Speaker: R. Pötter (Austria)*

#### Special Session: New Trends in Cervical Cancer Chemotherapy and Radiation Oncology

■ 11:30 - 12:30

*Chair: A. Rovirosa (Spain)*

#### Novel Systemic treatments and immunotherapy - how to combine

*Speaker: P. Vici (Italy)*

#### IMRT: Stargate to more intense chemotherapy schedules?

*Speaker: A. Klopp (USA)*

#### Late toxicity and quality of life results

*Speaker: P. Hoskin (United Kingdom)*

#### Discussion

#### Special Session: Cancer in Pregnancy

■ 15:15 - 16:15

*Chair: D.A. Cameron (United Kingdom)*

#### Breast cancer in pregnancy

*Speaker: S. Loibl (Germany)*

#### Gynecological cancer in pregnancy

*Speaker: R. Fruscio (Italy)*

#### The obstetrical, perinatal and pediatric point of view

*Speaker: F. Amant (Belgium)*

#### Discussion

#### Scientific Symposium: Biology Based Selected Drugs in Ovarian Cancer Treatment

■ 17:00 - 18:30

*Chair: R. Giavazzi (Italy)*  
*Co-Chair: I.B. Vergote (Belgium)*

#### Drug acting on ovarian cancer cells and tumour microenvironment

*Speaker: M. D'Incalci (Italy)*

#### Folate receptor blockers

*Speaker: I.B. Vergote (Belgium)*

#### Treatment opportunities for homologous recombinant deficiency (PARP Inhibitors)

*Speaker: S. Banerjee (United Kingdom)*

#### Immunotherapy opportunities in ovarian cancer

*Speaker: G. Coukos (Switzerland)*

#### Discussion & Roundup

### TUESDAY 29 SEPTEMBER 2015

#### Teaching Lecture: Laparoscopic and Robotic Surgery in the Treatment of Gynaecological Malignancy

■ 08:00 - 08:45

*Chair: G. Ferrandina (Italy)*  
*Speaker: G. Scambia (Italy)*

#### Debate: This House Believes that Ovarian Platinum-Sensitive Carcinoma in Relapse Needs Platinum Based Chemotherapy

■ 11:15 - 12:15

*Moderator: I. Ray-Coquard (France)*  
*Speaker in favour: J. Ledermann (United Kingdom)*  
*Speaker against: N. Colombo (Italy)*  
*Seconder in favour: P. Harter (Germany)*  
*Seconder against: A. González Martín (Spain)*

#### Discussion & Voting

## HAEMATOLOGICAL MALIGNANCIES

### SUNDAY 27 SEPTEMBER 2015

#### Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols

■ 09:15 - 11:15

*Chair: M. Pfreundschuh (Germany)*  
*Co-Chair: G. Mann (Austria)*

#### Introduction

*Speaker: M. Pfreundschuh (Germany)*

#### Burkitt's lymphoma in children

*Speaker: V. Minard-Colin (France)*

#### Burkitt's lymphoma in adults

*Speaker: L. Trümper (Germany)*

#### Lymphoblastic leukaemia in children

*Speaker: M. Heyman (Sweden)*

#### Lymphoblastic leukaemia in adults

*Speaker: N. Boissel (France)*

#### Discussion & Roundup

#### Scientific Symposium: Novel Look to Chronic Lymphoid Leukaemia

■ 17:00 - 18:30

*Chair: M. Ladetto (Italy)*  
*Co-Chair: A. Osterborg (Sweden)*

#### The molecular basis of CLL

*Speaker: G. Gaidano (Italy)*

#### The CLL microenvironment

*Speaker: J.G. Gribben (United Kingdom)*

#### First line treatment

*Speaker: T.R. Robak (Poland)*

#### Treatment for relapse/refractory disease

*Speaker: J. Delgado (Spain)*

#### Discussion & Roundup

### MONDAY 28 SEPTEMBER 2015

#### Teaching Lecture: How to Stage and Treat Hodgkin Lymphoma in the Era of PET

■ 08:00 - 08:45

*Chair: M. Ghielmini (Switzerland)*  
*Speaker: J. Radford (United Kingdom)*

#### Scientific Symposium: Evolving Concepts in T-Cell Lymphomas

■ 09:15 - 10:45

*Chair: N. Schmitz (Germany)*  
*Co-Chair: S.A. Pileri (Italy)*

#### Biology of T-cell lymphoma

*Speaker: P. Gaulard (France)*

#### Frontline treatment

*Speaker: F.A. D'Amore (Denmark)*

#### Relapsed disease

*Speaker: O. O'Connor (USA)*

#### Transplantation in T-cell lymphoma

*Speaker: P. Corradini (Italy)*

#### Discussion & Roundup



**Special Session: Genetic Traits for Myeloid Malignancies**

■ 11:30 - 12:30

*Chair: J. Stary (Czech Republic)*

**Current concepts for familial AML**  
*Speaker: J. Fitzgibbon (United Kingdom)*

**GATA2 deficiency**  
*Speaker: M. Wlodarski (Germany)*

**Genetic counselling**  
*Speaker: B. Schlegelberger (Germany)*

**Discussion**

**TUESDAY 29 SEPTEMBER 2015**

**Teaching Lecture: The Spectrum of Cutaneous Lymphomas: From Molecular Biology to Therapy**

■ 08:00 - 08:45

*Chair: M. Federico (Italy)*  
*Speaker: R. Dummer (Switzerland)*

**Debate: This House Believes that We Should Treat First Line Advanced Follicular Lymphoma without Chemotherapy**

■ 11:15 - 12:15

*Moderator: A. Lister (United Kingdom)*  
*Speaker in favour: M. Ghielmini (Switzerland)*  
*Speaker against: M. Federico (Italy)*  
*econder in favour: G. Salles (France)*  
*Seconder against: W. Hiddemann (Germany)*

**Discussion & Voting**

**HEAD AND NECK CANCER**

**SATURDAY 26 SEPTEMBER 2015**

**Teaching Lecture: Dose Escalation or De-Escalation in Head and Neck Cancer?**

■ 07:45 - 08:30

*Chair: D. Zips (Germany)*  
*Speaker: V. Gregoire (Belgium)*

**Debate: This House Believes that Concurrent Chemotherapy Combined with Hyperfractionated Radiotherapy Should Be the Current Standard in HPV Negative Locally Advanced Head and Neck Cancer**

■ 15:15 - 16:15

*Moderator: A. Psyrri (Greece)*  
*Speaker in favour: P. Blanchard (France)*  
*Speaker against: J.G. Eriksen (Denmark)*  
*Seconder in favour: W. Budach (Germany)*  
*Seconder against: M. Merlano (Italy)*

**Discussion & Voting**

**Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer**

■ 16:45 - 18:15

*Chair: L. Licitra (Italy)*  
*Co-Chair: U. Keilholz (Germany)*

**Genomic landscape of HPV related head and neck cancer**  
*Speaker: C.H. Chung (USA)*

**HPV targeted therapies in HPV associated oropharynx cancer**  
*Speaker: A. Psyrri (Greece)*

**EGFR targeted approaches in HPV related head and neck cancer: Is there any role?**  
*Speaker: L. Licitra (Italy)*

**Deintensification strategies in HPV positive oropharynx tumours**  
*Speaker: P. Lassen (Denmark)*

**Discussion & Roundup**

**SUNDAY 27 SEPTEMBER 2015**

**Special Session: Strategies to Change the Therapeutic Landscape of Head and Neck Cancer**

■ 11:30 - 12:30

*Chair: J. Machiels (Belgium)*

**Consequences of new imaging techniques in treatment of the neck**  
*Speaker: V. Gregoire (Belgium)*

**The future role of robotic surgery in head and neck cancer**  
*Speaker: R.L. Ferris (USA)*

**Novel compounds, trial designs and imaging modalities**  
*Speaker: J. Machiels (Belgium)*

**Discussion**

**IMAGING**

**SATURDAY 26 SEPTEMBER 2015**

**Special Session: Minimally Elevated PSA after Prostatectomy: Hold Your Horses or All Hands on Deck?**

■ 15:15 - 16:15

*Chair: W.J.G. Oyen (Netherlands)*

**Role of advanced MRI for detection of minimal disease**  
*Speaker: H.C. Thoeny (Switzerland)*

**Role of PSMA-PET/CT for detection of minimal disease**  
*Speaker: B.J. Krause (Austria)*

**All hands on deck: Early image-guided high-precision treatment**  
*Speaker: V. Khoo (United Kingdom)*

**Hold your horses: Wait and see, do not over treat**  
*Speaker: P. Abrahamsson (Sweden)*

**Discussion**

**SUNDAY 27 SEPTEMBER 2015**

**Multidisciplinary Tumour Board: Breast Cancer**

■ 11:30 - 12:30

*Chair: P. Poortmans (Netherlands)*

**Case presentation by young oncologist: Early disease**  
*Speaker: I. Kindts (Belgium)*

**Panel Discussion: Early disease**

**Case presentation by young oncologist: Locally advanced disease**  
*Speaker: E. Vicini (Italy)*

**Panel Discussion: Locally advanced disease**

**Case presentation by young oncologist: Advanced disease**  
*Speaker: M.V. Dieci (Italy)*

**Panel Discussion: Advanced disease**

**Pathologist**  
*Panel: H.G. Russnes (Norway)*

**Medical Oncologist**  
*Panel: F. Cardoso (Portugal)*

**Surgical Oncologist**  
*Panel: I.T. Rubio (Spain)*

**Pathologist**  
*Panel: J. Reis-Filho (United Kingdom)*

**Medical Oncologist**  
*Panel: M. Campone (France)*

**Oncology Nurse**  
*Panel: Y. Wengström (Sweden)*

**Multidisciplinary Tumour Board: Lung Cancer**

■ 11:30 - 12:30

*Chair: J. Vansteenkiste (Belgium)*

**Case presentation by young oncologist: Early disease**  
*Speaker: F. Cellini (Italy)*

**Panel Discussion: Early disease**

**Case presentation by young oncologist: Locally advanced disease**  
*Speaker: A. Legras (France)*

**Panel Discussion: Locally advanced disease**

**Case presentation by young oncologist: Advanced disease**  
*Speaker: R. Califano (United Kingdom)*

**Panel Discussion: Advanced disease**

**Radiation Oncologist**  
*Panel: J.S.A. Belderbos (Netherlands)*

**Surgical Oncologist**  
*Panel: J. Edwards (United Kingdom)*

**Pathologist**  
*Panel: E. Brambilla (France)*

**Radiologist**  
*Panel: J. Coolen (Belgium)*

**Oncology Nurse**  
*Panel: K. Cedermarck (Sweden)*

**Special Session: Strategies to Change the Therapeutic Landscape of Head and Neck Cancer**

■ 11:30 - 12:30

*Chair: J. Machiels (Belgium)*

**Consequences of new imaging techniques in treatment of the neck**  
*Speaker: V. Gregoire (Belgium)*

**The future role of robotic surgery in head and neck cancer**  
*Speaker: R.L. Ferris (USA)*

**Novel compounds, trial designs and imaging modalities**  
*Speaker: J. Machiels (Belgium)*

**Discussion**

**Special Session: Translating Innovations in Functional Imaging into Clinical Trials**

■ 11:30 - 12:30

*Chair: F. Giammarile (France)*

**Biological and clinical rationale of the use of functional imaging**  
*Speaker: H. Lyng (Norway)*

**How to apply functional imaging in the radiation oncology clinic**  
*Speaker: L. Mortensen (Denmark)*

**From image to dose prescription and back**  
*Speaker: W. Van Elmpt (Netherlands)*

**Discussion**

**Multidisciplinary Tumour Board: Genitourinary Malignancies - Prostate Cancer**

■ 15:15 - 16:15

*Chair: B. Escudier (France)*

**Case presentation by young oncologist: Early disease**  
*Speaker: G. Giannarini (Switzerland)*

**Panel Discussion: Early disease**

**Case presentation by young oncologist: Locally advanced disease**  
*Speaker: B. De Bari (Switzerland)*

**Panel Discussion: Locally advanced disease**

**Case presentation by young oncologist: Advanced**  
*Speaker: M.A. Ozturk (Turkey)*

**Panel Discussion: Advanced disease**

**Urologist**  
*Panel: T. De Reijke (Netherlands)*

**Radiotherapist**  
*Panel: J. Khoo (United Kingdom)*

**Radiologist**  
*Panel: J. Barentsz (Netherlands)*

**Pathologist**  
*Panel: T. Van Der Kwast (Canada)*

**MONDAY 28 SEPTEMBER 2015**

**Teaching Lecture: Image Guided Dose and Volume Adaptation in Cervix Cancer**

■ 08:00 - 08:45

*Chair: P. Hoskin (United Kingdom)*  
*Speaker: R. Pötter (Austria)*

**Debate: This House Believes that Mammographic Screening Should Be Discontinued**

■ 11:30 - 12:30

*Moderator: M. Rosselli del Turco (Italy)*  
*Speaker in favour: P. Zahl (Norway)*  
*Speaker against: D.A. Cameron (United Kingdom)*  
*Seconder in favour: G. Liefers (Netherlands)*  
*Seconder against: B. Borisch (Switzerland)*

**Discussion & Voting**

**Multidisciplinary Tumour Board: Gastrointestinal Malignancies - Colorectal Cancer**

■ 11:30 - 12:30

*Chair: G. Beets (Netherlands)*

**Case presentation by young oncologist: Early disease**  
*Speaker: J.R. Van der Vorst (Netherlands)*

**Panel Discussion: Early disease**

**Case Presentation by young oncologist: Locally advanced disease**  
*Speaker: F. Cellini (Italy)*

**Panel Discussion: Locally advanced disease**

**Case presentation by young oncologist:  
Advanced disease**

*Speaker: A. Hollebecque (France)*

**Panel Discussion: Advanced disease**

**Medical Oncologist**

*Panel: C. Koehne (Germany)*

**Radiation Oncologist**

*Panel: K. Haustermans (Belgium)*

**Pathologist**

*Panel: P. Quirke (United Kingdom)*

**Radiologist**

*Panel: G. Brown (United Kingdom)*

**Special Session: The Prerequisite  
for Ideal Biobanking**

■ 15:15 - 16:15

*Chair: J. Dillner (Sweden)*

**How much is important for the basic  
research the material and the dataset?**

*Speaker: F. Carneiro (Portugal)*

**From the operating room to the  
laboratory. The value of surgery  
standardisation and data collection in  
a tissue bank**

*Speaker: G. Corso (Italy)*

**Interventional radiologist's  
perspective**

*Speaker: J. Futterer (Netherlands)*

**Discussion**

**Integrated Session: How to  
Personalise Treatment Modalities  
in Locally Advanced Rectal Cancer**

■ 16:45 - 18:45

*Chair: A.F. Sobrero (Italy)*

*Co-Chair: R.J. Heald (United Kingdom)*

**Introduction**

*Speaker: A.F. Sobrero (Italy)*

**By imaging**

*Speaker: G. Brown (United Kingdom)*

**By drug combination**

*Speaker: R. Glynn-Jones (United Kingdom)*

**By modulation radiotherapy volume  
and dose**

*Speaker: C. Marijnen (Netherlands)*

**By supporting decision tools**

*Speaker: V. Valentini (Italy)*

**Discussion & Roundup**

**TUESDAY 29 SEPTEMBER 2015**

**Teaching Lecture: Staging the  
Axilla: Imaging and Sentinel Node  
Technologies**

■ 08:00 - 08:45

*Chair: L. Wyld (United Kingdom)*

*Speaker: I.T. Rubio (Spain)*

**Teaching Lecture: Rectal Cancer  
and the Role of Imaging in  
Treatment Planning**

■ 08:00 - 08:45

*Chair: V. Valentini (Italy)*

*Speaker: G. Beets (Netherlands)*

**IMMUNOTHERAPY  
OF CANCER**

**SATURDAY 26 SEPTEMBER 2015**

**Scientific Symposium: Cellular  
Immunotherapy of Cancer**

■ 10:30 - 12:00

*Chair: I. Melero (Spain)*

*Co-Chair: W. Fridman (France)*

**Making the most adoptive T-cell  
therapy**

*Speaker: P. Hwu (USA)*

**Deploying gene-engineered T-cells in  
the cancer battlefield**

*Speaker: C. June (USA)*

**Making the most of dendritic cell-  
based immunotherapy**

*Speaker: C. Figdor (Netherlands)*

**Is cancer immunosurveillance  
relevant?**

*Speaker: J. Galon (France)*

**Discussion & Roundup**

**Special Session: Combining  
Radiation and Immunotherapy**

■ 15:15 - 16:15

*Chair: A. Melcher (United Kingdom)*

**Molecular basis for radiotherapy in  
synergy with immunotherapy**

*Speaker: S. Demaria (USA)*

**Radiotherapy, immunotherapy and  
virotherapy riddles**

*Speaker: K. Harrington (United Kingdom)*

**Learning radioimmunotherapy**

*Speaker: P. Beckhove (Germany)*

**Discussion**

**SUNDAY 27 SEPTEMBER 2015**

**Educational Symposium: Advances  
in Cancer Therapy Through  
Modulation of the Immune System**

■ 09:15 - 11:15

*Chair: B. Van den Eynde (Belgium)*

**Role of the immune system on the  
outcome of cancer therapy**

*Speaker: G. Coukos (Switzerland)*

**How does ionising radiation contribute  
to the induction of anti-tumour  
immunity?**

*Speaker: G. Multhoff (Germany)*

**Targeting tumour microenvironment**

*Speaker: P. Allavena (Italy)*

**Adoptive cell therapy**

*Speaker: R. Hawkins (United Kingdom)*

**Discussion & Roundup**

**TUESDAY 29 SEPTEMBER 2015**

**Integrated Session:  
Immunotherapy in NSCLC - 2015**

■ 09:00 - 11:00

*Chair: L. Paz-Ares (Spain)*

*Co-Chair: M. Reck (Germany)*

**Introduction**

*Speaker: L. Paz-Ares (Spain)*

**Lung cancer: An immunogenic tumour?**

*Speaker: S.A. Quezada (United Kingdom)*

**Any place for vaccination strategies?**

*Speaker: J. Vansteenkiste (Belgium)*

**Check point inhibitors - where do we  
stand and where are we going?**

*Speaker: M. Reck (Germany)*

**Biomarkers - a realistic perspective?**

*Speaker: K. Kerr (United Kingdom)*

**Discussion & Roundup**

**Integrated Session:  
Immunotherapy in the  
Management of Metastatic  
Melanoma**

■ 09:00 - 11:00

*Chair: A.M.M. Eggermont (France)*

*Co-Chair: P.A. Ascierto (Italy)*

**Introduction**

*Speaker: A.M.M. Eggermont (France)*

**Biomarkers for the complex biology of  
melanoma immunotherapy**

*Speaker: C. Robert (France)*

**Immunogens and immunostimulatory  
monoclonal antibodies**

*Speaker: I. Melero (Spain)*

**Melanoma targeted therapies in the  
interface with immunotherapy**

*Speaker: A. Ribas (USA)*

**Virotherapy and immunotherapy**

*Speaker: A. Melcher (United Kingdom)*

**Discussion & Roundup**

**INNOVATIONS  
IN RADIATION  
ONCOLOGY**

**SATURDAY 26 SEPTEMBER 2015**

**Scientific Symposium: New  
Trends in Molecular Targeting for  
Radiation Oncology**

■ 16:45 - 18:15

*Chair: Y. Shiloh (Israel)*

*Co-Chair: B. Wouters (Canada)*

**Immunotherapy and radiation therapy**

*Speaker: E. Deutsch (France)*

**The link between receptors and  
signalling pathways and radiation  
therapy**

*Speaker: K. Harrington (United Kingdom)*

**Angiogenesis and tumour vasculature  
influences radiation effects**

*Speaker: M. Pruschy (Switzerland)*

**Why DNA repair is so important for  
radiation oncologists**

*Speaker: T. Helleday (Sweden)*

**SUNDAY 27 SEPTEMBER 2015**

**Teaching Lecture: Technical  
Innovations in Radiotherapy**

■ 08:00 - 08:45

*Chair: D. Verellen (Belgium)*

*Speaker: C. Grau (Denmark)*

**Special Session: Translating  
Innovations in Functional Imaging  
into Clinical Trials**

■ 11:30 - 12:30

*Chair: F. Giammarile (France)*

**Biological and clinical rationale of the  
use of functional imaging**

*Speaker: H. Lyng (Norway)*

**How to apply functional imaging in the  
radiation oncology clinic**

*Speaker: L. Mortensen (Denmark)*

**From image to dose prescription and  
back**

*Speaker: W. Van Elmpt (Netherlands)*

**Discussion**

**Special Session: Think Big:  
Large Databases for Research in  
Radiation Oncology**

■ 15:15 - 16:15

*Chair: M. Baumann (Germany)*

**Big databases and outcome research:  
Opportunities and challenges for  
radiation oncology**

*Speaker: A. Dekker (Netherlands)*

**Radplan Bio: Database for  
individualised radiation oncology**

*Speaker: M. Krause (Germany)*

**The breast cancer example: Lesson  
from large databases**

*Speaker: B. Offersen (Denmark)*

**Discussion**

### Educational Symposium: Radiation Combined with Targeted Agents- The Example of Head and Neck Cancer

■ 16:45 - 18:45

Chair: M. Krause (Germany)

**Principles and theory behind**  
Speaker: M. Krause (Germany)

**The clinical outcome**  
Speaker: L. Licitra (Italy)

**How to manage toxicity**  
Speaker: E. Deutsch (France)

**The HPV story**  
Speaker: J.G. Eriksen (Denmark)

**Discussion & Roundup**

### MONDAY 28 SEPTEMBER 2015

### Society Session: European Society for Radiotherapy & Oncology (ESTRO)

■ 09:15 - 11:15

Chair: P. Poortmans (Netherlands)

**Regaud Award Lecture: Minimal effective treatments in the personalised era: The breast model**

Award Lecturer: R. Orecchia (Italy)

**ESTRO Honorary Members Award Lectures**

**Title to be announced**  
Award Lecturer: A.L. Zietman (USA)

**Title to be announced**  
Award Lecturer: A. Cervantes (Spain)

**Company Award Lectures**

**Accuray Award**  
Award Lecturer: To be announced

**Varian Award**  
Award Lecturer: To be announced

### Debate: This House Believes that Local Radiation Therapy Also Has Therapeutic Effects Outside the Radiation Fields and thereby Contributes to Treatment Outcome

■ 11:30 - 12:30

Moderator: M. Verheij (Netherlands)  
Speaker in favour: F. Wenz (Germany)  
Speaker against: B. Offersen (Denmark)  
Seconder in favour: S.C. Morgan (Canada)  
Seconder against: D. Vordermark (Germany)

**Discussion & Voting**

### Special Session: How to Use Omics Data for Precision Radiation Oncology

■ 15:15 - 16:15

Chair: D. Zips (Germany)

**How to bring “radio-omics” and functional tests in the clinic**  
Speaker: B. Wouters (Canada)

**Systems biology for precision radiation oncology: Moving between the forest and the trees**  
Speaker: Y. Shiloh (Israel)

**Implications of new knowledge for trial design**  
Speaker: A.H. Ree (Norway)

**Discussion**

### TUESDAY 29 SEPTEMBER 2015

### Teaching Lecture: Personalised Radiotherapy: Dream or Reality?

■ 08:00 - 08:45

Chair: P. Poortmans (Netherlands)  
Speaker: M. Baumann (Germany)

### Scientific Symposium: High-Tech Innovations for Precision Radiation Oncology: Concept, Status and Clinical Benefit

■ 09:00 - 10:30

Chair: P. Poortmans (Netherlands)  
Co-Chair: D. Georg (Austria)

**How can protons contribute to radiation oncology**  
Speaker: M. Schwarz (Italy)

**Might it be heavier? Irradiation with carbon and other ions**  
Speaker: R. Orecchia (Italy)

**How to get most out of photon based radiation therapy**  
Speaker: D. Verellen (Belgium)

**MR-Linac is a way to improve treatment delivery**  
Speaker: M. van Vulpen (Netherlands)

**Discussion & Roundup**

### Special Session: Stereotactic Hypofractionated Radiation Therapy for Oligometastatic Disease: For Whom and When?

■ 11:15 - 12:15

Chair: E. Lartigau (France)

**Clinical and biological concept & rationale**  
Speaker: J. Bussink (Netherlands)

**Clinical Results: Can we cure oligometastatic disease?**  
Speaker: M. Hoyer (Denmark)

**How to manage target motion during treatment**  
Speaker: M. Guckenberger (Germany)

**Discussion**

## LUNG CANCER - LOCALISED/LOCAL REGIONAL AND METASTATIC

### SATURDAY 26 SEPTEMBER 2015

### Teaching Lecture: New Perspectives in Small Cell Lung Cancer

■ 07:45 - 08:30

Chair: Chair: J. Douillard (France)  
Speaker: C. Faiure-Finn (United Kingdom)

### Special Session: Lung Cancer Screening and Prevention

■ 15:15 - 16:15

Chair: W. Weder (Switzerland)

**Lung cancer prevention and smoking cessation**  
Speaker: To be announced

**Lung cancer screening: Ready for standard of care in Europe?**  
Speaker: G. Veronesi (Italy)

**Discussion**

### Educational Symposium: Profiling Lung Cancer - Collection of Rare Cancers

■ 16:45 - 18:45

Chair: E. Brambilla (France)

**Targets in squamous cell carcinoma**  
Speaker: B. Besse (France)

**Targets in adenocarcinoma**  
Speaker: J.C. Soria (France)

**Targets in SCLC**  
Speaker: M.C. Pietanza (USA)

**Upfront biomarker analysis to guide stage VI treatment: Practical use**  
Speaker: S. Peters (Switzerland)

**Discussion & Roundup**

### SUNDAY 27 SEPTEMBER 2015

### Multidisciplinary Tumour Board: Lung Cancer

■ 11:30 - 12:30

Chair: J. Vansteenkiste (Belgium)

**Case presentation by young oncologist: Early disease**  
Speaker: F. Cellini (Italy)

**Panel Discussion: Early disease**

**Case presentation by young oncologist: Locally advanced disease**  
Speaker: A. Legras (France)

**Panel Discussion: Locally advanced disease**

**Case presentation by young oncologist: Advanced disease**  
Speaker: R. Califano (United Kingdom)

**Panel Discussion: Advanced disease**

**Radiation Oncologist**  
Panel: J.S.A. Belderbos (Netherlands)

**Surgical Oncologist**  
Panel: J. Edwards (United Kingdom)

**Pathologist**  
Panel: E. Brambilla (France)

**Radiologist**  
Panel: J. Coolen (Belgium)

**Oncology Nurse**  
Panel: K. Cedermarck (Sweden)

### Scientific Symposium: Innovations Broadening the Horizon for Locally-Advanced Non-Small Cell Lung Cancer

■ 17:00 - 18:30

Chair: Y. Lievens (Belgium)  
Co-Chair: B. Besse (France)

**New insights in tumour biology**  
Speaker: L. Bubendorf (Switzerland)

**Minimally invasive surgery for locally advanced tumours**  
Speaker: M. Dylewsky (USA)

**Novel radiotherapy technology improving the therapeutic index**  
Speaker: J.S.A. Belderbos (Netherlands)

**(Neo)adjuvant treatment: Which way to go?**  
Speaker: B. Besse (France)

**Discussion & Roundup**

### MONDAY 28 SEPTEMBER 2015

### Teaching Lecture: Targeted Therapies for Adenocarcinoma of the Lung

■ 08:00 - 08:45

Chair: J.C. Soria (France)  
Speaker: E. Felip (Spain)

### Integrated Session: Novel Approaches to Brain Metastases

■ 09:15 - 11:15

Chair: S. Combs (Germany)  
Co-Chair: A. Eniu (Romania)

**Biology of brain metastases**  
Speaker: P.S. Steeg (USA)

**Novel systemic therapy approaches to brain metastases: Lung**  
Speaker: S. Popat (United Kingdom)

**Novel systemic therapy approaches to brain metastases: Breast**  
Speaker: M. Preusser (Austria)

**Novel systemic therapy approaches to brain metastases: Melanoma**  
Speaker: D. Schadendorf (Germany)

**Advances in loco-regional treatments**  
Speaker: M. Brada (United Kingdom)

**Tolerability of brain metastasis treatments**  
Speaker: R. Soffetti (Italy)

**Response assessment in brain metastases**  
Speaker: N. Lin (USA)

**Discussion & Roundup**

### Debate: This House Believes that Surgery Remains the Gold Standard for Early Stage NSCLC

■ 11:30 - 12:30

Moderator: G. Veronesi (Italy)  
Speaker in favour: W. Weder (Switzerland)  
Speaker against: U. Ricardi (Italy)  
Seconder in favour: S. Novello (Italy)  
Seconder against: V. Surmont (Belgium)

**Discussion & Voting**



### Scientific Symposium: Evolution of Targeted Therapies in Lung Cancer: Where Are We Today and Where Are We Going?

■ 17:00 - 18:30

Chair: R. Buettner (Germany)  
Co-Chair: S. Popat (United Kingdom)

#### Targeted treatment in squamous cell lung cancer

Speaker: J. Wolf (Germany)

#### EGFR Inhibition - current status and future perspectives

Speaker: T. Mok (China)

#### ALK Inhibition - current status and future perspectives

Speaker: A.T. Shaw (USA)

#### Beyond EGFR and ALK - future targets

Speaker: S. Peters (Switzerland)

#### Discussion & Roundup

### TUESDAY 29 SEPTEMBER 2015

#### Teaching Lecture: Is There a Dose Response Relationship in Localised Lung Cancer

■ 08:00 - 08:45

Chair: Y. Lievens (Belgium)  
Speaker: D. De Ruysscher (Belgium)

#### Integrated Session: Immunotherapy in NSCLC - 2015

■ 09:00 - 11:00

Chair: L. Paz-Ares (Spain)  
Co-Chair: M. Reck (Germany)

#### Introduction

Speaker: L. Paz-Ares (Spain)

#### Lung cancer: An immunogenic tumour?

Speaker: S.A. Quezada (United Kingdom)

#### Any place for vaccination strategies?

Speaker: J. Vansteenkiste (Belgium)

#### Check point inhibitors - where do we stand and where are we going?

Speaker: M. Reck (Germany)

#### Biomarkers - a realistic perspective?

Speaker: K. Kerr (United Kingdom)

#### Discussion & Roundup

### Special Session: Resistance in Patients with Oncogenic Alterations

■ 11:15 - 12:15

Chair: D.R. Camidge (USA)

#### Tumour cells heterogenetics evolution

Speaker: C. Swanton (United Kingdom)

#### Overcoming resistance in patients with ALK translocations

Speaker: D.R. Camidge (USA)

#### Perspectives in management of EGFR resistance

Speaker: F. Cappuzzo (Italy)

#### Discussion

## MELANOMA AND SKIN CANCER

### MONDAY 28 SEPTEMBER 2015

#### Teaching Lecture: Immunotherapy in Melanoma: From Frustration to Enthusiasm

■ 08:00 - 08:45

Chair: P.A. Ascierto (Italy)  
Speaker: J. Becker (Austria)

#### Integrated Session: Novel Approaches to Brain Metastases

■ 09:15 - 11:15

Chair: S. Combs (Germany)  
Co-Chair: A. Eniu (Romania)

#### Biology of brain metastases

Speaker: P.S. Steeg (USA)

#### Novel systemic therapy approaches to brain metastases: Lung

Speaker: S. Popat (United Kingdom)

#### Novel systemic therapy approaches to brain metastases: Breast

Speaker: M. Preusser (Austria)

#### Novel systemic therapy approaches to brain metastases: Melanoma

Speaker: D. Schadendorf (Germany)

#### Advances in loco-regional treatments

Speaker: M. Brada (United Kingdom)

#### Tolerability of brain metastasis treatments

Speaker: R. Soffietti (Italy)

#### Response assessment in brain metastases

Speaker: N. Lin (USA)

#### Discussion & Roundup

#### Special Session: Biomarkers in Melanoma

■ 11:30 - 12:30

Chair: H. Gogas (Greece)

#### Immunotherapy: Is there any predictive biomarkers?

Speaker: L. Zitvogel (France)

#### The role circulating tumour cells in melanoma

Speaker: C. Dive (United Kingdom)

#### cfDNA

Speaker: A. Thierry (France)

#### Discussion

#### Scientific Symposium: Mechanisms of Resistance to Targeted Therapies

■ 17:00 - 18:30

Chair: R. Marais (United Kingdom)  
Co-Chair: D. Schadendorf (Germany)

#### BRAF signalling in melanoma

Speaker: R. Marais (United Kingdom)

#### Signalling networks and resistance

Speaker: R. Dummer (Switzerland)

#### Metabolism and resistance

Speaker: D. Peeper (Netherlands)

#### Mechanisms and resistance

Speaker: G. Long (Australia)

#### Discussion & Roundup

### TUESDAY 29 SEPTEMBER 2015

#### Teaching Lecture: Update on the Role of Surgery in Melanoma: From Margins to SLNB to Metastasectomy

■ 08:00 - 08:45

Chair: A.M.M. Eggermont (France)  
Speaker: A. Testori (Italy)

### Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

■ 09:00 - 11:00

Chair: A.M.M. Eggermont (France)  
Co-Chair: P.A. Ascierto (Italy)

#### Introduction

Speaker: A.M.M. Eggermont (France)

#### Biomarkers for the complex biology of melanoma immunotherapy

Speaker: C. Robert (France)

#### Immunogens and immunostimulatory monoclonal antibodies

Speaker: I. Melero (Spain)

#### Melanoma targeted therapies in the interface with immunotherapy

Speaker: A. Ribas (USA)

#### Virotherapy and immunotherapy

Speaker: A. Melcher (United Kingdom)

#### Discussion & Roundup

#### Special Session: How Do We Sequence or Combine Immunotherapies with Targeted Therapies in Melanoma?

■ 11:15 - 12:15

Chair: P.A. Ascierto (Italy)

#### The US view

Speaker: A. Ribas (USA)

#### The Australian view

Speaker: G. Long (Australia)

#### The European view

Speaker: C. Robert (France)

#### Discussion

## ONCOLOGY NURSING

### SATURDAY 26 SEPTEMBER 2015

#### Teaching Lecture: Online Information and Support: Benefits and Risks

■ 07:45 - 08:30

Chair: A. Margulies (Switzerland)

#### The role of patient experiences as an online resource

Speaker: L. Carrasqueiro (United Kingdom)

#### Benefits and risks of e-health information sources for people living with cancer

Speaker: I. Verdonck-de Leeuw (Netherlands)

#### Society Session: European Oncology Nursing Society (EONS) - Innovations in Cancer Nursing Roles: Learning from Each Other

■ 10:30 - 12:30

Chair: K. Lokar (Slovenia)  
Co-Chair: T. Wiseman (United Kingdom)

#### The nursing role in interventional radiology

Speaker: To be announced

#### Nurses leading multi-professional person-centred rounds

Speaker: To be announced

#### Research grant 2012

Speaker: M. Eicher (Switzerland)

#### Clinical travel grant 2014

Speaker: Y. Hanhauser (Ireland)

#### Clinical travel grant 2014

Speaker: F. Maddalena (Belgium)

#### Research travel grant 2014

Speaker: P. Stolz Baskett (Switzerland)

#### Research travel grant 2014

Speaker: A. Harrow (United Kingdom)

### Special Session: Patient Safety and the Nursing Workforce - Issues for Cancer Nursing

■ 15:15 - 16:15

Chair: D. Kelly (United Kingdom)

#### The importance of staff wellbeing and patient experience

Speaker: J. Maben (United Kingdom)

#### Assessing patient safety in oncology

Speaker: D.L.B. Schwappach (Switzerland)

#### Patient safety: The features of safe organisational culture - lessons from beyond oncology

Speaker: A. Jones (United Kingdom)

#### Discussion

#### Scientific Symposium: Managing Older People with Cancer and Other Co-Morbidities - An Increasing Challenge

■ 16:45 - 18:15

Chair: M. Wells (United Kingdom)  
Co-Chair: L. Sharp (Sweden)

#### New models of follow-up for increasingly complex patient profiles

Speaker: G. Catania (Italy)

#### Meeting complex care needs in the clinic. The example of polypharmacy

Speaker: F. Van den Berkmortel (Netherlands)

#### The importance of appropriate assessment for older people with cancer

Speaker: C. Kenis (Belgium)

#### Being innovative to support older people with cancer in clinical settings

Speaker: I. Rahm Hallberg (Sweden)

#### Discussion & Roundup



**SUNDAY 27 SEPTEMBER 2015****Special Session: Living with and Beyond Cancer**

■ 11:30 - 12:30

*Chair: E. Van Muilekom (Netherlands)***The benefits of physical activity during and following cancer treatment: The patient perspective***Speaker: N. Howie (United Kingdom)***Living with cancer risk: Supporting patients and families with examples from breast cancer***Speaker: D. Razavi (Belgium)***Beyond cancer: The fear of cancer recurrence***Speaker: G. Ozakinci (United Kingdom)***Discussion****Special Session: Nutrition and Body Image Changes - A Concern for All Patients with Cancer**

■ 15:15 - 16:15

*Chair: M.C. Lacerda (Portugal)***Weight gain during cancer therapy: Issues for cancer practice***Speaker: Y. Wengström (Sweden)***Swallowing difficulties: Lessons from head and neck cancer***Speaker: M. Wells (United Kingdom)***Cancer cachexia: What can we do to help?***Speaker: F. Strasser (Switzerland)***Discussion****Scientific Symposium: The Changing Face of Cancer Care for Oncology Nurses: The Rising Demand Being Placed on Cancer Services**

■ 17:00 - 18:30

*Chair: M.C. Lacerda (Portugal)  
Co-Chair: K. Lokar (Slovenia)***Meeting the support needs of patients, carers & families after cancer treatment***Speaker: C. Foster (United Kingdom)***Factors underpinning workplace stress: Lessons for cancer nursing***Speaker: R. Caruso (Italy)***Multi-disciplinary rehabilitation in advanced bladder cancer***Speaker: B. Thoft-Jensen (Denmark)***Reducing emergency cancer admissions: A case study***Speaker: C. Bailey (United Kingdom)***Discussion & Roundup****ONCOPOLICY****SATURDAY 26 SEPTEMBER 2015****Oncopolicy Forum: Timebombs in Oncology: Cancer Survivorship**

■ 13:00 - 14:30

*Chair: To be announced*

This session will seek to address the key challenges presented by the increasing number of cancer survivors. The survivorship timebomb poses many policy challenges, including how to implement effective 'back to work' schemes for those willing and able to return to the workplace.

**SUNDAY 27 SEPTEMBER 2015****Oncopolicy Forum: Inequalities in Treatment Outcomes**

■ 08:00 - 09:00

*Chair: M. Piccart (Belgium)  
Chair: I. Banks (United Kingdom)*

This session will look at inequalities in treatment outcomes both between and within European countries and the multi-stakeholder effort required to ensure equality of access. With more and more expensive drugs coming to the market, it will be important to consider joint efforts between professionals, governments and industry.

**Oncopolicy Forum: Timebombs in Oncology: Cancer in the Elderly**

■ 13:00 - 14:30

*Chair: R.A. Audisio (United Kingdom)*

With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have recognised this and are implementing workplace initiatives to address the problem. This session will seek to provide policy solutions for the timebomb of cancer in the elderly.

**MONDAY 28 SEPTEMBER 2015****Oncopolicy Forum: EU Funding Opportunities for You and Your Team**

■ 11:30 - 12:30

*Chair: A. Costa (Italy)*

This session will unlock the possibilities for cancer research funding under the EU budget 2014 - 2020. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020.

**Oncopolicy Forum: Timebombs in Oncology: The Oncology Workforce**

■ 13:00 -14:30

*Chair: To be announced*

This session will consist of a multidisciplinary cancer panel giving their perspectives on the timebomb that is the oncology workforce. Discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

**Oncopolicy Forum: Tackling Rare Cancers Requiring Specialist Care: European Reference Networks**

■ 17:00 - 18:30

*Chair: P. Casali (Italy)*

This session will address the cross-border movement of cancer patients and the setting up of European Reference Networks. Patients and the rare cancers community will provide their perspectives on this development.

**PAEDIATRIC ONCOLOGY****SATURDAY 26 SEPTEMBER 2015****Teaching Lecture: Myelodysplastic Syndrome - Children & Adults**

■ 07:45 - 08:30

*Chair: R. Riccardi (Italy)  
Speaker: C. Niemeyer (Germany)***Society Session: European Society for Pediatric Oncology (SIOPE)**

■ 10:30 - 12:30

*Chair: Gilles Vassal (France)*

*Details to be announced in the online searchable programme and final programme as soon as possible*

**Special Session: Precision Medicine and New Drugs for the Treatment of Children and Adolescents with Cancer**

■ 15:15 - 16:15

*Chair: G. Vassal (France)***Tumour molecular profiling to guide new drug development: Experiences from Germany, France, UK and Netherlands***Speaker: S. Pfister (Germany)***Is B-RAF and MEK pathway relevant in paediatric malignancies?***Speaker: B. Geoerger (France)***Monoclonal antibodies in paediatric acute leukaemias***Speaker: A. von Stackelberg (Germany)***Discussion****Scientific Symposium: Childhood Cancer- Bad Luck or Bad Genes?**

■ 16:45 - 18:15

*Chair: L. Brugieres (France)  
Co-Chair: F. Bourdeaut (France)***Status of predisposition to paediatric malignancies: The known and unknown***Speaker: K. Wimmer (Austria)***Dysregulated RAS signalling in paediatric cancer and developmental disorders***Speaker: M. Tartaglia (Italy)***Li-Fraumeni syndrome***Speaker: M.T. Frebourg (France)***Research and counselling in genetic predisposition to paediatric malignancies: Ethical issues***Speaker: F. Bourdeaut (France)***Discussion & Roundup****SUNDAY 27 SEPTEMBER 2015****Integrated Session: Treating Lymphoid Malignancies in Children and Adults with the Same Protocols**

■ 09:15 - 11:15

*Chair: M. Pfreundschuh (Germany)  
Co-Chair: G. Mann (Austria)***Introduction***Speaker: M. Pfreundschuh (Germany)***Burkitt's lymphoma in children***Speaker: V. Minard-Colin (France)***Burkitt's lymphoma in adults***Speaker: L. Trümper (Germany)***Lymphoblastic leukaemia in children***Speaker: M. Heyman (Sweden)***Lymphoblastic leukaemia in adults***Speaker: N. Boissel (France)***Discussion & Roundup****Debate: This House Believes that Proton and Particle Therapy is Standard Treatment for Paediatric Malignancies**

■ 15:15 - 16:15

*Moderator: K. Pritchard-Jones (United Kingdom)  
Speaker in favour: B. Timmermann (Germany)  
Speaker against: K. Dieckmann (Austria)  
Seconder in favour: A. Crellin (United Kingdom)  
Seconder against: T. Merchant (USA)*

**Discussion & Voting****Integrated Session: Teenage and Young Adult Oncology**

■ 16:45 - 18:45

*Chair: R. Ladenstein (Austria)  
Co-Chair: S. Bielsack (Germany)***Introduction***Speaker: R. Ladenstein (Austria)***Improving access to clinical trials***Speaker: N. Gaspar (France)***EU Curriculum***Speaker: D. Stark (United Kingdom)***Treatment and care of teenagers and young adults with a germ cell tumour?***Speaker: G. Calaminus (Germany)*

**How to build on networking**  
*Speaker: L. Fern (United Kingdom)*

**Discussion & Roundup**

**MONDAY 28 SEPTEMBER 2015**

**Teaching Lecture: Cardiotoxicity Is a Late Effect in Cured Paediatric Patients**

■ 08:00 - 08:45

*Chair: K. Pritchard-Jones (United Kingdom)*  
*peaker: R. Skinner (United Kingdom)*

**Scientific Symposium: Empowering Survivors - The Survivorship Passport**

■ 09:15 - 10:45

*Chair: L.J. Hjorth (Sweden)*  
*Co-Chair: S. Karner (Austria)*

**The survivorship passport: How to empower former Cancer Care Services**  
*Speaker: R. Haupt (Italy)*

**Guidelines for long term follow-up of Cancer Care Services**  
*Speaker: R. Skinner (United Kingdom)*

**Availability resources for childhood cancer survivors in Europe**  
*Speaker: S. Karner (Austria)*

**Preliminary results from the PanCareSurFup project**  
*Speaker: M. Jankovic (Italy)*

**Discussion & Roundup**

**Special Session: Immunotherapy of Paediatric Malignancies**

■ 11:30 - 12:30

*Chair: M. Schrappe (Germany)*

**CAR T cell targeting of childhood cancers**  
*Speaker: C. Rossig (Germany)*

**Are PD1 and PDL1 relevant targets in paediatric malignancies?**  
*Speaker: J. Gray (United Kingdom)*

**Discussion**

**Special Session: New Perspective for the Treatment of High-Risk Neuroblastoma**

■ 15:15 - 16:15

*Chair: A. Pearson (United Kingdom)*

**Lessons and perspective in the treatment of high-risk neuroblastoma: The SIOPEN strategy**  
*Speaker: D. Valteau-Couanet (France)*

**Strategies for improving maintenance therapy in high-risk neuroblastoma patients**  
*Speaker: R. Ladenstein (Austria)*

**Introducing ALK inhibition therapy in neuroblastoma treatment**  
*Speaker: A. Eggert (Germany)*

**Discussion**

**Integrated Session: Medulloblastoma**

■ 16:45 - 18:45

*Chair: S.J. Rutkowski (Germany)*  
*Co-Chair: B. Geoerger (France)*

**Introduction**  
*Speaker: S.J. Rutkowski (Germany)*

**Molecular classification of medulloblastoma**  
*Speaker: S. Pfister (Germany)*

**Current concepts and future directions in pharmacotherapy of medulloblastoma**  
*Speaker: B. Geoerger (France)*

**Recent results and current concepts for risk adapted medulloblastoma treatment: Experiences from the German HIT-studies and the SIOP-Europe PNET working group**  
*Speaker: S.J. Rutkowski (Germany)*

**Optimising efficacy and limiting toxicity of radiotherapy for medulloblastoma**  
*Speaker: S. Combs (Germany)*

**Management of adult medulloblastoma - using the evidence from children and adolescents**  
*Speaker: A.A. Brandes (Italy)*

**Discussion & Roundup**

**TUESDAY 29 SEPTEMBER 2015**

**Educational Symposium: Common Approaches & Pathways in Adult and Paediatric Malignancies**

■ 09:00 - 11:00

*Chair: R. Riccardi (Italy)*

**AML biology in adults and children**  
*Speaker: M. van den Heuvel (Netherlands)*

**Data mining in cancer: Interim's report from p-Medicine**  
*Speaker: N. Graf (Germany)*

**Targeting osteosarcoma: What is different between adult and paediatric patients?**  
*Speaker: S. Bielack (Germany)*

**Robust endpoints when evaluating novel "targeted" therapies**  
*Speaker: M.G. Valsecchi (Italy)*

**Discussion & Roundup**

**PATHOLOGY**

**SATURDAY 26 SEPTEMBER 2015**

**Teaching Lecture: Use of Liquid Biopsies**

■ 07:45 - 08:30

*Chair: C. Caldas (United Kingdom)*  
*Speaker: C. Dive (United Kingdom)*

**Educational Symposium: What is the Optimal Endocrine Therapy in Premenopausal Women with Early Breast Cancer**

■ 16:45 - 18:45

*Chair: F. André (France)*

**What is the definition of an ER+ breast cancer?**  
*Speaker: J. Reis-Filho (United Kingdom)*

**Which endocrine therapy for a premenopausal woman with ER+/Her2+++ disease? Update on TEKST and SOFT trials**  
*Speaker: V. Tjan-Heijnen (Netherlands)*

**Unusual molecular and clinical profiles: ER+ 1-10%, ER-/PR+ and large tumours in premenopausal women**  
*Speaker: J. Bergh (Sweden)*

**Pregnancy and adjuvant endocrine therapy: Is there any window for opportunity?**  
*Speaker: S. Loibl (Germany)*

**Discussion & Roundup**

**Scientific Symposium: New Insights in Colon Cancer**

■ 16:45 - 18:15

*Chair: D. Aust (Germany)*  
*Co-Chair: P. Laurent Puig (France)*

**Biomarkers to guide therapy today, what to assess and how**  
*Speaker: H. Van Krieken (Netherlands)*

**Novel insights into CRC biology**  
*Speaker: S. Tejpar (Belgium)*

**The immune landscape of colon cancer**  
*Speaker: J. Galon (France)*

**Novel insights on tumour adaptation and clinical implications**  
*Speaker: E.S. Kopetz (USA)*

**Discussion & Roundup**

**Educational Symposium: Profiling Lung Cancer - Collection of Rare Cancers**

■ 16:45 - 18:45

*Chair: E. Brambilla (France)*

**Targets in squamous cell carcinoma**  
*Speaker: B. Besse (France)*

**Targets in adenocarcinoma**  
*Speaker: J.C. Soria (France)*

**Targets in SCLC**  
*Speaker: M.C. Pietanza (USA)*

**Upfront biomarker analysis to guide stage VI treatment: Practical use**  
*Speaker: S. Peters (Switzerland)*

**Discussion & Roundup**

**Scientific Symposium: Predictive Factors in Different Areas of Prostate Cancer**

■ 16:45 - 18:15

*Chair: R. Cathomas (Switzerland)*  
*Co-Chair: B. Tombal (Belgium)*

**How to distinguish between significant and insignificant localised prostate cancer**  
*Speaker: A. Bjartell (Sweden)*

**Predictive factors in radiotherapy induced toxicity**  
*Speaker: D.P. Dearnaley (United Kingdom)*

**Detection of predictive biomarkers in prostate cancer with novel molecular tools**  
*Speaker: T. Van Der Kwast (Canada)*

**Predictive factors for treatment choice in metastatic castration resistant prostate cancer**  
*Speaker: H. Scher (USA)*

**Discussion & Roundup**

**Scientific Symposium: Emerging Developments and Treatment Strategies in HPV Positive Head and Neck Cancer**

■ 16:45 - 18:15

*Chair: L. Licitra (Italy)*  
*Co-Chair: U. Keilholz (Germany)*

**Genomic landscape of HPV related head and neck cancer**  
*Speaker: C.H. Chung (USA)*

**HPV targeted therapies in HPV associated oropharynx cancer**  
*Speaker: A. Psyrri (Greece)*

**EGFR targeted approaches in HPV related head and neck cancer: Is there any role?**  
*Speaker: L. Licitra (Italy)*

**Deintensification strategies in HPV positive oropharynx tumours**  
*Speaker: P. Lassen (Denmark)*

**Discussion & Roundup**

**Scientific Symposium: Neoadjuvant Treatment - When Is It of Benefit for the Patient and Doctor?**

■ 16:45 - 18:15

*Chair: R.A. Audisio (United Kingdom)*  
*Co-Chair: R. Glynne-Jones (United Kingdom)*

**Surgical issues and cancer outcomes**  
*Speaker: S. Gonzalez-Moreno (Spain)*

**The timing of radiotherapy in the NT setting**  
*Speaker: J.F. Bosset (France)*

**What does complete response look like?**  
*Speaker: R.G.H. Beets-Tan (Netherlands)*

**Pathological CR: Predicament or promise?**  
*Speaker: A.P. Dei Tos (Italy)*

**Discussion & Roundup**

**Scientific Symposium: Cancer Genetics for Oncologists - Issues in Clinical Practice**

■ 16:45 - 18:15

*Chair: S. Postel-Vinay (France)*  
*Co-Chair: J. Rodon (Spain)*

**Germ line genetic testing for cancer patients**  
*Speaker: To be announced*

**Implementation of widespread BRCA testing - the oncologist's perspective**  
*Speaker: S. Banerjee (United Kingdom)*

**Molecular profiling of cancers- clinical utility and limitations**  
*Speaker: N. Normanno (Italy)*

**What do cancer patients understand about genetic testing?**  
*Speaker: J. Geissler (Germany)*

**Discussion & Roundup**

SUNDAY 27 SEPTEMBER 2015

Multidisciplinary Tumour Board: Breast Cancer

■ 11:30 - 12:30

Chair: P. Poortmans (Netherlands)

Case presentation by young oncologist: Early disease

Speaker: I. Kindts (Belgium)

Panel Discussion: Early disease

Case presentation by young oncologist: Locally advanced disease

Speaker: E. Vicini (Italy)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced disease

Speaker: M.V. Dieci (Italy)

Panel Discussion: Advanced disease

Pathologist

Panel: H.G. Russnes (Norway)

Medical Oncologist

Panel: F. Cardoso (Portugal)

Surgical Oncologist

Panel: I.T. Rubio (Spain)

Pathologist

Panel: J. Reis-Filho (United Kingdom)

Medical Oncologist

Panel: M. Campone (France)

Oncology Nurse

Panel: Y. Wengström (Sweden)

Debate: This House Believes that Supplementary Rectal Irradiation can Avoid Surgery and Achieve more Complete Clinical Remission

11:30 - 12:30

Moderator: H. Rutten (Netherlands)  
Speaker in favour: C. Rödel (Germany)  
Speaker against: D. Sebag-Montefiore (United Kingdom)  
Seconder in favour: C. Marijnen (Netherlands)  
Seconder against: A. Martling (Sweden)

Discussion & Voting

Multidisciplinary Tumour Board: Lung Cancer

■ 11:30 - 12:30

Chair: J. Vansteenkiste (Belgium)

Case presentation by young oncologist: Early disease

Speaker: F. Cellini (Italy)

Panel Discussion: Early disease

Case presentation by young oncologist: Locally advanced disease

Speaker: A. Legras (France)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced disease

Speaker: R. Califano (United Kingdom)

Panel Discussion: Advanced disease

Radiation Oncologist

Panel: J.S.A. Belderbos (Netherlands)

Surgical Oncologist

Panel: J. Edwards (United Kingdom)

Pathologist

Panel: E. Brambilla (France)

Radiologist

Panel: J. Coolen (Belgium)

Oncology Nurse

Panel: K. Cedermark (Sweden)

Special Session: Management of Sarcoma Patients in Reference Centres

■ 11:30 - 12:30

Chair: S. Bonvalot (France)

Scandinavian experience

Speaker: M. Eriksson (Sweden)

Treatment in reference centres: The turning point in UK

Speaker: I. Judson (United Kingdom)

Why is it difficult to implement? Next steps

Speaker: R. Haas (Netherlands)

Recent data: Are promises fulfilled?

Speaker: I. Ray-Coquard (France)

Discussion

Multidisciplinary Tumour Board: Genitourinary Malignancies - Prostate Cancer

■ 15:15 - 16:15

Chair: B. Escudier (France)

Case presentation by young oncologist: Early disease

Speaker: G. Giannarini (Switzerland)

Panel Discussion: Early disease

Case presentation by young oncologist: Locally advanced disease

Speaker: B. De Bari (Switzerland)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced

Speaker: M.A. Ozturk (Turkey)

Panel Discussion: Advanced disease

Urologist

Panel: T. de Reijke (Netherlands)

Radiotherapist

Panel: V. Khoo (United Kingdom)

Radiologist

Panel: J. Barentsz (Netherlands)

Pathologist

Panel: T. Van Der Kwast (Canada)

Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury

■ 15:15 - 16:15

Moderator: E. De Álava (Spain)  
Speaker in favour: J. Coindre (France)  
Speaker against: J.V.M.G. Bovee (Netherlands)  
Seconder in favour: W.T.A. Van der Graaf (Netherlands)  
Seconder against: A. Le Cesne (France)

Discussion & Voting

Scientific Symposium: Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer

■ 17:00 - 18:30

Chair: A. Børresen-Dale (Norway)  
Co-Chair: C. Caldas (United Kingdom)

Inference of tumour evolution during chemotherapy

Speaker: S. Aparicio (Canada)

Heterogeneity and treatment failure in HER2 positive breast cancers

Speaker: L. Carey (USA)

Role of liquid vs solid biopsies in monitoring treatment

Speaker: C. Caldas (United Kingdom)

New frontiers in molecular imaging to improve targeting of high risk disease

Speaker: E.G.E. De Vries (Netherlands)

Discussion & Roundup

Scientific Symposium: Muscle Invasive Bladder Cancer

■ 17:00 - 18:30

Chair: T. De Reijke (Netherlands)  
Co-Chair: C.N. Sternberg (Italy)

Biomarkers in bladder cancer

Speaker: J. Bellmunt (USA)

Surgical treatments: What is new?

Speaker: T. Lebreton (France)

Chemoradiotherapy

Speaker: N.D. James (United Kingdom)

Neo-adjuvant versus adjuvant treatment

Speaker: C.N. Sternberg (Italy)

Discussion & Roundup

MONDAY 28 SEPTEMBER 2015

Scientific Symposium: New Drugs on the Horizon II

■ 09:15 - 10:45

Chair: E. Raymond (Switzerland)  
Co-Chair: M.E. Scheulen (Germany)

TNBC: Biomarkers and opportunities for individualised therapy

Speaker: F. Cardoso (Portugal)

Prostate cancer: From therapeutic nihilism to diversity in treatment options - what can be added?

Speaker: B. Tombal (Belgium)

Multiple myeloma: Of new drugs and new combinations

Speaker: P. Moreau (France)

Discussion & Roundup

Multidisciplinary Tumour Board: Gastrointestinal Malignancies - Colorectal Cancer

■ 11:30 - 12:30

Chair: G. Beets (Netherlands)

Case presentation by young oncologist: Early disease

Speaker: J.R. Van der Vorst (Netherlands)

Panel Discussion: Early disease

Case Presentation by young oncologist: Locally advanced disease

Speaker: F. Cellini (Italy)

Panel Discussion: Locally advanced disease

Case presentation by young oncologist: Advanced disease

Speaker: A. Hollebecque (France)

Panel Discussion: Advanced disease

Medical Oncologist

Panel: C. Koehne (Germany)

Radiation Oncologist

Panel: K. Haustermans (Belgium)

Pathologist

Panel: P. Quirke (United Kingdom)

Radiologist

Panel: G. Brown (United Kingdom)

Special Session: Biomarkers in Melanoma

■ 11:30 - 12:30

Chair: H. Gogas (Greece)

Immunotherapy: Is there any predictive biomarkers?

Speaker: L. Zitvogel (France)

The role circulating tumour cells in melanoma

Speaker: C. Dive (United Kingdom)

ctDNA

Speaker: A. Thierry (France)

Discussion

Special Session: The Molecular and Histological Classification of Gastro-Oesophageal Cancer: Implications for Treatment

■ 11:30 - 12:30

Chair: M. Hidalgo (Spain)

Re-classification of OG Cancer through distinct molecular phenotypes

Speaker: A. Bass (USA)

Implication for therapeutic exploitation

Speaker: D. Cunningham (United Kingdom)

Tailored surgical approach

Speaker: F. Roviello (Italy)

Discussion

Special Session: The Prerequisite for Ideal Biobanking

■ 15:15 - 16:15

Chair: J. Dillner (Sweden)

How much is important for the basic research the material and the dataset?

Speaker: F. Carneiro (Portugal)

From the operating room to the laboratory. The value of surgery standardisation and data collection in a tissue bank

Speaker: G. Corso (Italy)

Interventional radiologist's perspective

Speaker: J. Futterer (Netherlands)

Discussion



### Scientific Symposium: Personalised Medicine: Biomarkers, Surrogacy and Companion Diagnostics

■ 17:00 - 18:30

Chair: S. Litière (Belgium)  
Co-Chair: L.L. Siu (Canada)

#### Pharmacologic biomarkers in the development of stratified cancer medicine

Speaker: H. Newell (United Kingdom)

**One size doesn't fit all - current status of commonly used surrogate markers across tumours: Paradigms from colorectal, lung and breast cancer**  
Speaker: M. Buyse (Belgium)

**Companion diagnostic co-development in personalised medicine (including circulating tumour cells)**  
Speaker: L.L. Siu (Canada)

**Is MRD a valid surrogate endpoint for evaluation of new drugs in leukaemia?**  
Speaker: M.G. Valsecchi (Italy)

#### Discussion & Roundup

### Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome

■ 17:00 - 18:30

Chair: Y. Van der Linden (Netherlands)  
Co-Chair: P. Naredi (Sweden)

#### Prognostic tools in palliative radiotherapy

Speaker: Y. Van der Linden (Netherlands)

#### Prognostic tools in palliative systemic therapies

Speaker: A. Reyners (Netherlands)

#### Prognostic tools in palliative surgery

Speaker: P. Naredi (Sweden)

#### Nurses' perspectives on supporting prognostic information in palliative care

Speaker: L. Fallowfield (United Kingdom)

#### Discussion & Roundup

### Scientific Symposium: Making Survivor Care Evidence Based for the Growing Number of Survivors: Patients at the Forefront of Their Own Survivorship Care

■ 17:00 - 18:30

Chair: S. Diler (Turkey)  
Co-Chair: J. Gietema (Netherlands)

#### How late effects in testicular cancer guide follow-up

Speaker: H.S. Haugnes (Norway)

**Exploiting dormant information on long-term follow-up outcome of EORTC Lymphoma trials: The EORTC survivorship initiative**  
Speaker: L. Moser (Portugal)

**How to involve the primary care physician in survivor care for growing number of survivors**  
Speaker: E. Grunfeld (Canada)

#### Patients in control of navigating their own survivor care plan

Speaker: J. Gietema (Netherlands)

#### Discussion & Roundup

### TUESDAY 29 SEPTEMBER 2015

### Integrated Session: Immunotherapy in NSCLC - 2015

■ 09:00 - 11:00

Chair: L. Paz-Ares (Spain)  
Co-Chair: M. Reck (Germany)

#### Introduction

Speaker: L. Paz-Ares (Spain)

#### Lung cancer: An immunogenic tumour?

Speaker: S.A. Quezada (United Kingdom)

#### Any place for vaccination strategies?

Speaker: J. Vansteenkiste (Belgium)

#### Check point inhibitors - where do we stand and where are we going?

Speaker: M. Reck (Germany)

#### Biomarkers - a realistic perspective?

Speaker: K. Kerr (United Kingdom)

#### Discussion & Roundup

### Integrated Session: Immunotherapy in the Management of Metastatic Melanoma

■ 09:00 - 11:00

Chair: A.M.M. Eggermont (France)  
Co-Chair: P.A. Ascierto (Italy)

#### Introduction

Speaker: A.M.M. Eggermont (France)

#### Biomarkers for the complex biology of melanoma immunotherapy

Speaker: C. Robert (France)

#### Immunogens and immunostimulatory monoclonal antibodies

Speaker: I. Melero (Spain)

#### Melanoma targeted therapies in the interface with immunotherapy

Speaker: A. Ribas (USA)

#### Virotherapy and immunotherapy

Speaker: A. Melcher (United Kingdom)

#### Discussion & Roundup

### Special Session: Management Strategies for Hereditary Gene Mutation Carriers with Early Breast Cancer

■ 11:15 - 12:15

Chair: P. Poortmans (Netherlands)

#### Expanding the range of gene testing as next generation sequencing enters clinical practice

Speaker: F. Fostira (Greece)

#### Surgical strategies for gene carriers: Breast conservation versus unilateral or bilateral mastectomy

Speaker: O. Gentilini (Italy)

#### Tailoring chemotherapy for hereditary breast cancer carriers

Speaker: A. Tutt (United Kingdom)

#### Discussion

## PATIENT ADVOCACY

### SATURDAY 26 SEPTEMBER 2015

### Patient Advocacy Session: Information Provision

■ 10:30 - 12:30

Chair: I. Banks (Belgium)  
Chair: J. Gore-Booth (France)

#### Introduction

Speaker: I. Banks (Belgium)

#### Patient Information

**Communication skills that support and facilitate shared decision making**  
Speaker: B. Hacking (United Kingdom)

**Getting through when fear gets in the way**  
Speaker: N. Van den Cruyce (Belgium)

**Communicating sexual issues**  
Speaker: E. McCaughan (United Kingdom)

#### Discussion

**Doctor/Patient communication - role play**  
Speakers: To be announced

### Patient Advocacy Session: Inequalities in Genetic and Biomolecular Testing

■ 15:15 - 16:15

Chair: S. Erdem (Turkey)  
Chair: J. Kelly (Ireland)

#### What is genetics?

Speaker: To be announced

**Genetic screening: What should you know?**

Speaker: J. Brunet (Spain)

#### Discussion

### Patient Advocacy Session: Ensuring Quality of Treatment

■ 16:45 - 18:15

Chair: S. Diler (Turkey)

**What are generics and biosimilars?**  
Speaker: R. Bergström (Belgium)

**Counterfeits: Generics, substandard drugs, counterfeit medicines - what is the difference?**  
Speaker: M. Isles (United Kingdom)

**Regulating medicines and medical devices**  
Speaker: To be announced

**The European Atlas of Access to Myeloma Treatment**  
Speaker: E. Low (United Kingdom)

#### Discussion

### Patient Advocacy Session: Rehabilitation

■ 09:15 - 11:15

**Childhood and Adolescents**  
Chair: G. Bode (Germany)  
Chair: W. Tse Yared (Belgium)

**Family and youth rehabilitation**  
Speaker: S. Sauter (Germany)

**Mentoring: Patients helping each other**  
Speaker: M. Willi (Austria)

**Create your future: Supporting survivors into the workforce**  
Speaker: S. Karner (Austria)

#### Discussion

**Adults**  
Chair: K. Oliver (United Kingdom)  
Chair: J. Pelouchova (Czech Republic)

**Cancer in the workplace**  
Speaker: I. Banks (Belgium)

**Your Life: For patients who want to take action themselves**  
Speaker: S. Houmand Lysdal (Denmark)

**Rehabilitation: Summary and analysis of actions among European countries**  
Speaker: K.O'Regan (Belgium)

#### Discussion

### Patient Advocacy Session: Multidisciplinary Teams under the Microscope

■ 15:15 - 16:15

Chair: K. Mastris (United Kingdom)  
Chair: J. Borrás (Spain)

**Pain, pride and prejudice**  
Speaker: K. Mastris (United Kingdom)

**The patient and the pathologist**  
Speaker: K. Oliver (United Kingdom)

**The bill of rights**  
Speaker: P. Selby (United Kingdom)

#### Discussion

### Patient Advocacy Session: Communication - Stop Press Session

■ 17:00 - 18:30

Chair: J. Geissler (Germany)

**Wrap up discussion /recommendations from the patient advocacy track**  
Facilitator: J. Geissler (Germany)

Details to be announced in the online searchable programme and final programme as soon as possible

### MONDAY 28 SEPTEMBER 2015

### Patient Advocacy Session: Clinical Trials- What Really Matters to Patients

■ 09:15 - 10:45

Chair: M. Piccart (Belgium)  
Co-Chair: B. Ryll (Sweden)  
Panel: A.M.M. Eggermont (France)  
Panel: J. Reis-Filho (USA)  
Panel: L.L. Siu (Canada)  
Panel: To be announced

## SARCOMA: SOFT TISSUE AND BONE

**SATURDAY 26 SEPTEMBER 2015**

### Teaching Lecture: Is There Any New Treatment in Metastatic STS?

■ 07:45 - 08:30

Chair: I. Judson (United Kingdom)  
Speaker: J.Y. Blay (France)

### Special Session: Successes and Uncertainties for Targeted Therapies of Sarcomas

■ 15:15 - 16:15

Chair: J.Y. Blay (France)

### Trabectedine and M2 macrophages

Speaker: M. D'Incalci (Italy)

### MDM2/CDK4: Good targets?

Speaker: O. Mir (France)

### CSF1R Ab or Ib

Speaker: G. Demetri (USA)

### Discussion

**SUNDAY 27 SEPTEMBER 2015**

### Teaching Lecture: Long Term Physical Outcomes of Bone Sarcoma Surgery in Children and Young Adults

■ 08:00 - 08:45

Chair: R. Ladenstein (Austria)  
Speaker: R.J. Grimer (United Kingdom)

### Scientific Symposium: Local Treatment Is the Key Medical Scientific Question

■ 09:15 - 10:45

Chair: S. Bonvalot (France)  
Co-Chair: P. Rutkowski (Poland)

### Quality assurance in surgery

Speaker: A. Gronchi (Italy)

### Hallmarks of hyperthermia

Speaker: R.D. Issels (Germany)

### Nanoparticle therapies

Speaker: S. Bonvalot (France)

### New questions for RT in randomised trials

Speaker: R. Haas (Netherlands)

### Discussion & Roundup

### Special Session: Management of Sarcoma Patients in Reference Centres

■ 11:30 - 12:30

Chair: S. Bonvalot (France)

### Scandinavian experience

Speaker: M. Eriksson (Sweden)

### Treatment in reference centres: The turning point in UK

Speaker: I. Judson (United Kingdom)

### Why is it difficult to implement? Next steps

Speaker: R. Haas (Netherlands)

### Recent data: Are promises fulfilled?

Speaker: I. Ray-Coquard (France)

### Discussion

### Debate: This House Believes that Molecular Diagnosis of Sarcoma is a Luxury

■ 15:15 - 16:15

Moderator: E. de Álava (Spain)  
Speaker in favour: J. Coindre (France)  
Speaker against: J.V.M.G. Bouee (Netherlands)  
Seconder in favour: W.T.A. van der Graaf (Netherlands)  
Seconder against: A. Le Cesne (France)

### Discussion & Voting

## SUPPORTIVE CARE AND PALLIATION

**SATURDAY 26 SEPTEMBER 2015**

### Scientific Symposium: ECCO/MASCC Joint Symposium

■ 16:45 - 18:15

Details to be announced in the online searchable programme and final programme as soon as possible

**MONDAY 28 SEPTEMBER 2015**

### Teaching Lecture: Developing and Testing Supportive Care Interventions

■ 08:00 - 08:45

Chair: A. Margulies (Switzerland)  
Speaker: M. Eicher (Switzerland)

### Special Session: The Challenge of Spiritual Caring in Supportive Care and Palliation

■ 15:15 - 16:15

Chair: A. Charalambous (Cyprus)

### What does spiritual caring mean - from patient perspective

Speaker: C. Puchalski (USA)

### Why is it difficult to care for the patient spiritually?

Speaker: D. Baldacchino (Malta)

### Discussion

### Scientific Symposium: How to Select the Best Palliative Treatments on the Basis of Survival and Treatment Outcome

■ 17:00 - 18:30

Chair: Y. Van der Linden (Netherlands)  
Co-Chair: P. Naredi (Sweden)

### Prognostic tools in palliative radiotherapy

Speaker: Y. Van der Linden (Netherlands)

### Prognostic tools in palliative systemic therapies

Speaker: A. Reyners (Netherlands)

### Prognostic tools in palliative surgery

Speaker: P. Naredi (Sweden)

### Nurses' perspectives on supporting prognostic information in palliative care

Speaker: L. Fallowfield (United Kingdom)

### Discussion & Roundup

**TUESDAY 29 SEPTEMBER 2015**

### Teaching Lecture: Lessons Learned from a Study to Reduce Fatigue in Men with Prostate Cancer

08:00 - 08:45

Chair: C. Ripamonti (Italy)  
Speaker: J. Armes (United Kingdom)

### Educational Symposium: New Drugs for Symptom Management of Pain, Cancer Cachexia and Depression in Cancer Patients

■ 09:00 - 11:00

Chair: A. Cervantes (Spain)

### How to identify, assess and monitor pain, cachexia and depression in routine (busy) care?

Speaker: S. Kaasa (Norway)

### Cancer pain: New drugs and interventions

Speaker: M. Fallon (United Kingdom)

### Cancer cachexia

Speaker: F. Strasser (Switzerland)

### Depression

Speaker: To be announced

### Discussion & Roundup

### Special Session: Paediatric Palliative Care - Complexity Calls for Novelty

■ 11:15 - 12:15

Chair: C. Ripamonti (Italy)

### Management of cancer related pain

Speaker: To be announced

### Home management of dying children

Speaker: To be announced

### Psychosocial support for dying children and their parents: The nursing role

Speaker: T. Tsitsi (Cyprus)

### Discussion

## SURGICAL ONCOLOGY

**SATURDAY 26 SEPTEMBER 2015**

### Teaching Lecture: Surgery in Synchronous Oligometastatic Disease

■ 07:45 - 08:30

Chair: C.J.H. Van de Velde (Netherlands)  
Speaker: P. Naredi (Sweden)

### Society Session: European Society of Surgical Oncology (ESSO)

10:30 - 12:30

Chair: R.A. Audisio (United Kingdom)  
Chair: S. Gonzalez-Moreno (Spain)

### Presentation of the ESSO Award

Speaker: L. Wyld (United Kingdom)

### UEMS approved Surgical Curriculum

Speaker: L. Wyld (United Kingdom)

### The training in surgical oncology across the EU

Speaker: J.R. Van der Vorst (Netherlands)

### Travelling fellowship in surgical oncology across the Atlantic

Speaker: D. Perez (Germany)

### The surgical lead of MDTs

Speaker: H. Malik (United Kingdom)

### Virtual reality, cadaver lab and tele-tutoring: Can new teaching paradigm decrease learning curves assuring surgical quality?

Speaker: D. D'Ugo (Italy)

### Questions & Answers

### Special Session: Highly Skilled Surgery and Patients Outcomes

■ 15:15 - 16:15

Chair: S. Gonzalez-Moreno (Spain)

### Learning curve for complex cancer surgery

Speaker: S. Kusamura (Italy)

### Locally advanced pelvic lesions

Speaker: P. Tekkis (United Kingdom)

### Robots: Nurse's role in high-tech surgical theatres

Speaker: D. Lichosik (Italy)

### Discussion

### Scientific Symposium: Neoadjuvant Treatment - When is It of Benefit for the Patient and Doctor?

■ 16:45 - 18:15

Chair: R.A. Audisio (United Kingdom)  
Co-Chair: R. Glynne-Jones (United Kingdom)

### Surgical issues and cancer outcomes

Speaker: S. Gonzalez-Moreno (Spain)

### The timing of radiotherapy in the NT setting

Speaker: J.F. Bosset (France)

### What does complete response look like?

Speaker: R.G.H. Beets-Tan (Netherlands)

### Pathological CR: Predicament or promise?

Speaker: A.P. Dei Tos (Italy)

### Discussion & Roundup

## SUNDAY 27 SEPTEMBER 2015

### Special Session: Excisional Margins in 2015

■ 15:15 - 16:15

Chair: I.T. Rubio (Spain)

#### Is the excisional margin important in breast cancer treatment?

Speaker: I.T. Rubio (Spain)

#### What minimal excisional margin in liver surgery can be accepted?

Speaker: G. Poston (United Kingdom)

#### Local recurrence after radically resected pancreatic cancer - what have we missed?

Speaker: C. Verbeke (Sweden)

### Discussion

## MONDAY 28 SEPTEMBER 2015

### Teaching Lecture: Radical Approach to Peritoneal Surface Malignancies using Cytoreductive Surgery

■ 08:00 - 08:45

Chair: S. Eurard (France)

Speaker: S. Gonzalez-Moreno (Spain)

### Special Session: The Right Surgery for the Right Patient - Predictions & Outcomes

15:15 - 16:15

Chair: T. Gruenberger (Austria)

#### Selection for risk reduction surgery in hereditary syndromes

Speaker: To be announced

#### Individualised treatment for older cancer patients

Speaker: R.A. Audisio (United Kingdom)

#### Have guidelines improved outcomes or not?

Speaker: S. Sandrucci (Italy)

### Discussion

## YOUNG ONCOLOGISTS

### SATURDAY 26 SEPTEMBER 2015

#### Young Oncologists Mentorship Session 1

■ 13:00 - 14:30

Chair: J.R. Van der Vorst (Netherlands)

#### Basic/Translational Research

Mentor: R. Marais (United Kingdom)

#### Medical Oncology

Mentor: C.C. Zielinski (Austria)

#### Radiation Oncology

Mentor: M. Baumann (Germany)

#### Surgical Oncology

Mentor: A. Baildam (United Kingdom)

#### Oncology Nursing

Mentor: A. Margulies (Switzerland)

Ticketed session

### Workshop: How to Avoid Burnout - Achieving Optimal Work-Life Balance

■ 13:00 - 14:30

Coordinator: M. Strijbos (Belgium)

Speaker: S. Banerjee (United Kingdom)

### Special Session: Career Opportunities for Young Oncologists in Europe

■ 15:15 - 16:15

Chair: R. Califano (United Kingdom)

#### How to get the most out of a research fellowship abroad - medical oncology and lab opportunities?

Speaker: G. Mountzios (Greece)

#### Surgical research opportunities

Speaker: J.R. Van der Vorst (Netherlands)

#### Radiotherapy research opportunities

Speaker: E.C. Moser (Portugal)

### Discussion

### Scientific Symposium: Cancer Genetics for Oncologists - Issues in Clinical Practice

■ 16:45 - 18:15

Chair: S. Postel-Vinay (France)

Co-Chair: J. Rodon (Spain)

#### Germ line genetic testing for cancer patients

Speaker: To be announced

#### Implementation of widespread BRCA testing - the oncologist's perspective

Speaker: S. Banerjee (United Kingdom)

#### Molecular profiling of cancers- clinical utility and limitations

Speaker: N. Normanno (Italy)

#### What do cancer patients understand about genetic testing?

Speaker: J. Geissler (Germany)

### Discussion & Roundup

## SUNDAY 27 SEPTEMBER 2015

### Special Session: How to Improve Cancer Training and Career Planning?

■ 11:30 - 12:30

Chair: S. Banerjee (United Kingdom)

#### Oncological surgical training and career plans

Speaker: J. Butler (United Kingdom)

#### Medical oncology training and career plans

Speaker: R. Popescu (Switzerland)

#### Radiotherapy training and career plans

Speaker: S. Rivera (France)

### Discussion

#### Young Oncologists Mentorship Session 2

■ 13:00 - 14:30

Chair: R. Califano (United Kingdom)

#### Basic/Translational Research

Mentor: T. Helleday (Sweden)

#### Medical Oncology

Mentor: A. Cervantes (Spain)

#### Radiation Oncology

Mentor: P. Poortmans (Netherlands)

#### Surgical Oncology

Mentor: T. de Reijke (Netherlands)

#### Oncology Nursing

Mentor: L. Sharp (Sweden)

Ticketed session

### Workshop: How to Break Significant News

■ 13:00 - 14:30

Coordinator: J.R. Van der Vorst (Netherlands)

Speaker: D. Schmitt (Germany)

Speaker: L. Fallowfield (United Kingdom)

## MONDAY 28 SEPTEMBER 2015

#### Young Oncologists Mentorship Session 3

■ 13:00 - 14:30

Chair: S. Banerjee (United Kingdom)

#### Basic/Translational Research

Mentor: A. Børresen-Dale (Norway)

#### Medical Oncology

Mentor: B. Escudier (France)

#### Radiation Oncology

Mentor: Y. Lievens (Belgium)

#### Surgical Oncology

Mentor: S. Gonzalez-Moreno (Spain)

#### Oncology Nursing

Mentor: D. Kelly (United Kingdom)

Ticketed session

### Workshop: Making the Right Oncology Career Choices for You

■ 13:00 - 14:30

Coordinator: E. Martinelli (Italy)

Speaker: F. Cardoso (Portugal)



## Young Oncologists @ ECC2015

Undoubtedly, the European Cancer Congress is the must-attend event for all young oncologists in Europe in 2015.

The Congress is the leading European platform for presenting practice-changing scientific data and a unique multidisciplinary context where different areas of oncology converge to explore innovative solutions to help cancer patients. These factors combine to create the best environment to foster the professional growth of a young oncologist.

However, the European Cancer Congress traditionally does much more than that for our promising young oncologists and ECC2015 takes this tradition even further.

The programme includes a special track dedicated to young professionals in the field of oncology. This track is designed to provide advanced knowledge building a bridge between scientific progress and the clinical setting ("Cancer Genetics for Oncologists – Issues in Clinical Practice") as well as provide deeper understanding of broader aspects of cancer care ("How to Break Significant News").

At the same time, the Congress programme makes a point of providing invaluable mentorship opportunities for young oncology professionals. The Congress gathers in one place the most brilliant scientists and practitioners who have a strong commitment to the sharing of their experience and wisdom with the new generation of specialists. At ECC2015, young oncologists will be able to participate in special mentorship sessions designed to ensure this handover of learning acquired through a wealth of experience at the highest level of oncology practice.

Learning won't stop there – the programme will offer sessions focused on key topics that affect every young oncologist in Europe. Experts will offer guidance on issues such as career opportunities in Europe and making the right choices among them, improving cancer training and avoiding burnout by ensuring a good work/life balance.

The Congress offers numerous networking opportunities which will help young specialists build invaluable and enduring working relationships to support their professional future.

**We encourage young oncologists to register early for ECC2015 and make the most of this extraordinary career-making event!**

**Put your knowledge  
to the test on  
26 September 2015**

## ESMO Examination

### Why take the ESMO Examination?

- Assess your knowledge in medical oncology
- Become an ESMO Certified Member
- Collect ESMO-MORA CME points

The ESMO Examination will take place during the European Cancer Congress in Vienna with simultaneous sessions in other locations.

Register now at [esmo.org](http://esmo.org)

**Early Registration:** 16 March 2015  
**Late Registration:** 22 July 2015

### How to prepare

- Review the ESMO Examination Trial Questions online
- Access educational material online via OncologyPRO's Tumour Knowledge Portal
- Attend the **ESMO Academy, 28-30 August 2015** for an interactive, in-depth update about the major topics in oncology. Reduced fees and travel grants available for attendees pre-registered for the ESMO Examination

## Patient Advocacy @ ECC2015

Developments and innovations in oncology that will lead to better outcomes can only happen by listening to patients. Without actively listening to the needs and wishes of patients, it will be impossible to fully understand and assess whether treatments are effective and this will be particularly important with the growth of personalised medicine. This is why the ECC Patient Advocacy Track Chair and experts have worked together with ECC2015 scientific track chairs to enrich the scientific programme with the patient perspective.

Patient advocates will participate in a roundtable discussion on oncology drug development in the era of genomic sequencing and will contribute their views on the evaluation of the clinical benefit of cancer drugs as well as what matters to patients in clinical trials.

The perspective of patients on survivor care will be provided in a scientific symposium looking for ways to make survivor care evidence-based for the growing number of survivors. Empowering each survivor to play a leading role in his/her own care will be a recurring theme at ECC2015. The European Cancer Congress will re-examine and shed new light on key topics for patients and survivors so that stakeholders can explore areas of collaboration particularly aimed at tackling inequalities in cancer care. A full session will look at the flow of information between healthcare professionals and patients and address topics like communication skills that facilitate shared decision making, dealing with fear both from a patient and from a healthcare professional perspective, communication on issues of sexuality and all other quality of life angles.

ECC2015 will provide educational opportunities for patient advocates so they can deepen their understanding of topics such as genetic and biomolecular testing, generics and sub-standard drugs.

Attendance scholarships covering travel and registration costs will be available to patient advocates to facilitate their participation at the European Cancer Congress.

Details will be published on [www.europeancancercongress.org](http://www.europeancancercongress.org)

## Oncopolicy Forum

Unique to the European Cancer Congress is the inclusion of a **track dedicated to public policy in cancer control**, featuring the most pertinent issues faced by practitioners and other actors across the cancer continuum. The **Oncopolicy Forum (OPF)** harnesses the expertise and experience of the entire oncology community to bridge the gap between science and policy, and maximise the potential for achieving positive policy development with patient interests at the core.

The OPF has repeatedly re-affirmed itself as a unique platform for fruitful exchange between experts across the cancer continuum and decision-makers, leading to increased understanding of mutual needs and priorities towards informed policy making and tangible change.

The previous edition of the Oncopolicy Forum dealt with issues such as innovative approaches to the organisation of personalised cancer care across Europe, facilitating personalised care for rare cancer patients through European Reference Networks, and aligning evidence and policy for the optimal prioritisation of scarce resources in oncology. High level participants included the Commissioner for Health Tonio Borg and Member of the European Parliament Teresa Riera Madurell, Rapporteur on the Horizon 2020 Programme for Research and Innovation.

This year's OPF will once more look at the most pressing issues in oncology and how public policy can play an important role in providing cancer care professionals, researchers and patients with the political and regulatory frameworks necessary to advance patient outcomes.

On Saturday 26 September, the OPF2015 will kick-off with the first in a series of **'Timebombs in oncology'**, starting with **cancer survivorship**. This timebomb poses many policy challenges including how to implement effective 'back to work' schemes for those willing and able to return to the workplace. **Cancer in the elderly** will be in focus on Sunday 27 September. With the retirement age increasing in many countries, the number of people working with long-term medical conditions including certain cancers will also increase. Some employers have recognised this and are implementing workplace initiatives to address the problem. Finally, the **oncology workforce** will be put under the microscope on Monday 28 September and discussion with the audience will seek to solicit possible policy solutions in anticipation of workforce shortages in essential disciplines.

**Inequalities in treatment outcomes** - both between and within European countries - are among the other topical issues at the OPF2015. Thus, on Sunday 27 September, we will look at the current state of affairs and evaluate the multi-stakeholder effort required to ensure effective equality of access to treatment and medicines.

Another important session on Monday 28 September will unlock the possibilities for **cancer research funding under the EU budget 2014 - 2020**. It will enable participants to understand the sometimes complex landscape and identify the most relevant opportunities to benefit from available programmes, such as Horizon 2020. On the same day, the OPF2015 will address the critical developments on cross-border movement of cancer patients and the setting up of brand-new European Reference Networks in rare cancers.

OPF participants will have the opportunity to engage as part of an exceptional pool of multi-disciplinary cancer stakeholders - patients and professionals, to raise awareness on the issues in day-to-day oncology care, and ultimately contribute to influencing policy making in Europe.

## Call for Abstracts

### When to Submit

**Abstract submission open: 26 January 2015**  
**Abstract submission deadline: 28 April 2015, 21:00 Central European Time**

#### Abstracts submitted after the stipulated deadline will not be considered.

Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

### Abstract Policy and Regulations

Abstracts on case studies will be rejected.

With the submission of an abstract to European Cancer Congress 2015, the presenting author:

- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the European Cancer Congress 2015.
- Agrees to submit updated data for important large studies presented (in part) at previous meetings. Violation of this policy may result in rejection of the submitted abstract.

- Certifies that the information in the abstract is for exclusive presentation in the European Cancer Congress 2015 Scientific Programme and will not be presented during the ECC2015 at any Satellite Symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- For abstracts containing clinical trial data include: Trial abbreviation; Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure (s), Analysis, Trial status, Trial sponsor(s)
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- Releases the copyright on behalf of all authors, to ECCO and gives permission for the abstract, when selected for presentation, to be published in the European Cancer Congress 2015 Abstract book - a European Journal of Cancer Supplement (in electronic format), as well as on the ECC2015 website.
- **Trials in Progress** abstracts and encore presentations **will not** be accepted.

### Abstract Selection Process

Abstracts submitted for presentation in the European Cancer Congress 2015 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

The following presentation formats are applicable at the European Cancer Congress 2015:

#### Oral presentation

The abstract is selected for oral presentation in one of the proffered papers sessions. Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective.

#### Poster Presentation

Abstracts that have been selected for poster presentation will be displayed on poster boards in a prominent poster viewing area next to the exhibition. The posters will be grouped by topic and displayed for four hours each. A specific time will be devoted to poster viewing to ensure delegates have sufficient opportunity to acquaint themselves with the presented data.

#### Poster Discussion

Prominent experts will provide a thematic overview and discuss the findings from selected abstracts chosen for poster presentation. Delegates will be offered an expert review-at-a-glance of the presented findings and will be able to further refine their interest in specific abstracts.

#### Poster Spotlight Sessions

The Scientific Committee will make a special selection of posters which will be highlighted through short oral presentations followed by moderated discussion. These sessions will facilitate dynamic exchange on selected findings of broad interest.

### Abstract Withdrawal

ECCO cannot guarantee any request for withdrawal of an abstract that in any way delays the ECC2015 publications. Requests to withdraw abstracts will be accepted until 10 July 2015. After this date, abstracts selected presentation must be presented. If the presenting author of a selected abstract cannot attend, they should assign a replacement and inform ECCO of the replacement as soon as possible.

**The presenting author** will receive a letter with the result of the review and the Scientific Committee's decision on the abstract by early July.

#### Abstract Submission Fee

Each submitted abstract must be accompanied by a 35 EUR abstract submission fee. The submission fee can only be paid by credit card. This fee is non-refundable regardless of the final status of the abstract.

**Note:** Submitting an abstract for presentation in the European Cancer Congress 2015 does not constitute registration for the Congress. Abstract presenters must register to attend the European Cancer Congress 2015.

### Late-Breaking Abstracts

**Abstract submission open: 22 July 2015**  
**Abstract submission deadline: 5 August 2015, 21:00 Central European time**

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel



cancer biology with therapeutic implications – in each case the results should not have been fully available by the regular abstract submission deadline.

**Note:** The late-breaking abstract deadline is not an extension of regular abstract submission deadline.

### Policy & Regulation

Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered.

Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.

The data in the abstract cannot be published (manuscript or abstract) prior to the Congress.

With the submission of a late-breaking abstract to European Cancer Congress 2015, the presenting author must:

- Submit by the **deadline of 5 August 2015**
- Provide rationale on why the abstract should be considered as late-breaking (complete this section in the submission system).
- Ensure submission of the abstract adheres to the regular abstract submission policy and regulations in addition to the specific guidelines listed above.
- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.

### Submission

Late-breaking abstracts can only be submitted online through the submission system which will be available on the Congress website from **22 July 2015 until 5 August 2015**.

Please refer to the Abstract Submission Fee section in the Call for Abstracts.

### Selection

All late-breaking abstracts will undergo a formal peer-review evaluation by the Executive Scientific Committee and will be judged solely on the data submitted. The final decision on the status of the abstract lies with the Scientific Committee.

Late-breaking abstracts will only be considered for **oral presentation in Proffered Paper sessions** or the **Presidential sessions**. If a late-breaking abstract does not meet the criteria for oral presentation, the abstract will be rejected.

The presenting author will receive confirmation of acceptance or rejection by **20 August 2015**.

For questions regarding the submission process, e-mail [abstracts@ecco-org.eu](mailto:abstracts@ecco-org.eu)

### Embargo Policy

**Late-breaking abstracts** and **abstracts selected for media** for the European Cancer Congress 2015 are embargoed until the first day of presentation. Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at the ECC2015. The first author and co-authors must not release the research/study to news media. If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

In case of any abstract related queries please contact: [abstracts@ecco-org.eu](mailto:abstracts@ecco-org.eu)

## Abstract Topic Categories

Topic	Sub-Topic
<b>Basic Science</b>	
	Aging and Cancer, Telomerase Animal Models of Cancer Bystander and Abscopal Effects Cancer Cell Metabolism Cancer Initiating Cells/Cancer Stem Cells Cell Cycle, Cell Death, Senescence, Cell Proliferation DNA Damage and Repair Epigenetics Functional Genomics Gene Expression, Transcriptional Regulation Genomic Alterations in Cancer miRNA Oncogenes Receptors and Signal Transduction Tumour Angiogenesis Tumour Immunology Tumour Microenvironment Tumour Progression: Invasion and Metastasis Tumour Suppressor Genes Viral Oncogenesis
<b>Breast Cancer - Advanced Disease</b>	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
<b>Breast Cancer - Early Disease</b>	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
<b>Cancer in the Elderly</b>	
	Epidemiology Multi-Modality Radiotherapy Surgery Symptom Science Systemic Therapy

Topic	Sub-Topic
<b>Cancer Screening and Prevention</b>	
	Primary Prevention Secondary Prevention Tertiary Prevention
<b>Central Nervous System</b>	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
<b>Diagnostic/Biomarkers</b>	
	Biomarkers Expression Profiling Genetic Alteration
<b>Early Drug Development</b>	
	Angiogenic Inhibitors Apoptosis Inducers Cyclins and CDKs DNA Repair Mechanisms Drug Design Drug Resistance and Modifiers Drug Screening Drug Synthesis Formulation Research Monoclonal Antibodies and Targeted Toxins/Nuclides Natural Products and Marine Compounds New Molecular Targets Radiation Interactive Agents Signal Transduction Modulators Telomerase-Targeting Agents Topoisomerase Inhibitors Toxicology Tubulin-Interacting Agents Tyrosine Kinase Inhibitors
<b>Epidemiology</b>	
	General Epidemiology Genetic Epidemiology

Topic	Sub-Topic
Gastrointestinal Malignancies - Colorectal Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Gastrointestinal Malignancies - Noncolorectal Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Genitourinary Malignancies - Nonprostate Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Genitourinary Malignancies - Prostate Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Gynaecological Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Haematological Malignancies	
	Basic Science Radiotherapy Systemic Therapy Translational Research

Topic	Sub-Topic
Head and Neck Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Imaging	
	CT-scan Molecular Imaging MRI Multimodality Imaging New Methodologies Nuclear Medicine Ultrasound
Immunotherapy of Cancer	
	Adoptive Immunotherapy Combination Therapy Engineered T-Cell Therapy Immunocytokines Immunomodulation Monitoring of Immunotherapy Vaccines
Lung Cancer - Localised/Local Regional Disease	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Lung Cancer - Metastatic Disease	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Melanoma and Skin Cancer	
	Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research

Topic	Sub-Topic
New Technologies in Cancer	
	Basic Medical Engineering Clinical Medical Engineering Computational Models of Biological Systems DNA Detection Technologies Integrated Biology Internet Technology for Oncology Nanotechnology New Imaging Technologies New Non Ionising Radiation Treatment Technology New Treatment Technologies: Ionising Radiation Novel Communication Systems Novel IT for Oncology Novel Navigation Systems Oncology Information Systems Patient Safety Systems Technology Proteomics/Mass Spectrometry RNA Detection Technologies Telemetry and Cyber Physical Systems for Oncology Tele-Oncology
Oncology Nursing	
	Advanced Nursing Roles End of Life Care Impact of Cancer on Patients and Families New Developments Supportive and Palliative Care Survivorship and Rehabilitation Symptom Management Transitions in Care
Paediatric Oncology	
	Multi-Modality Radiotherapy Surgery Systemic Therapy
Public Health, Health Economics, Policy	

Topic	Sub-Topic
Radiobiology/Radiation Physics/ Radiotherapy Techniques	
	Basic Radiation Physics Basic Radiobiology Biomarkers for Radiation Oncology Clinical Radiation Physics Clinical Radiobiology Combined Modality Treatment Health Economics in Radiation Oncology Imaging for Radiotherapy Modification of Radiation Response Monitoring of Response During Radiation Therapy Multiprofessional Team Development New Radiation Therapy Technologies Prediction and Stratification in Radiation Oncology Professional Development Quality Assurance Radiotherapy Outcome Assessment Radiotherapy Techniques Technology Assessment in Radiation Oncology Treatment Delivery Treatment Planning
Sarcoma: Soft Tissue and Bone	
	Basic science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research
Supportive Care and Palliation	
	Palliative Care Psychosocial Aspects Quality of Life Supportive care
Surgical Oncology	
	Experimental Surgical Oncology Image-Guided Surgery Intraoperative Radiation Therapy Local Ablative Treatment Oncoplastic Surgery Regional Treatment Robotic-Assisted surgery

Topic	Sub-Topic
<b>Translational Research</b>	
	Antibody Based Therapies
	Biomarkers with Clinical Relevance
	Bystander and Abscopal Effects
	Cancer Genomics & Bioinformatics
	Cancer Vaccine Therapies
	Cellular Therapies
	Emerging Targets
	Epigenetics
	Inflammation and Cancer
	Molecular Biology in the Clinic
	Molecular Pathology
	Prognostic Biomarkers of Therapy Response
	Prognostic Value of Oncogenomics
	Signalling Pathways
	Tumour Microenvironment
	Tumour Stem Cells

Topic	Sub-Topic
<b>Other</b>	



## ECCO/EJC Young Investigator's Award

ECCO - the European CanCer Organisation and EJC - European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator's Award, to be presented at 18<sup>th</sup> ECCO - 40<sup>th</sup> ESMO European Cancer Congress.

The ECCO/EJC Young Investigator's Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.

For details on the application criteria and process, visit [www.europecancercongress.org/EJC](http://www.europecancercongress.org/EJC)

**Deadline for applications: 5 May 2015**

Applications should be sent to Anne Blondeel, Congress Programme Coordinator via Email: [anne.blondeel@ecco-org.eu](mailto:anne.blondeel@ecco-org.eu)

## Fellowship Grants - Application

Fellowship grants will be made available to young oncology professionals (doctors, basic scientists, oncology nurses and radiotherapy technicians) to attend the 18<sup>th</sup> ECCO - 40<sup>th</sup> ESMO - European Cancer Congress.

ECCO member societies strongly believe in the importance of facilitating access to the Congress for young oncologists as a way to help them take their next steps towards professional excellence and best practice.

- **15 Fellowship grants** are offered to young oncology professionals from countries with lower-middle income economies as per World Bank classification.
- **10 Fellowship grants** are offered to young oncology professionals from Eastern European countries.

### The following Member Societies will provide additional fellowship grants:

- EACR – 3 Fellowships (applicable to EACR members only)
- EONS – 5 Fellowships (applicable to EONS members only)
- ESMO – 3 Fellowships (applicable to ESMO members only)
- ESSO – 3 Fellowships (applicable to ESSO members only)
- SIOPE – 5 Fellowships (applicable to SIOPE members only)

Find out all you need to know on the requirements and the application process and deadlines at [www.europecancercongress.org](http://www.europecancercongress.org)

## Novice Research Dissemination Award for Oncology Nurses

If this is the first time you have submitted an abstract for an international congress and you have less than five years' experience doing research, your abstract may be considered for presentation in the **'New Oncology Nursing Research'** session.

To be considered, you must tick the box entitled **'Novice Research Dissemination Award'** during abstract submission. New oncology nursing researchers who tick this box and have their abstract accepted will be eligible for this new award.

All abstracts in this category will be judged by a panel, who will select **2 winners**. Each award winner will receive **free registration** for ECC2015, and a contribution up to **1500 EUR** will be reimbursed after the Congress **to cover travel and accommodation**.



# ESTRO AWARDS



## ESTRO - VARIAN AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of radiobiology, radiation physics, clinical radiotherapy or radiation technology.

### CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO members, having completed the submitted work in the previous year.
2. Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.
3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
4. Candidates should submit:
  - A curriculum vitae and a list of publications
  - A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
  - An English summary of their work (max 2 pages).



## ESTRO - ACCURAY AWARD

A prize of 2,500 euros will be given to a radiation oncology professional for research in the field of "High Precision Radiotherapy". Awardees may be qualified in the field of clinical radiotherapy, radiation physics, radiation technology or radiobiology.

### CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO Members, having completed the submitted work in the previous or current year.
2. Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research.
3. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
4. Candidates should submit:
  - A curriculum vitae and a list of publications,
  - A copy of the abstract on the project which should have been submitted for the European Cancer Congress (indicate abstract title and submitting author with your application)
  - An English summary of their work (max 2 pages).

### APPLICATIONS FOR THE ABOVE LISTED AWARDS ARE TO BE ADDRESSED TO:

Eralda Azizaj  
ESTRO Programme Manager  
Rue Martin V 40, 1200 Brussels, Belgium  
Tel: +32 2 775 93 40  
E-mail: [eralda.azizaj@estro.org](mailto:eralda.azizaj@estro.org)

**Deadline for submission: 1 April 2015**



Elsevier Oncology Products  
**Providing Answers**

## What do oncologists need?

Reliable, trusted research and answers fast!  
Make an impact! Get your research read worldwide.

### European Journal of Cancer (EJC)

- The official journal of the **EORTC**, **ECCO**, the **EACR** and **EUSOMA**
- Editor-in-Chief:  
**Alexander M.M. Eggermont**,  
*Villejuif, France*
- Impact Factor: 4.819  
JCR, Thomson Reuters 2013
- Available to read on your **mobile** and your **iPad**
- More than **1.2 million articles** downloaded worldwide each year
- **Open access** publishing options available



## Stay well-informed, don't miss a thing

Get monthly eTOCs and updates free: [ejcancer.com](http://ejcancer.com)

# Global readership with an immediate and far-reaching impact



Publish with *The Lancet Oncology*, the global leader in clinical oncology, and open your research to the eyes and minds of oncologists around the world.

*The Lancet Oncology* has a global online audience of 16 million researchers, clinicians, and academics across 170 countries, who this year alone accessed more than 1 million articles from our online platforms; the journal is also free online to all low-to-middle income HINARI countries.

In fact, more than 11 000 oncologists in North America and over 5000 in Europe and Asia receive the full print journal. Key articles are featured in more than 3000 news stories annually and nearly 50 000 oncologists receive our e-alert announcements.

Ensure your research has an immediate and far-reaching impact. Publish with us and make a difference in the world of clinical oncology.

**JOIN  
US** in delivering science  
for better health

THE LANCET  
Oncology

THE LANCET® is a registered trademark of Reed Elsevier Properties SA, used under licence.

## The European Cancer Congress 2015

# GROUND-BREAKING RESEARCH TRANSFORMING MODERN ONCOLOGY



- Showcase your work at this unique multidisciplinary oncology platform
- Gain cutting-edge knowledge from a wealth of sessions tailored to your research interests:
  - A dedicated EACR society session
  - A Scientific Symposium on the Therapeutic Implication of Intra Tumour Heterogeneity in Breast Cancer, chaired by A. Børresen-Dale
  - A Scientific Symposium on the Mechanisms of Resistance to Targeted Therapies, chaired by R. Marais
  - An Integrated Session on Immunotherapy in the Management of Metastatic Melanoma, chaired by A. M. M. Eggermont

Full details on:

[www.europeancancercongress.org](http://www.europeancancercongress.org)

**Special  
rates for  
EACR  
members**

**Abstract  
submission  
deadline: 28  
April 2015**







## Why You Should Participate at ECC2015

### ■ Largest European Cancer Platform:

In 2015, the 18<sup>th</sup> ECCO – 40<sup>th</sup> ESMO European Cancer Congress (ECC2015) is the largest European multidisciplinary oncology platform for all oncology stakeholders to meet, learn and discuss new ground breaking data and share best practice to provide each cancer patient with optimal treatment and care.

### ■ Impressive number of late-breaking abstracts presentations:

The European Cancer Congress is renowned for attracting and presenting a remarkable number of practice changing abstracts.

### ■ Global Impact:

The abundance of practice-changing data presented at the European Cancer Congress is widely disseminated to a global readership thanks to our worldwide media coverage generated by the hundreds of journalists attending or reporting on the Congress.

### ■ Unique Multidisciplinary Approach:

We have designed more integrated sessions bringing about dialogue and debate in overlapping areas of scientific research. The programme is therefore more streamlined, with fewer tracks, facilitating an even more productive experience for delegates.

### ■ Oncopolicy:

The European Cancer Congress remains the only European cancer meeting with a dedicated Oncopolicy forum. The Oncopolicy Forum in Amsterdam tackled topics including research, personalised medicine and care, organisation of specialised care, and translation of evidence into policy. The recommendations derived from these discussions will be revisited at the Oncopolicy Forum in Vienna in 2015.

### ■ Vienna, Trailblazer in Medicine – Host City:

Vienna is a natural host of ECC2015. Its track record as a leader in medical thought and practice speaks for itself – it has made its mark in key areas like radiotherapy, clinical diagnosis and public health to name a few.

In 2015, the thirty fifth Congress of the European Society of Surgical Oncology will take place within the multidisciplinary programme of the ECC2015.

Once again, ESSO has joined forces with the other founding members of ECCO-the European Cancer Organisation to offer an exciting scientific programme promoting multidisciplinary.

The ECC2015 scientific programme will also feature a strong **surgical oncology track** throughout the meeting covering all aspects of the investigation and treatment of the common solid cancers that form the workload of cancer surgeons.

#### Highlights of the surgical track include:

- Special Session on Excisional Margins in 2015
- Special Session on The Right Surgery for the Right Patient: Predictions & Outcomes
- Special Session on Highly Skilled Surgery and Patients Outcomes
- Teaching Lecture on Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Teaching Lecture on Surgery in Synchronous Oligometastatic Disease
- Scientific Symposium on Neoadjuvant Treatment - When Is It of Benefit for the Patient and Doctor
- Society Award Session on Education in Cancer Surgery

**Don't miss the opportunity to take part in the largest oncology congress in Europe!**

- Submit an abstract and deliver your surgical messages to the largest multidisciplinary audience in Europe.
- Learn from leaders in the field of oncology and widen your network of peers.
- Take advantage of the significant discounted rates for ESSO members !





# Oncology Advance

/Disseminating Research/Advancing Care/Improving Lives

Where cancer researchers and oncologists find the latest peer-reviewed research and reviews.

A convenient one-stop resource that:

- announces latest Articles-in-Press from Elsevier's comprehensive portfolio of Oncology journals
- provides access to the new editions and archive of the EJC News Focus updates
- transmits free Podcasts from leading publications
- keeps you informed on industry meetings and events
- and much more...



Visit [OncologyAdvance.com](http://OncologyAdvance.com) today.

ONE CLICK ACCESS TO ESSENTIAL RESOURCES IN ONCOLOGY



European  
Cancer  
Congress  
2015

See you  
in  
Vienna!

Discuss innovative  
approaches  
and their  
implications

Gain new insights  
in every area:  
from genetics to  
survivorship

Benefit from the  
special SIOPE  
member  
registration rate

Get an all-access  
pass to  
comprehensive  
multidisciplinary  
sessions

This publication has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no HEALTH-F2-2011-261474.





Gain new insights in every area:  
from leadership to genetics or  
holistic issues to survivorship



Get an all-access pass  
to comprehensive  
multidisciplinary  
sessions

Discuss  
innovative  
clinical  
approaches  
with your  
European  
colleagues

**Nurses, join us in Vienna and be part of  
the largest oncology congress in Europe!**

Our biennial multidisciplinary congress has an exciting scientific programme designed to meet practical nursing needs. The dedicated oncology nursing track is accompanied by a strong nursing component throughout all 27 tracks a part of the learning experience. Whether your nursing needs are clinical, research, or career driven you will find all you need to make a difference.

**European Cancer Congress, Vienna, 25-29th September 2015**

**[www.ecco-org.eu/ecc2015](http://www.ecco-org.eu/ecc2015)**

Photograph: The Royal Marsden NHS Foundation Trust

# 2015 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology

## Call for Nominations

ECCO – the European CanCer Organisation and the Pezcoller Foundation are pleased to announce the Call for Nominations for the 2015 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology.

For 2015, in collaboration with ECCO – The European CanCer Organisation, the Pezcoller Foundation-ECCO Recognition for Contribution to Oncology will be awarded to a single individual for his/her professional life dedication to the improvement of cancer treatment, care and research. The award is open to all professions and specialties within the oncology field.

Nominations will be accepted for candidates irrespective of race, gender or nationality. Institutions, groups or associations are not eligible. Self-nominations will not be considered. Candidates must be nominated on the official form by one who is, or has been, affiliated with a university or medical institution.

A curriculum vitae and description of the candidate's professional contribution to the field of oncology should be included with the application form.

Nominators are requested to keep their nomination confidential and to refrain from informing the nominee. The awardee will be selected by an International Committee appointed by the ECCO President with the agreement of the Council of the Pezcoller Foundation. The decision concerning the 2015 winner will be taken in April 2015.

The award consists of a prize of 30.000 EUR and a commemorative plaque. The Award Ceremonies will be held in Rovereto (Italy), on 11 September 2015 and in Vienna, during the 18th ECCO - 40th ESMO - European Cancer Congress as a Plenary Lecture to be delivered during the Presidential Session of Sunday 27 September 2015.

## Award Committee

The Award Committee is composed of 3 representatives from the Pezcoller Foundation and 3 representatives from the European CanCer Organisation (ECCO).

Those representatives are appointed by their respective Board of Directors and are not eligible for receiving the award. The ECCO CEO and ESO Director are ex-officio members of the Award Committee.

The Award Committee will convene in April 2015 under the Chairmanship of the ECCO President, Martine Piccart, Institut Bordet, Belgium.

## About the Pezcoller Foundation

*The Pezcoller Foundation was established in 1980 through a most generous donation from Professor Alessio Pezcoller, a dedicated Italian surgeon, who devoted his life to his profession. Professor Pezcoller not only made important contributions to medicine but through his generosity and foresight, provided his lifetime's savings for others to do likewise.*

*Formerly, until 1997, the Pezcoller Foundation presented an award in collaboration with the European School of Oncology (ESO). The Pezcoller Foundation-ECCO Recognition for Contribution to Oncology builds on this tradition.*

**ecco**

**Fondazione  
Pezcoller**

## More Information:

For more information about the nomination process and to submit a completed form and support documentation please contact

**Davi Kaur:**

**Tel: + 32 2 775 29 31, Fax: +32 2 775 02 00,**

**Email: [davi.kaur@ecco-org.eu](mailto:davi.kaur@ecco-org.eu)**

Nomination forms can be downloaded at:

**[www.ecco-org.eu](http://www.ecco-org.eu)**

**(select "About ECCO" > "Awards")**

**and must be completed and received by  
15 March 2015.**





# We take cancer personally

Patients are at the heart of everything we do at Roche.

They motivate and inspire us to search for and develop innovative medicines and therapeutic solutions with the goal of transforming the lives of people with cancer around the globe.

We've come a long way, but there's still a long way to go.



## Registration Fees

<b>Early Rate</b> Deadline: Tuesday 9 April 2015	<b>ECC 2015</b>
Early Rate Members	380
Early Rate Non Members	699
Early Rate Groups	699
Early Rate Junior Participants	175
Early Rate Emerging Economy	130
Early Rate Nurses Members	250
Early Rate Nurses Non-Members	375
Early Rate Patient Advocates	125
<b>Regular Rate</b> Deadline: Tuesday 4 August 2015	
Regular Rate Members	699
Regular Rate Non Members	999
Regular Rate Groups	999
Regular Rate Junior Participants	199
Regular Rate Emerging Economy	-
Regular Rate Nurses Members	355
Regular Rate Nurses Non-Members	485
Regular Rate Patient Advocates	150
<b>Late Rate</b> Deadline: Friday 18 September 2015	
Late Rate Members	999
Late Rate Non Members	1099
Late Rate Junior Participants	220
Late Rate Emerging Economy	-
Late Rate Nurses Members	460
Late Rate Nurses Non-Members	585
Late Rate Patient Advocates	170
<b>Onsite Rate</b> Deadline: As of 19 September 2015	
Onsite Rate Members/Non Members	1199
Onsite Rate Nurses Members/Non Members	685
Onsite Rate Junior Participants	235
Onsite Rate Patient Advocates	190
Day rate	355

ALL **POWER**  
OF THE **SEA**  
NOW **AGAINST**  
**CANCER**

Pharma  
Mar  
Grupo Zeltia

## Exhibition & Sponsorship Opportunities

Showcase your latest scientific data through this **uniquely powerful** platform of European and global oncology science and clinical practice.

ECC2015 offers you a wide range of opportunities to achieve the highest level of exposure to a **multidisciplinary audience** from Europe and around the world.

A vast majority of Congress participants spends time in the Exhibition Hall with an overwhelming number **expressly seeking product and technology updates**.

The Congress provides you opportunities of **proven effectiveness** like Satellite Symposia, Exhibitor Spotlight Sessions and many others.

We look forward to working with you to identify and secure the items best suited to your objectives for your participation in ECC2015.

### We look forward to greeting you in Vienna!

For information on sponsorship and exhibition opportunities, please contact:

Bruno De Man

Phone: +32 2 775 02 04

Email: [bruno.deman@ecco-org.eu](mailto:bruno.deman@ecco-org.eu)

To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECC2015 website at: [www.europeancancercongress.org](http://www.europeancancercongress.org)

## General Information

### Accommodation

Mondial Congress & Events has been appointed as the official local housing partner for the 18<sup>th</sup> ECCO – 40<sup>th</sup> ESMO European Cancer Congress and is offering hotel accommodation and other services for both groups and individuals.

Booking Accommodation for individuals are open since **1 October, 2014**.

For all accommodation queries and information, please contact:

#### Mondial Congress & Events

Operngasse 20b

1040 Vienna, Austria

Tel: +43 1 58804 0

Fax: +43 1 58804 185

E-mail: [ECC2015@mondial-congress.com](mailto:ECC2015@mondial-congress.com)

We kindly ask you to contact the appointed local housing partner directly.

The Congress secretariat cannot provide accommodation-related information or handle any such related requests.

### Congress Update Service

The Congress Update Service is the official electronic newsletter of the European Cancer Congress. It is specifically designed to share with you essential updates and notable developments in the lead up to the Congress.

Launching six months in advance, this monthly newsletter is sent to all registrants.

Please visit the website if you wish to subscribe:

[www.europeancancercongress.org](http://www.europeancancercongress.org)

### ECCO and its Founding Members

As founding members of ECCO - the European CanCer Organisation - ESMO, ESTRO, ESSO, EACR, EONS and SIOPE have joined forces once again to create a powerful platform promoting multidisciplinary. These organisations support a multidisciplinary approach as the ultimate way to ensure the best outcomes and quality of life for all cancer patients.



**ECC2015 gives you the opportunity to:**

- Join Society Sessions (see programme for full details)
- Attend Society General Assemblies (see programme for full details)
- Meet Society Secretariats at their exhibition stands
- Fast-track your Society membership application and renewal at each Society's stand
- Network in a friendly professional environment and discuss in comfort all the exciting developments at ECC2015 – all in your Society's Exclusive Member Lounge

**Insurance**

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

**Language and Translation**

The official language of the Congress is English. No simultaneous translation will be provided.

**Lunch and Refreshments**

Lunch or refreshments are not included as part of the registration fee.

**Official Carrier****Save up to 20% on travel with the Star Alliance network**

The Star Alliance™ member airlines have been appointed as the Official Airline Network for the 18<sup>th</sup> ECCO – 40<sup>th</sup> ESMO European Cancer Congress, Vienna, 25 – 29 September 2015.

Registered participants travelling to the event may qualify for a Star Alliance Conventions Plus discount of up to 20%, depending on fare and class of travel booked. To obtain the discount, please quote the event code: **OS13S15** when calling the reservation office of a participating Star Alliance member airline.

**For booking office information please visit:**

[www.staralliance.com/conventionsplus](http://www.staralliance.com/conventionsplus)

The participating airlines for this event will be announced soon on the Congress website:

**[www.europeancancercongress.org](http://www.europeancancercongress.org)**

Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

**Please note:** For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

**Networking at ECC2015**

Meeting peers from a variety of disciplines and from all around the world is at the heart of the ECC2015 experience. The Congress will provide a variety of opportunities for delegates to interact, exchange ideas and share best practice. The Congress Update Service newsletter will provide more detailed information closer to the meeting.

**Informal Networking Event**

Take this opportunity to meet colleagues from all over the world in a relaxed, friendly environment. The Congress Informal Networking Event will take place on Monday 28 September as of 20:30 at the Volksgarten Clubdiskothek, Burgring, A-1010 Vienna. Tickets can be purchased for **65 EUR** at the time of registration or onsite at the Congress (subject to availability).

**Transportation**

With their Congress badges, delegates can travel for free with Vienna's public transport system (25-29 September 2015).

The Congress Centre Messe Wien is easy to reach both by public transportation and by car. It is conveniently located within just **10 minutes** from Vienna's city centre.

**Messe Wien** is well served by underground: line **U2**, station '**Messe-Prater**', and by bus: lines **11A** and **80B**.

To reach Messe Wien by car, please use **GPS** destination **1020 Vienna, Ausstellungsstraße** or **Trabrennstraße**.





## BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC


WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the European Cancer Congress 2015 in Vienna, Austria.

And with over 18,500 flights a day to 1,316 destinations across 192 countries, our 27 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code OS13S15 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline's frequent flyer programme you belong to, you can earn and redeem miles across all 27 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to [www.staralliance.com/conventionsplus](http://www.staralliance.com/conventionsplus)



For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches that accelerate the pace and progress of cancer care.

To learn more, please visit [www.lillyoncology.com](http://www.lillyoncology.com)

ATONC00148/December 2014 © Lilly USA, LLC 2014. ALL RIGHTS RESERVED.

[www.staralliance.com](http://www.staralliance.com)  
Information correct as of 01/2015

STAR ALLIANCE  
THE WAY THE EARTH CONNECTS




Lilly | ONCOLOGY






Activated T Cell



Inactivated T Cell



PD-L1

PD-1 Receptor

PD-L2

PD-1 Receptor

PD-L1

## Discover PD-1: An immune checkpoint pathway<sup>1</sup>



Artist's interpretation based on scanning electron microscopy.

### Some tumor cells can evade the body's immune response, which may result in disease progression<sup>2,3</sup>

- One function of the body's immune response is to detect and destroy tumor cells through activated T cells and other mechanisms; tumor cells express multiple antigens that are not expressed in normal tissue.<sup>1-3</sup>
- However, some tumor cells may evade the body's immune response by exploiting the PD-1 checkpoint pathway through expression of the dual PD-1 ligands PD-L1 and PD-L2.<sup>1,2,4-7</sup>
- PD-L1 and PD-L2 engage the PD-1 receptor on T cells in order to inactivate T cells, which may allow tumor cells to evade the immune response.<sup>1,2,8</sup>

**MSD is committed to furthering the understanding of immunology in cancer, including the role of the PD-1 pathway.**

### Visit the MSD booth to learn more.

PD-1=programmed cell death protein 1; PD-L1=programmed cell death ligand 1; PD-L2=programmed cell death ligand 2.

**References:** **1.** Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–264. **2.** Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol*. 2008;26:677–704. **3.** Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674. **4.** Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. *Br J Cancer*. 2013;108(8):1560–1565. **5.** Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol*. 2008;8(6):467–477. **6.** Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med*. 2003;198(6): 851–862. **7.** Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res*. 2007;13(7):2151–2157. **8.** Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol*. 2001;2(3):261–268.



Euro Plaza, Gebäude G, 5. Stock, Am Euro Platz 2, A-1120 Wien. © Registered Trademark. © Urheberrechtlich geschützt

für Merck Sharp & Dohme Corp., ein Unternehmen von Merck & Co., Inc., Whitehouse Station, NJ, U.S.A. 12-15-ONCO-1138243-0000; Erstellt: Dezember 2014

